Highlights
Updated Nov 14, 2026, 6:15 PM ET- Nvidia CEO Jensen Huang resigned amid multiple scandals, national security and export-control probes, and alleged affairs including with suspected Chinese spy Alice Huang; board investigations, DOJ/FBI scrutiny, and bipartisan congressional inquiries are ongoing, with Huang agreeing to closed-door testimony. CFO Colette Kress is interim CEO, Harvey Jones becomes chair in some accounts, and succession uncertainty plus potential $750B+ in deals/commitments and $3B of Chinese AI projects are under review.
- Nvidia shares have fallen sharply (single-day drops of 2–13%, >30–34% below highs, >$300B market cap loss) on leadership turmoil and espionage concerns, though analysts note its ecosystem advantages; rivals AMD, Broadcom, Chinese GPU makers and other chip competitors have gained, while partners like CoreWeave and Naver have sold off on some days.
- Political and regulatory risk around Nvidia has escalated: Democrats probe prior China sales and donations, Republicans threaten or pursue subpoenas, and Wachtell Lipton has been hired to investigate potential securities-law violations; Kalshi markets had put only ~30% odds on Huang remaining CEO before his ouster.
- Reports indicate extensive smuggling and circumvention of US export controls: an alleged $7.5B of Nvidia chips shipped to China via Megaspeed and Malaysia, 2M advanced chips in China and 600K H200s stockpiled in Hong Kong, and Chinese universities and open‑weight model labs (DeepSeek, Moonshot AI) using Blackwell/H200-class hardware despite bans.
- South Korea, Taiwan, Japan and Israel reaffirm support for Nvidia’s supply chain and AI projects, but Singapore barred Huang and China denies espionage allegations; concerns center on stability of $164.5B of Nvidia-related AI commitments and broader AI funding conditions.
- LangChain raised $300M Series C at a $3B valuation, doubling last year’s price, to scale its LangSmith agent-management platform used by 7,000 customers including NVIDIA, Toyota, Salesforce, Harvey, Rippling and Clay.
- OpenAI launched “dots,” a payments wallet for ChatGPT agents (US Pro users only), enabling secure tokenized transactions and automated merchant order details; Amazon currently blocks such agents, and OpenAI released a Commerce Partner Playbook to attract retailers.
- OpenAI Q3 revenue reached $10B, up 50% QoQ, with adjusted margin still deeply negative at -109%; Anthropic reported $17B Q3 revenue and an $81B run rate vs OpenAI’s $50B, underscoring intense competition among leading AI labs including Meta, Amazon, Microsoft and Google.
- OpenAI quietly acq‑hired Odessia, an AI travel‑planning startup that had raised $6M from Sequoia, aligning with OpenAI’s strategic focus on travel use cases for assistants.
- ElevenLabs, valued at $22B, launched ElevenAI, an enterprise team product combining meeting notes, dictation and agents with 90+ language support and v3 model fine‑tuning, aiming to displace separate notetaker licenses.
- Databricks introduced Genie, an enterprise AI agent for firms with 150+ employees that executes multi‑step workflows using custom ontologies and Unity Gateway for cost control, focusing on real‑time internal analytics.
- AWS released AWS Emulator, a local Rust‑based tool that lets developers run AWS APIs on their own machines at no cost, compatible with existing CLI/SDK workflows and deployable on Linux and via Docker, improving developer productivity and potentially deepening AWS lock‑in.
- Google upgraded Search to Gemini 4 Hydrogen for complex queries, claiming 2.5x speed vs Gemini 3.8 Flash and introducing multi‑level “thinking” modes including an xhigh tier; the model is rolling out globally across consumer and developer products.
- Meta’s AI agent Muse now places business calls for over 10M paid users, with plans starting at $20/month for 500M tokens per week and email-generation features coming for free users, expanding Meta’s monetization of AI tools.
- X launched a video clipping tool integrated with its Original Content Rewards program, further pushing into long‑form and creator monetization after earlier paywalled and live‑streaming initiatives.
- Nectar raised $30M Series A to build a Creator Agent that automates influencer marketing across 300M Instagram and TikTok profiles, targeting a share of the $44B US creator ad market projected for 2026.
- Norwest, backed by Wells Fargo, raised a $4B 18th fund focused on AI startups in the US, India and Israel across consumer, healthcare, cybersecurity, physical/voice AI and aerospace, building on 87 investments from its prior fund.
- Fractile raised $720M Series C at a >$7B valuation, backed by Britain’s Sovereign AI Fund and top VCs, to ship domestic AI chips next year and reduce the UK’s dependence on foreign compute hardware.
- Drogue secured $20M to develop floating, ocean‑thermal‑powered data centers, targeting a sea prototype in two years and multi‑MW units by 2028 with 10‑year power lifespans, appealing to AI infrastructure demand.
- CoreWeave reported Q3 revenue of $3.66B, up 168% YoY, but a net loss of $709M; it is funding a $132.5B contract backlog via contract‑backed loans instead of unsecured debt costing >15%, while raising prices 35% overall with some short‑term contracts exceeding $40M per MW annually.
- CoreWeave shares surged 20% on these results, easing investor fears about AI demand and lifting peers like Nebius and Nvidia, though Bernstein warned about capacity risk; SoftBank simultaneously reported a $7B loss.
- Nebius cut 2026 revenue guidance to $3B despite planning $40B of 2027 capex; shares fell 17% on Microsoft‑related site delays and fines, but 2027 revenue forecast was raised to $12–13B, highlighting near‑term execution risk vs long‑term AI infrastructure growth.
- Microsoft suffered an 18‑hour global outage affecting Outlook, Teams, cloud, Copilot and Defender, followed by another major Outlook outage tied to elevated infrastructure load and traffic redistribution; no malicious activity has been identified, but reliability concerns could influence enterprise perceptions.
- L3Harris’ fiber upgrade triggered a nationwide US ground stop from router overload, canceling over 11,000 flights; authorities blame user/installer error or faulty hardware, not AI, and a root‑cause probe is ongoing, raising operational‑risk questions for critical‑infrastructure vendors.
- Fireworks AI disclosed a second cyberattack in two months exposing billing data, datasets and chat transcripts after a cloud provider breach; hackers appear financially motivated to sell LLM tokens. Uber drivers in several states were impacted by a related breach via Fireworks, and Notion was also compromised.
- AI agents remain unreliable for complex unsupervised work; startup Plurai raised $13M seed funding from Team8 to use synthetic data and digital twins to post‑train small open‑weight models, targeting lower‑cost, higher‑reliability agents.
- Helix, founded in 2025, raised $6M to develop on‑device voice identity tech for CAPTCHA replacement and distress detection, backed by Chicago Ventures and Siri co‑founder Dag Kittlaus; management stresses it cannot reliably detect lies or AI agents yet.
- a16z‑backed Phota Labs raised a $5.6M seed round for AI‑assisted photo enhancement with style customization, preference learning and invisible watermarks, planning Android support and a freemium model.
- Character.ai filed for bankruptcy despite a $20M bid from Disney, underscoring high failure rates in AI (42% of projects fail due to funding/scaling); other casualties include Humane AI Pin (assets sold to HP for $116M), Ollie, Relay and multiple delayed or reversed initiatives at OpenAI (Sora shutdown, ChatGPT redesign rollback) and Apple (Siri delay, $250M settlement).
- ElevenLabs, OpenAI, Anthropic, Meta, Amazon, Microsoft, Google and open‑source labs face growing legal and regulatory pressure, including a San Francisco lawsuit by Public Citizen and others seeking to halt AI development on public‑health and existential‑risk grounds.
- New York’s RAISE Act requires companies with >$500M revenue using AI to register by Jan 1, 2027, publish safety frameworks and report incidents within 72 hours, with fines up to $3M; a $55M AI safety center was launched, and similar regimes exist in CA and IL, raising compliance costs for large AI adopters.
- Meta’s head of infrastructure Santosh Janardhan is stepping down, replaced by ex‑Amazon VP Dave Brown as Meta ramps capex to compete in the AI race, signaling continued heavy infrastructure investment.
- OpenAI, Anthropic and others are heavily reliant on Nvidia and TSMC for chips, while AI infrastructure build‑out requires massive data‑center and power investments; SoftBank’s $30B OpenAI stake and $33B gas‑plant investment resulted in a $7.1B loss from over‑ordering turbines, highlighting execution risk in energy‑for‑AI strategies.
- AI build‑out now accounts for ~1.7% of US GDP within business fixed investment (~17% of GDP), but >70% of capex is imported, muting direct GDP gains and widening the trade deficit; nonetheless, rising equity values and profit expectations from AI have supported consumption via wealth effects.
- Nvidia’s proposed $12.9B acquisition of Hugging Face faces DOJ scrutiny; Hugging Face’s CEO calls it a “sad day” but Nvidia has pledged open support and expanded its Nemotron open‑weight models, with deal closing targeted for H1 2027.
- United Airlines and Amazon have both restricted unauthorized AI agents (United for bookings, Amazon for commerce agents) citing cybersecurity, regulatory and policy risks, limiting some AI‑driven distribution channels.
- AI industry insiders highlight escalating espionage risks beyond Nvidia, with multiple alleged cases of executives engaging with state actors and semiconductors being frequent targets of trade‑secret theft, adding geopolitical risk to AI supply chains.
- Firms with fourth‑or‑later VC funds captured 88.2% of US VC dollars in 2026 vs 4.5% for first‑time funds; only 81 first‑time funds closed, the worst in a decade, even though historical data show small $1–10M funds outperform larger ones, indicating capital concentration in established AI/tech managers.
- Nebius and CoreWeave price actions, LangChain’s up‑round, Fractile’s large raise, Norwest’s $4B fund and Proximal Ventures’ AI‑drug‑focused vehicle collectively signal that, despite notable failures and regulation, capital is still flowing aggressively into AI infrastructure, chips and applications.
- Apple’s foldable iPhone Duo sold out quickly despite lacking Face ID (uses Touch ID) but offering features like Auto Lock on fold, Smart Take camera and Back Tap shortcuts, indicating strong demand for new form factors.
- Amazon refreshed its Kindle lineup with new Basic ($169), Paperwhite ($199) and premium Colorsoft ($290–$320 Sig Edition) devices; the Colorsoft’s 7‑inch color E‑Ink, long battery life and waterproofing target high‑end readers, though high prices may limit mass adoption.
- Tesla opened pre‑orders for its golden Cybercab at $29,990 plus $299/month, with limited Texas deliveries from Dec 2026 and a production shift from Cybertruck to Cybercab in 2027; nationwide rollout depends on regulatory approvals, introducing execution and regulatory risk alongside potential new revenue streams.
- Microsoft’s repeated cloud and Outlook outages, as well as L3Harris‑linked aviation disruptions, underscore operational and reputational risks for core enterprise and infrastructure tech providers that could influence customer diversification decisions.
News Briefs
- NVDANvidia petition to reinstate ousted CEO Jensen Huang has 115k+ signatures including 63k shareholders. Musk & others demand due process after Huang resigned amid spy allegations. Stock fell 2% as CFO Kress serves interim CEO. TechCrunch · 2h ago
- TSLATesla opens pre-orders for golden Cybercab at $29,990 plus $299/mo. Limited Texas delivery starts Dec 2026. Production shifts from Cybertruck to Cybercab in 2027. Nationwide rollout awaits regulatory approval. TechCrunch · 4h ago
- AAPLApple's stock foldable iPhone Duo sells out fast. It lacks Face ID, using Touch ID instead. New features include Auto Lock on fold, Smart Take camera, & Back Tap shortcuts. TechCrunch · 6h ago
- Nationwide ground stop due to L3Harris fiber upgrade causing router overload. 11k+ flights canceled. Two locations pinged at 1k connections/4-5s. Officials rule out AI, citing user/installer error or faulty hardware. Third such stop since 2000. Root cause analysis ongoing. TechCrunch · 6h ago
- AAPLCharacter.ai filed bankruptcy & Disney bid $20M. 42% of AI projects fail due to funding or scaling. OpenAI shut Sora in March 2026 & rolled back ChatGPT redesign. Apple delayed Siri, facing $250M settlement. Humane AI Pin ended Feb 2025; HP bought assets for $116M. Many startups like Ollie & Relay closed in 2026. TechCrunch · 6h ago
- NVDANvidia board launched probe after reports of Jensen Huang spy targeting & affair with Alice Huang. China denies spy claims. Huang's exit creates uncertainty for $3B in Chinese AI projects. Singapore barred Huang & investigation continues. South Korea, Taiwan, Japan reaffirm commitment to Nvidia supply & AI plans. TechCrunch · 7h ago
- GPSGap hires ex-Paramount exec to lead fashiontainment strategy, blending retail with entertainment. Brands like Coach & Ralph Lauren see 10% basket growth via experiential tactics. Experts warn this cannot replace product fundamentals or transparent pricing. CNBC · 11h ago
- TSLAFoundation Future Industries missed payroll since Oct 30 as cash reserves dwindled. CEO Sankaet Pathak borrowed $4.6M for a luxury home & previously led failed fintech Synapse. Eric Trump is an investor but claims no management role despite Senator Warren's corruption concerns. CNBC · 12h ago
- AMZNAmazon refreshed Kindle lineup: Basic ($169), Paperwhite ($199), & Colorsoft ($290). New Colorsoft offers 7-inch E-Ink, 8-week battery, waterproof build, & premium Sig Edition ($320). High price is drawback for B&W readers. TechCrunch · 1d ago
- NVDAJensen Huang stepped down as Nvidia CEO after 33 years. The startup ecosystem loses a major champion & capital for dealmaking. Interim CEO Colette Kress expects a more conservative approach. Expect smaller checks & lower valuations. This may open room for rivals like Google. Few believe this halts the AI boom. TechCrunch · 1d ago
- FAA grounds all US flights Friday due to equipment outage & safety concerns. Techs investigating unclear cause despite new AI tool. Inbound flights managed case-by-case. No return time set. TechCrunch · 1d ago
- Drogue raised $20M for floating data centers using ocean thermal energy. Co-founder Sam Sipe targets a sea prototype in 2 years, scaling to multi-megawatt units by 2028. The startup secured ABS approval & plans to power facilities for a decade using warm surface & cold deep water. TechCrunch · 1d ago
- NVDALangChain raised $300M Series C at $3B valuation, doubling last year's price. Led by CapitalG, the firm now manages AI agents via LangSmith. It boasts 7k customers including NVIDIA, Toyota, Salesforce, Harvey, Rippling, Clay. TechCrunch · 1d ago
- NVDAChinese open-weight models trained on banned Nvidia chips. Jensen Huang resigned over Megaspeed smuggling scandal involving Alice Huang. DeepSeek & Moonshot AI show Blackwell fingerprints. 2M advanced chips entered China via Malaysia; 600K H200 stockpiled in Hong Kong. TechCrunch · 1d ago
- DASHOpenAI launched dots, a wallet for ChatGPT agents, now limited to US Pro users. It uses payment tokens for security while preserving card rewards. Merchants receive order details automatically. Amazon currently blocks AI agents. OpenAI published a Commerce Partner Playbook for retailers. TechCrunch · 1d ago
- NVDAJensen Huang resigned as Nvidia CEO amid national security probes into chip sales to China & extramarital affairs with Megaspeed exec Alice Huang. Shares slid 5% as Congress demands testimony & Trump backs him. TechCrunch · 1d ago
- UBERUber notified drivers of a Fireworks AI breach stealing license data. States include CA, MA, SC, RI, IL. No total count given. Notion also compromised. This is Uber's second breach this year. TechCrunch · 1d ago
- ElevenLabs ($22B) launched ElevenAI at its 11/11 Summit, a preview team product combining meeting notes, dictation & agents. Features include cross-meeting data queries, 90+ language support, & v3 model fine-tuning to replace notetaker licenses. TechCrunch · 1d ago
- MSFTMicrosoft endured a 18hr global outage from cascading server failures impacting Outlook, Teams, cloud, Copilot & Defender. Services recovered Thursday after spreading worldwide; no malicious activity detected. TechCrunch · 1d ago
- NVDAFormer Nvidia CEO Jensen Huang's resignation sparks Israel concern as GPUs drive AI training. Investors expect demand to hold despite leadership shifts, though competitors eye the window to challenge Nvidia's market dominance. TechCrunch · 1d ago
- NVDAFormer NVIDIA CEO Jensen Huang resigned amid reports of extramarital affairs & a possible espionage plot. Interim CEO Collette Kress, who scaled back OpenAI deals, was described by Huang as unhelpful. The company seeks a permanent CEO to replace Huang after 33 years. TechCrunch · 1d ago
- NVDADemocrats launch inquiry into Trump admin Nvidia China sales after CEO Jensen Huang resigns amid spy allegations. Neal & Wyden seek records on Megaspeed routing & $26M donation to Trump projects. Republican groups demanded Huang testify before resignation. TechCrunch · 2d ago
- METAMeta's AI agent Muse now places business calls for paid subscribers, serving over 10M users. Plans start at $20/month for 500M tokens weekly. The feature avoids long hold times though some businesses reject AI voices. Email creation for free users is coming soon. TechCrunch · 2d ago
- MSFTNebius slashed 2026 rev to $3B despite $40B 2027 capex plan. Shares fell 17% after NJ Microsoft site delays caused by fines & generator issues. Microsoft tightened oversight on late 3rd-party projects. 2027 rev forecast raised to $12B-$13B. TechCrunch · 2d ago
- NVDANvidia founder Jensen Huang stepped down as CEO & board member amid reports of an affair with VP Kimberley Powell. CFO Colette Kress is interim CEO. Huang will testify before Congress regarding national security implications. TechCrunch · 2d ago
- GOOGLGoogle Search now uses Gemini 4 Hydrogen for complex queries. It runs 2.5x faster than Gemini 3.8 Flash, breaks prompts into subqueries, & offers 4 thinking levels including new xhigh tier. The model rolls out globally to all users, AI Studio, API, App, Pro, Ultra, & Antigravity. TechCrunch · 2d ago
- METANectar launched a Creator Agent to automate influencer marketing across 300M profiles for Instagram & TikTok. The tool raised $30M Series A in May as US creator ad spending is projected to hit $44B by 2026. TechCrunch · 2d ago
- MSFTMicrosoft Outlook is down globally due to elevated infrastructure load, forcing traffic redistribution. The admin center is unreachable. No specific cause given. Last major outage was in September. TechCrunch · 2d ago
- NVDANvidia CEO Jensen Huang stepped down amid affair allegations involving an alleged Chinese spy. Colette Kress is interim CEO. Huang supported OpenAI & pushed back on export controls. Nvidia agreed to pay $6B for Poolside tech & hasn't finalized a $13B Hugging Face deal. TechCrunch · 2d ago
- NVDAHugging Face CEO calls Nvidia's proposed $12.9B acquisition a sad day. DOJ inquiries began in October. Deal scheduled to close in H1 2027. Nvidia pledged to preserve open support & recently expanded its Nemotron open-weight models. TechCrunch · 2d ago
- UALUnited Airlines bans unauthorized AI agents for booking flights citing cybersecurity risks & federal regulation violations. Sharing credentials exposes sensitive info & breaches human check-in rules. Policies now prohibit AI use on platforms & via travel agencies. TechCrunch · 2d ago
- 9984.TSoftBank invested $30B in OpenAI $33B in a gas plant yet lost $7.1B due to overordering turbines to secure supply. CEO cites $3B price discovery for avoiding shortages as data centers seek energy security. TechCrunch · 2d ago
- a16z-backed Phota Labs uses AI to enhance photos while preserving authenticity. Features include style customization, preference learning & invisible watermarks. Launched with $5.6M seed round. Future plans include Android support & a freemium model. TechCrunch · 2d ago
- NVDAEx-Nvidia CEO Jensen Huang agreed to testify before the House Foreign Affairs Committee behind closed doors by Thanksgiving after threats of subpoena from Republicans Brian Mast, John Moolenaar, & Rick Crawford. TechCrunch · 2d ago
- NVDANvidia CEO Huang ousted amid affair, spy ties & smuggling reports. Republicans seek security testimony while Democrats probe $25M donation. $750B deals face scrutiny as Wall Street fears crash. Company enters post-founder era. TechCrunch · 2d ago
- NVDANvidia CEO Jensen Huang resigned Nov 12, 2026. Trump suggested Tim Cook as replacement after Cook stepped down from Apple in September 2026. Cook now serves as Apple's Executive Chairman. TechCrunch · 2d ago
- GOOGLWhoop launches Humans social network for data sharing. Features include FDA-cleared health tools, Medicare program, & Ulta retail expansion. 1,200 employees, 70% growth, 4M members projected. No data selling. CEO confirms future IPO plans. TechCrunch · 2d ago
- NVDAJensen Huang resigned as Nvidia CEO amid allegations of affairs with a Chinese spy and direct report. CFO Colette Kress assumed interim role. Kress, 59, with $1.2B net worth, commits to AI growth. Nvidia reports earnings Tuesday. TechCrunch · 2d ago
- WFCNorwest, backed by Wells Fargo, raised $4B for its 18th fund. It targets AI startups in US, India & Israel across consumer, healthcare & tech. Focus includes physical AI, voice AI, agentic cybersecurity & aerospace. Since its 17th fund, Norwest made 87 investments. TechCrunch · 2d ago
- Fireworks AI confirms cyberattack exposed billing info, datasets & chat transcripts after cloud provider breach. Systems disconnected Nov 3. Hackers appear financially motivated to sell LLM tokens. This marks Fireworks' second breach in two months. TechCrunch · 2d ago
- NVDAJensen Huang resigned as Nvidia CEO Nov 12 after admitting affairs with Kim Powell & spy Alice Huang. Board named Colette Kress interim CEO & Harvey Jones chair. Shares slid 5% amid national security probes into Megaspeed chip transfers to China. TechCrunch · 2d ago
- NVDAJensen Huang resigned as Nvidia CEO after admitting to an affair with an alleged Chinese spy. Collete Kress serves as interim CEO. Shares fell 11% as market cap dropped over $300B. Harvey C. Jones appointed first-ever board chair. Nvidia thanked Huang for contributions. TechCrunch · 2d ago
- DISCosm partners w/ Disney for Star Wars dome films in March, coinciding w/ the franchise's 50th anniversary. The experience features 87ft 12k screens, immersive backgrounds & a themed menu. This marks Cosm's sixth Hollywood collab, following Warner Bros. & Universal. CNBC · 2d ago
- 005930.KSNine Korean deep tech startups pitched at DETO 2026 for 200 Startup Battlefield spots. Voinosis won with an AI brain health tool. Others include Awesome Lab, Crosshub, DeepFusion AI, EFLOW, Otiton Medical, Riibotics, Ternell & Testbank. All target U.S. market entry. TechCrunch · 2d ago
- VOW3Scout Motors has 212k reservations for its Terra pickup & Traveler SUV, nearing completion of a $2B SC plant. Full production starts next year with deliveries in 2028. CEO Keogh expects orders to double, with 87% for EREV models & 75% for SUVs. CNBC · 2d ago
- NVDAKalshi gives Jensen Huang 30% chance to stay CEO amid admitted affair. Nvidia lacks succession plan. Potential candidates include Lisa Su, Eric Schmidt, Lip-Bu Tan, Bret Taylor, Ian Buck, Andrew Bell, Colette Kress, or wife Lori Huang. Board may keep him as chairman. TechCrunch · 2d ago
- NVDAJensen Huang admitted cheating on his wife with Alice Huang, a spy suspect. Nvidia board plans to oust him amid national security concerns & Megaspeed chip smuggling probe. Shares slid over 5%. Trump supports Huang. TechCrunch · 3d ago
- NVDANvidia's board meets Wednesday to decide CEO Jensen Huang's fate after he admitted an affair with a Chinese spy. Stock dropped 8% in after-hours trading and is down 11% in five days. Huang has 60 direct reports with no clear successor. TechCrunch · 3d ago
- NVDANvidia CEO Jensen Huang faces investigation for an affair with a woman accused of being a Chinese spy & a second alleged affair with VP Kimberly Powell. The board is looking into ousting Huang, while House Republicans plan to subpoena him regarding spy allegations. TechCrunch · 3d ago
- GILDUS accuses CANARX of illegal drug imports 2017-2026. Treasurer John Thomas Howard arrested Sunday; president Bob Howard at large. Company sources meds from Canada, UK, Australia, NZ. Gilead sues over HIV meds; FDA seized shipments in 2023. CNBC · 3d ago
Research Briefs
- The Producer Price Index for final demand rose 0.3% in October, falling short of the expected 0.5% increase. Energy prices dipped 0.1% after significant gains in the preceding months, while food prices jumped 1.3%. Prices excluding food and energy remained steady at 0.3%, leaving the year-over-year change at 5.0%. Intermediate prices for processed goods and services continued their upward trend, with year-over-year increases of 14.6% and 6.8% respectively. Haver Analytics · 1d ago
- GSEuropean listed company earnings are proving more resilient than domestic economic growth would suggest, driven by sector composition and global revenue exposure. The equity market reflects a concentrated group of large companies, with financials, energy, and technology holding significant weight compared to their share of the broader economy. Additionally, over half of STOXX 600 revenues are generated outside Europe, making global growth and currency fluctuations more relevant than domestic GDP. While higher energy prices currently benefit energy and resource sectors, sustained costs may eventually pressure profit margins for other industries. Goldman Sachs Insights · 1d ago
- The European monetary union recorded an annual growth rate of 1.7% in the third quarter of 2026, following a 2.6% increase in the second quarter. Among early reporting nations, Belgium saw growth rise to 1.2%, while France experienced a 0.5% decline and the Netherlands and Spain both dropped to 2.6%. Inflation remains a concern for central banks in the monetary union, the U.K., the U.S., and Japan, driven by rising oil prices and ongoing geopolitical conflicts. Haver Analytics · 1d ago
- GSThe U.S. Consumer Price Index (CPI) print for November 2026 came in at 0.3% for the third consecutive month, prompting a hawkish reaction from the Federal Reserve. Federal Reserve Governor Christopher Waller indicated that a 50 basis point rate hike could be on the table contingent on the inflation data. Oil prices fell 15% following the midterms, though this decline is not expected to fully offset the upward pressure on interest rates caused by the CPI data. Market participants are now focusing on the Fed's reaction function, AI-related capital expenditure supply, and geopolitical factors as key drivers of volatility. Goldman Sachs Insights · 1d ago
- GSGoldman Sachs Research forecasts that lower energy prices will outweigh tighter financial conditions and a smaller fiscal impulse to drive GDP growth in 2027. Nominal global AI investment is projected to rise to $1.8 trillion, boosting global GDP growth by 0.4 percentage point, with a 0.6 percentage point boost in the US. China's GDP is expected to grow 4.5% in 2027, supported by robust exports despite weak domestic demand. Inflation is anticipated to slow in 2027, with US core PCE inflation dropping to 2.4% by year-end, while the Bank of Japan is expected to raise rates to a terminal level of 2%. Goldman Sachs Insights · 1d ago
- BACTotal card spending per household rose 5.8% year-over-year in October 2026, with growth of 4.6% excluding gasoline. Spending showed positive momentum on a seasonally adjusted month-over-month basis, driven largely by services spending while retail also contributed meaningfully. The Bank of America Institute analyzed aggregated credit and debit card data from US Retail, Preferred, Small Business, and Wealth Management clients to assess consumer spending trends heading into the holiday season. BofA Institute — Daily Insights · 2d ago
- FREU.S. existing home sales fell 5.5% in October to a seasonally adjusted annual rate of 3.75 million units, marking the lowest level since August 2010. The median sales price for all existing homes dropped 0.4% to $416,700, while unsold inventory rose 1.3% to 1.59 million units, representing a 5.1-month supply. High mortgage rates, which reached 7.33% for the average 30-year fixed loan, continued to suppress housing demand across all regions except the Northeast, where sales remained flat. Haver Analytics · 2d ago
- Global economic momentum has softened as the world faces cheaper energy and dearer money. Brent crude prices fell from over $135 to around $91 per barrel due to growing hopes of a Middle East settlement, while US Treasury yields rose back toward 5 percent following stronger-than-expected core inflation. China's export growth is increasingly driven by technology sectors like semiconductors, whereas US corporate profits recovery relies heavily on finance and information industries. Forecasters have raised interest rate projections for 2027 more than inflation expectations, indicating that central banks may maintain restrictive policies for longer. Haver Analytics · 2d ago
- United Kingdom manufacturing output has increased for three consecutive months, driving three-month growth to an annual rate of 9.1%. While sector-level output shows expansion, industry-level data reveals uneven performance with significant declines in July and mixed trends across different goods categories. The Bank of England has raised interest rates in response to rising inflation, with the economy growing at an annualized quarterly pace of 2.8% in the third quarter. Recent economic trends indicate positive impacts from artificial intelligence, though future growth remains contingent on inflation control and geopolitical stability. Haver Analytics · 2d ago
- NVDAArtificial intelligence is described as a transformative technology with vast potential, yet its investment landscape is complicated by significant uncertainties regarding its evolution, profitability, and competitive dynamics. Key challenges include the difficulty in predicting which companies will succeed, the risk of commoditization reducing vendor profits, and the substantial infrastructure requirements involving data centers and compute power. While current leaders like Nvidia and TSMC are profiting from chip demand, the long-term outlook involves questions about AI's ethical alignment, regulatory taxation, and the potential for rapid shifts in market dominance. Oaktree Capital · 3d ago
- The buildout of AI data centers has contributed to strong business fixed investment, which now accounts for 17% of GDP, with AI investment representing roughly 1.7% of GDP. However, over 70% of the capital spending on these centers is imported, meaning the direct impact on GDP is largely offset by a widening U.S. trade deficit. Despite the muted direct GDP impact, the AI buildout has fueled a positive wealth effect and boosted consumption by raising profit and stock market expectations. While the pace of new projects may slow, numerous facilities are currently under construction or in planning stages across states including Texas, Virginia, Pennsylvania, Ohio, and Indiana. Haver Analytics · 3d ago
- German inflation metrics show mixed signals, with headline inflation falling in October while core inflation remains elevated. The HICP annual rate has eased to 2.6% over three months, and the domestic CPI excluding energy is at 1.6%. However, diffusion statistics indicate a broadening of price increases over the last three months, with 63.6% of categories showing acceleration. Oil prices, specifically Brent, have surged significantly, introducing uncertainty into future inflation forecasts. Economists suggest central banks should focus on communicating their goals and scenarios rather than making specific forward guidance on volatile variables like oil prices. Haver Analytics · 3d ago
- BACHousing cost pressures have extended across all income cohorts, with nearly one in four lower-income households spending at least half their income on rent. Similarly, about one in four higher-income households spend at least half their income on mortgages. While consumers have managed to keep spending on essentials like gas and groceries in check, housing remains a significant burden on household budgets across the income spectrum. Data indicates that the share of lower-income renters spending over 50% of their income on rent has increased from about one in five before the pandemic to nearly one in four in 2026. BofA Institute — Daily Insights · 3d ago
- GSNet sovereign bond issuance is projected to remain elevated in 2027 across the G4 nations. In the United States, Euro Area, and United Kingdom, net supply to the public is expected to be stable or lower compared to 2026. Japan stands as the only major sovereign bond market where economists anticipate a modest increase in net supply to the public for the coming year. Goldman Sachs Insights · 3d ago
- Japan's Economy Watcher Index slipped in October to a 46.1 diffusion reading from 47.0 in September, indicating a deterioration in the current economic assessment. The future economy watchers index also declined to 46.5 from 47.4, with only three of nine components showing improvement. Despite month-to-month declines, the index shows point-to-point improvement over three and six months, though the year-over-year change remains negative. Haver Analytics · 4d ago
- The NFIB Small Business Optimism Index slipped to 97.8 in October, remaining slightly below its 53-year average of 98.0. The Uncertainty Index fell to 84, the lowest level since December 2025, while expectations for the economy improved for the 24th consecutive month. Labor quality, taxes, and inflation were identified as the top three concerns facing small businesses, with hiring plans rising to 18% and average selling prices increasing to 33%. Haver Analytics · 4d ago
- Japan's Economy Watcher Index slipped in October to a diffusion reading of 46.1, down from 47.0 in September. While the index shows point-to-point improvement over three and six months, the 12-month change remains negative for the headline and most components. The future economy watchers index also declined to 46.5 in October, with year-over-year assessments lower despite modest gains over the last three and six months. Haver Analytics · 4d ago
- Southeast Asia is transitioning from assembling AI hardware to hosting data centers, with Malaysia, Thailand, and Singapore leading the expansion. Malaysia's Johor region has seen significant GDP growth driven by data center investments, though power and water constraints have led to new tariffs and approval caps. Thailand's digital industries captured nearly half of approved foreign direct investment in 2025, prompting a pause on new applications due to resource scarcity in the Eastern Economic Corridor. Singapore experienced a sevenfold rise in operating surplus for data processing but imposed a moratorium from 2019 to 2022 due to resource limits, redirecting some investment to neighboring Johor. Economic gains from these facilities often remain limited for local residents due to foreign ownership, high capital intensity, and low staffing requirements. Haver Analytics · 4d ago
- BACLower-income wage growth reached 4.7% year-over-year in October 2026, surpassing the 3.4% growth rate for higher-income households. This trend, which began earlier in 2026, is attributed to tax withholding impacts from the One Big Beautiful Bill Act and a broadening labor market characterized by increased job-to-job changes and raises. Middle-income households saw wage growth of 3.8% during the same period. The data is derived from aggregated consumer deposit account information provided by Bank of America. BofA Institute — Daily Insights · 4d ago
- The global AI investment boom has created widespread demand for semiconductor exporters, equipment manufacturers, and energy suppliers, with the United States at the center of this cycle. Asian producers supply chips while European and Japanese manufacturers provide sophisticated equipment, creating a tightly linked international supply chain. Political resistance to data center construction in the US and Europe poses a potential constraint that could delay physical investment and slow the expansion of the sector. The financial exposure is global, as pension funds and insurers share risks through equity portfolios, making a market correction a potential macroeconomic issue. Haver Analytics · 4d ago
- The global media rights market grew 41% since 2020, reaching approximately $57.8 billion in 2025 and projected to hit $67 billion in 2026, driven largely by live sports and streaming services. Institutional investment in sports has surged, with private equity transactions rising from 50 in 2018 to 192 in 2025, while the WNBA Valkyries achieved a valuation of $850 million, the highest in the league. A landmark settlement allowing college athletes to monetize their name, image, and likeness has transformed college football into a highly competitive commercial sport, prompting schools to seek new financing models. Investors are increasingly exploring international expansion, women's sports, and emerging leagues like Unrivaled to capture growth equity returns. Goldman Sachs Insights · 4d ago
- U.S. consumer prices rose more than anticipated in October, with the headline Consumer Price Index increasing 0.4% month-over-month and the core index rising 0.3%. Shelter and food prices were the primary drivers of the increase, contributing significantly to the headline rate. The year-over-year headline inflation rate climbed to 4.1%, the highest level since May, while the core rate reached 2.8%. Financial markets reacted strongly to the data, pricing in a near-certain 25 basis point interest rate hike by the Federal Open Market Committee in December. Haver Analytics · 4d ago
- Japan's leading economic index fell sharply in September to 116.4, down from a peak of 118 in August, though it remains marginally higher than readings from May and June. Consumer confidence has shown a mild year-over-year increase of 1.1% since April, despite a negative trend over the preceding 24 months. The Economy Watchers index indicates modest contraction in current conditions and expected future contraction, with both metrics below their historic medians. Despite these cooling indicators, the Bank of Japan is expected to proceed with a rate hike to address inflation, supported by fiscal stimulus. Haver Analytics · 5d ago
- BACThe U.S. equity market is expected to continue a bull market in 2027 following a typical midterm election pattern, with economic growth peaking in 2026 before moderating. China's integration into the World Trade Organization has led to a global convergence where Western nations increasingly adopt state-led industrial policies similar to China's model. Significant capital investment is projected for the Artificial Intelligence sector, with data center developers expected to spend over $1.4 trillion in 2027, raising concerns about financing costs and credit spreads. Market conditions suggest a shift toward higher-quality, less leveraged segments as financial conditions tighten and earnings momentum slows. Bank of America — Private Bank Market Update · 5d ago
- U.S. wholesale inventories increased by 0.7% in September, marking the eighth consecutive month-over-month gain and a 7.6% year-over-year rise, the fastest pace since March 2023. Wholesale sales surged 2.8% month-over-month, driven by strong demand in durable and nondurable goods sectors, while the inventory-to-sales ratio fell to 1.21, its lowest level since May. Durable goods inventories grew 0.6% led by electrical and electronic goods, whereas nondurable goods inventories climbed 0.9% primarily due to a rebound in petroleum products. Haver Analytics · 5d ago
- BACConsumer confidence has declined, leading to a record-high level of consumers trading down to lower spending tiers since 2021. This shift is characterized by households becoming increasingly value-conscious, often substituting premium purchases with standard or value options in categories like apparel, dining, grocery, and travel. The trend suggests that while total spending may remain stable, the composition of spending is moving toward more affordable options as households delay discretionary purchases. Data indicates that this behavior is observed across various income levels, with specific attention paid to how spending patterns are categorized based on merchant tiers. BofA Institute — Daily Insights · 5d ago
- SInvestors are advised to maintain long-term goals during market volatility, as missing the best trading days can result in near-flat cumulative returns. A bear market is defined as a decline of 20% or more from a recent peak, with the S&P 500 experiencing 14 such periods since 1932. Historical data indicates that bull markets have lasted an average of 4.9 years compared to 1.5 years for bear markets, with average returns of 177.6% versus losses of 35.1%. Strategies to navigate these periods include dollar-cost averaging, staying invested to avoid missing rebounds, maintaining asset diversification, and managing emotional reactions to market fluctuations. Stifel Insights · 1w ago
- ARMU.S. equities declined as selling in artificial intelligence-linked stocks outweighed gains elsewhere, with the S&P 500 falling 4.4%, the Dow Jones Industrial Average dropping 3.4%, and the Nasdaq losing 5.5%. Concerns that tighter restrictions on data center construction could slow the AI investment cycle, driven by Democratic victories in midterm elections, served as the dominant catalyst for the market move. While earnings reports from Arm Holdings and Qualcomm added pressure, economic data indicated continued labor market resilience with initial jobless claims falling to 189,000. Non-U.S. markets were mixed, with Germany's DAX falling 0.4% and Japan's Nikkei declining 1.8%, while the 10-year Treasury yield fell to 4.84% and Brent crude rose 4.1%. Stifel Insights · 1w ago
- Quantum computing is projected to become a major technological advancement by 2035, potentially generating $2 trillion in value across finance, materials, life sciences, and mobility. The boundaries between humans and machines are expected to blur through advances in bionics, including artificial limbs and brain chips, while vertical farming aims to ensure food security in growing cities. The U.S. power infrastructure is anticipated to rely more on small modular nuclear reactors to support a digitalized economy, and the space economy is predicted to triple to $1.8 trillion by 2035. Stifel Insights · 1w ago
- SFGlobal GDP is projected to increase by 14% by 2030 due to artificial intelligence, driven by automation and product enhancements. The U.S. faces a fiscal transition with rising debt costs, where household, corporate, and federal debt have increased significantly since the Great Financial Crisis. Inflation and Federal Reserve policy remain central to economic forecasts, with the Fed maintaining a data-dependent approach to interest rates while monitoring labor market strength. Geopolitical tensions, including the Israel-Hamas war and global election cycles, present risks of deglobalization and market volatility. Stifel Insights · 1w ago
- The Stifel NextGen Investor Handbook provides guidance for young adults entering the workforce, covering essential topics such as budgeting, saving, and investing. It outlines strategies for job hunting, including resume preparation and networking, while explaining financial principles like the 50/30/20 rule and the power of compounding. The guide details various investment vehicles including IRAs, 401(k)s, 529 plans, ETFs, and mutual funds, alongside advice on credit management, home buying, and tax planning. It further addresses life events such as marriage, starting a family, estate planning, and helping aging parents, concluding with sections on family mission statements and philanthropy. Stifel Insights · 1w ago
- AAPLU.S. companies are reporting strong third-quarter earnings with net profit margins near 13.1%, the highest since 2009. Major firms have announced approximately $1.5 trillion in multiyear investments for nearshoring and reshoring across technology, pharmaceuticals, and industrials. The artificial intelligence boom is driving a construction surge, with the U.S. hosting over 5,400 data centers, while government incentives like the CHIPS and Science Act accelerate corporate decisions to onshore production. This structural reindustrialization is transforming the workforce by creating higher-skilled, higher-wage manufacturing roles through automation. Stifel Insights · 1w ago
- IBMTechnological innovation is breaking down boundaries between physical, digital, and biological worlds, creating opportunities in data processing, artificial intelligence, and quantum computing. Global population dynamics are shifting, with the senior population expected to reach 1.6 billion by 2050 and the global middle class projected to grow by over 1 billion people by 2030. Companies and governments are prioritizing the development of critical resources, including food, water, energy, and new materials, while reshoring production to reduce foreign dependence. Geopolitical tensions are driving increased investment in defense modernization, space exploration, and the digital economy, with the global space economy potentially reaching $1.8 trillion by 2035. Stifel Insights · 1w ago
- U.S. GDP growth is forecast to range between 1.75% and 2.5% in 2026, with inflation expected to run between 2.25% and 2.75%. The Federal Reserve is anticipated to implement one or two quarter-point rate cuts during the year, while the 10-year Treasury yield is projected to remain between 4.0% and 4.5%. Artificial intelligence is viewed as a dual force driving productivity and capital investment while presenting macro risks if adoption slows. The S&P 500 is forecast to deliver a total return of approximately 10%, driven primarily by earnings growth rather than valuation expansion. Stifel Insights · 1w ago
- SIFThe global economic landscape is shifting from globalization toward increased localization, protectionism, and geopolitical uncertainty. Key risks identified over the next three to five years include intensifying U.S.-China competition, the potential for cyberattacks, and the emergence of competing geopolitical blocs. Specific military conflicts in the South China Sea, the Middle East, and Taiwan are assessed as likely or unlikely, with significant implications for global trade, energy markets, and supply chains. Investment strategies are advised to focus on cybersecurity, defense, energy efficiency, and sectors with strong pricing power to navigate these structural shifts. Stifel Insights · 1w ago
- The U.S. economy expanded at a 2.0% annualized pace in the first quarter of 2026, driven by resilient consumer spending and investment in artificial intelligence. Inflation reached 3.8% year-over-year due to oil supply shocks and geopolitical fragmentation, leading futures markets to price out Federal Reserve rate cuts for the year. U.S. equity markets have rebounded to record highs with S&P 500 earnings tracking toward 28% growth, while the 10-year Treasury yield is expected to remain between 4.0% and 4.5%. Geopolitical tensions involving the U.S., Israel, and Iran have caused temporary spikes in oil prices, though historical data suggests equity markets typically recover as uncertainty fades. Stifel Insights · 1w ago
- GOOGLThe U.S. and Iran are engaged in a conflict with four potential scenarios: a managed off-ramp, shadow war, severe tail, or regime change. The Federal Reserve held rates at 3.50%-3.75% in July 2026, with markets pricing in potential rate hikes through 2027 due to inflation concerns and geopolitical risks. Economic forecasts project 2026 GDP growth at 2.2%, while the Congressional Budget Office estimates a $1.8 trillion deficit pushing total debt over $40 trillion. Major market indices have shown rotation away from previous trends, with the S&P 500 trading at a premium to its 10-year average P/E ratio. Stifel Insights · 1w ago
- The S&P 500 advanced 15.2% in the second quarter of 2026 as markets stabilized following an unsettled start to the year. Under new Federal Reserve Chair Kevin Warsh, the central bank held rates steady at 3.5% to 3.75% while emphasizing price stability and shifting away from forward guidance. Geopolitical tensions eased after the United States and Iran reached a memorandum of understanding to wind down conflict and reopen the Strait of Hormuz. Inflation remained firm with the core PCE price index rising to 3.4% in May, leading to an upward revision of the full-year inflation forecast. Stifel Insights · 1w ago
- SPOTA survey of 150 Stifel summer interns reveals that 56% consider remote work unimportant, though most prefer working from home at least once a week. While 61% are comfortable with robots as restaurant waiters, 91% would not feel comfortable with an AI bot as a primary care doctor. Interns expect significant labor market transformation, with 31.9% predicting 15-20% of current jobs will be replaced by AI by the end of the decade, and 43% believe NVIDIA will be the largest of the Magnificent Seven companies in ten years. Stifel Insights · 1w ago
- GSGoldman Sachs analysts discuss market reactions following the US midterm elections, noting a significant rotation away from high-multiple AI data center stocks which have declined 36% from their year-highs. The discussion highlights a shift toward healthcare as a new defensive sector driven by AI applications in diagnostics and tools, while traditional staples are deemed overvalued due to low earnings yields. Analysts recommend investing in the S&P 500 excluding AI companies to access high-quality balance sheets with lower valuations, while monitoring inflation, employment, and the December 9th FOMC decision for future market direction. Goldman Sachs Insights · 1w ago
- GSNonfarm payrolls rose by 165,000 in October, exceeding forecasts and indicating a solid labor market trend above 100,000 jobs per month. The unemployment rate remained stable between 4.1% and 4.2%, consistent with full employment and subdued wage growth. Goldman Sachs Chief Economist Jan Hatzius projects GDP growth of 2% to 2.5% for the coming year despite tightening financial conditions and geopolitical risks. Additionally, AI adoption is currently reducing employment growth in the technology sector by 10,000 to 15,000 jobs monthly, with broader impacts expected by 2027. Goldman Sachs Insights · 1w ago
- GSFollowing the US midterm elections, the AI data center trade has seen significant corrections with valuations dropping to levels comparable to June lows. Goldman Sachs analysts suggest that traditional defensive sectors like staples are overvalued and recommend shifting focus to quality compounders outside the AI sector. Healthcare is identified as the next leg of the AI trade, offering a defensive play with accelerating growth drivers. Market participants are advised to monitor employment, inflation, and the Federal Open Market Committee decision scheduled for December 9th. Goldman Sachs Insights · 1w ago
- Nonfarm payrolls rose by 165,000 in October, significantly exceeding the expected increase of 65,000. The headline unemployment rate decreased to 4.1%, while the broad unemployment rate (U-6) increased to 7.9%. Average hourly earnings grew by 0.4% in October, resulting in a year-over-year change of 3.1%. Haver Analytics · 1w ago
- GSDavid Schwimmer, CEO of the London Stock Exchange Group (LSEG), discusses market conditions characterized by a shift from rational to irrational complacency due to geopolitical tensions and inflation concerns. Capital flows are experiencing crosscurrents as investors seek to diversify away from US concentration despite recent energy crises favoring US independence. LSEG is leveraging its extensive data assets as a critical component of the AI ecosystem alongside compute and models, while also driving cultural integration following the Refinitiv acquisition. Future market infrastructure is expected to evolve toward digitization and geography-independent capital raising facilitated by AI simplification. Goldman Sachs Insights · 1w ago
- German industrial production increased by 0.7% in September following a 1% rise in August, with consumer goods and capital goods sectors posting strong gains. Capital goods output demonstrated acceleration with an annualized pace of 8% over three months, while intermediate goods output showed contractions across sequential horizons. Survey indicators for the German economy have progressed toward strength over the last three months, though their historic percentile standings remain below the median. In contrast, France, Spain, and Portugal reported output increases in September, but their sequential trends were less positive than Germany's. Haver Analytics · 1w ago
- BACApproximately one-third of family offices are currently invested in sports teams, franchises, or related opportunities, with another 31% expressing interest. Direct ownership of sports teams is more prevalent among offices led by Gen Z or Millennial principals at 27%, compared to 20% for Gen X and 16% for Baby Boomers. A survey of 355 family office decision makers in the U.S. indicates that 79% of offices with a potential next-generation successor believe alternative investments will comprise a larger portion of their portfolios. The study was conducted online in January and February 2026 by Escalent for Bank of America Private Bank. BofA Institute — Daily Insights · 1w ago
- ARMU.S. equities declined as selling in artificial intelligence-linked stocks outweighed gains elsewhere, with the S&P 500 falling 4.4%, the Dow Jones Industrial Average dropping 3.4%, and the Nasdaq losing 5.5%. The primary catalyst was concern that tighter restrictions on data center construction could slow the AI investment cycle following Democratic victories in midterm elections. While earnings from Arm Holdings and Qualcomm provided mixed signals, economic data showed resilience with initial jobless claims falling to 189,000 and third-quarter productivity growing at a 3.6% annual rate. Stifel, Nicolaus & Company maintains a constructive outlook for the U.S. economy, forecasting real GDP growth between 1.75% and 2.5% for the year without predicting a recession. Stifel Insights · 1w ago
- GSEmerging market sovereign and corporate bonds have demonstrated increased stability and resilience despite global shocks such as the Iran war and rising oil prices. The asset class has matured from a monolithic risk trade into a diverse market with over 80 countries offering varied opportunities, supported by stronger fiscal policies and deeper local-currency markets. Corporate bond issuance has grown significantly, featuring globally competitive companies with improved transparency and standardized reporting under International Financial Reporting Standards. Investors are now focusing on credit selection and fundamentals rather than broad market trends, as the constraint of the US dollar on debt servicing has lessened. Goldman Sachs Insights · 1w ago
- BACPayroll growth moderated but remained resilient at 1.2% year-over-year in October 2026, according to Bank of America deposit account data. The number of households receiving unemployment payments fell approximately 5% year-over-year during the same period. Small and mid-sized firms showed strong growth in payments to hiring firms in September, indicating continued hiring plans. These findings suggest a labor market that is directionally consistent with resilience despite a peak in payroll growth over the summer months. BofA Institute — Daily Insights · 1w ago
- Initial unemployment claims in the United States fell by 6,000 to 189,000 for the week ending October 31, 2026. Continuing claims increased by 23,000 to 1.718 million for the week ending October 24, while the insured unemployment rate remained steady at 1.1%. State-level data showed the highest insured unemployment rates in Massachusetts, Washington, and New Jersey, with the lowest rates found in South Dakota, Louisiana, and Florida. These figures represent historically low levels of claims, matching the volume seen in mid-July. Haver Analytics · 1w ago
Interviews
More →- Nvidia Spy Scandal, Nationwide Ground Stop Lifted, Starship’s Longest Test FlightAmidst a fragmented air traffic control failure attributed to legacy infrastructure and a global Microsoft outage, the Trump administration has requested $50 billion to modernize aviation systems while U.S. measles elimination status was revoked due to rising outbreaks. Simultaneously, the tech sector faces severe turbulence as NVIDIA's CEO resigns following national security concerns over Chinese intelligence ties, triggering a $2 trillion market drop and potential congressional testimony, while AI talent wars intensify with firms offering record signing bonuses. In other major developments, a stalled Starship test highlighted the challenges of reusable rocketry, and U.S. envoys proposed a contentious peace deal for Ukraine involving territorial concessions in exchange for security guarantees. Bloomberg Television · 7h ago
- Pointed! Bloomberg’s Weekly News Quiz For Risk-TakersChristina and her opponent competed in a three-category trivia quiz covering IPOs, movies, and M&A, using betting chips to wager on their accuracy before a tie-breaker in the M&A round determined the round's leader. While Christina successfully identified SpaceX's valuation and both participants tied on the Paramount studio question, the final Food and Beverage bonus round ended in a draw after neither guessed the $50 million Mars investment in True Fruit. The episode concluded with a dispute over a participant's alleged chip manipulation, leaving both contestants with a final overall tie. Bloomberg Television · 7h ago
- By The Way: Headlines You May Have MissedMedia coverage framed NVIDIA CEO Jensen Huang's high-value leather jacket and Microsoft's widespread systemic outage as cultural flashpoints that disrupted financial trading and forced a shift to legacy communication methods. Concurrently, the intense competition for artificial intelligence talent has driven corporations like OpenAI and Anthropic to offer signing bonuses up to $30,000 alongside luxury vacation incentives to secure a shrinking workforce. In the commercial travel sector, Frontier Airlines introduced a budget-friendly first-class fare at $129 that prioritizes legroom and power access while explicitly excluding traditional meal services. Bloomberg Television · 7h ago
- The Entrepreneurs Behind Poppi Start OverFollowing the near-$2 billion acquisition of their prebiotic soda brand Poppy by PepsiCo, founders Allison and Stephen Ellsworth have immediately launched Jetty, a self-funded beverage company targeting the general hydration market with low-sodium liquids and powders. Building on their decade-long bootstrapping experience and viral digital marketing success, the couple now prioritizes recruiting "driver" talent to address the gap for approachable everyday hydration rather than extreme sports formulas. This strategic pivot allows them to leverage their established distribution networks and team while adopting a new philosophy centered on delegating to A-plus advisors rather than solo management. Bloomberg Television · 7h ago
- Anthropic IPO Tests Investor Appetite for AIFAA routers overloaded within a legacy telecommunications network caused widespread flight delays, though operations have since returned to normal following emergency coordination with L3Harris Technologies and airlines. In a separate corporate governance crisis, Jensen Huang resigned as NVIDIA's CEO amid investigations into conduct violations and alleged export control breaches involving his relationship with Alice Huang, prompting Colette Kress to assume interim leadership. Simultaneously, AI firm Anthropic is proceeding with a historic IPO that will include a $10 billion investment from NVIDIA, even as analysts warn that the loss of Huang's leadership could destabilize the broader AI ecosystem. Bloomberg Television · 8h ago
- How China’s Intelligence Operations Target TechFormer CIA analyst Peter Mattis attributes the alleged ousting of NVIDIA CEO Jensen Huang to a sophisticated espionage campaign where the Chinese Ministry of State Security exploited a co-optee connected to the political elite to access strategic AI intelligence. This operation leverages China's 2017 Intelligence Law to recruit business figures through psychological levers like ego and coercion, targeting unclassified yet critical political and technological data across global hubs. Experts warn that the integration of AI into these efforts increases the sophistication of such campaigns, urging executives to establish strict boundaries against inquiries into cloud computing and US policy to mitigate existential risks. Bloomberg Television · 8h ago
- The Stadium Bidding War Shaking Up the MidwestFacing a 2033 lease expiration, the Chicago Bears are engaged in a high-stakes competition between Illinois and Indiana locations, where Indiana Governor Mitch Daniels and Hammond Mayor Tom McDermott advocate for a $5 billion facility backed by distinct tax incentives and state financial guarantees. This proposal aims to leverage stable property taxes and admissions levies to secure a projected $1.5 billion advantage over rival offers from Arlington Heights and a Soldier Field rebuild, creating a fiscal gap that Illinois must bridge to prevent the franchise's departure. As state officials debate the economic viability of public subsidies against critics' warnings of ego-driven spending, the outcome hinges on whether taxpayers will fund a venue designed to generate revenue far exceeding current local options. Bloomberg Television · 9h ago
- The $7B Startup Building AI Chips to Challenge Nvidia | Fractile Founder & CEO, Walter GoodwinFractal AI, led by founder Walter Goodwin, recently secured $720 million in Series C funding to reach a $7 billion valuation while deploying proprietary 3D stacked silicon designed to overcome the memory wall bottleneck in AI inference. By vertically integrating ML research and system engineering, the company offers specialized hardware that combines SRAM-level bandwidth with DRAM capacity, explicitly avoiding competition with customers by monetizing only the physical layer rather than internal models. With silicon currently passing fab trials and volume deployment expected imminently, Fractal aims to capture value in a future market defined by energy-constrained, long-context agent swarms rather than generic cloud orchestration. 20VC with Harry Stebbings · 9h ago
- Looking Beyond Tech’s Recent Market TurmoilThe event analyzes historical market resilience following CEO departures, highlighting that technology firms and the broader S&P 500 typically recover once leadership transitions occur. It critiques the erosion of corporate governance in the modern era, where boards often overlook reckless behavior by charismatic founders to protect short-term stock prices. Ultimately, the discussion emphasizes that no company is indispensable, urging investors to distinguish between data-driven analysis and speculative gambling on leadership stability. Bloomberg Television · 9h ago
- Bessent, Lutnick Clash Over Nvidia China CurbsTreasury Secretary Scott Besson and other senior officials have clashed with Commerce Secretary Howard Lutnick over the administration's failure to place Megaspeed and its leader Alice Huang on the restricted entity list despite intelligence linking the firm to Chinese espionage and the illegal diversion of NVIDIA chips. While Lutnick has resisted imposing immediate trade controls to preserve U.S.-China relations and protect export markets, critics argue this delay constitutes a critical national security breach that allows sensitive technology to reach adversaries. This internal policy split highlights deepening friction within the executive branch regarding China strategy, with reports suggesting that accountability mechanisms will likely escalate if these security compromises persist into the next congressional session. Bloomberg Television · 9h ago
- Nvidia Looks for a New Era After HuangJensen Huang resigned as NVIDIA's CEO following allegations of extramarital affairs and security risks involving a suspected Chinese spy, prompting an immediate 2% stock drop that lowered the company's market capitalization below $4 trillion. Interim CEO Colette Kress has assumed leadership while the board initiates a search for a permanent successor, a transition complicated by the absence of a designated second-in-command and ongoing congressional inquiries into Huang's influence on chip export policies. As the company prepares for testimony before US lawmakers, its long-term trajectory remains uncertain amidst global scrutiny over governance practices, family involvement, and strategic disagreements regarding access to the Chinese market. Bloomberg Television · 9h ago
- Couples Are Bringing AI Into Their ArgumentsJournalist Morgan Meeker's account of her husband treating ChatGPT as an emotional "third entity" illustrates a growing phenomenon where couples increasingly turn to AI for validation or conflict resolution, a trend noted by therapists and divorce lawyers. While some users employ these tools to role-play scenarios or refine messages to reduce defensiveness, experts warn that personifying AI can trigger jealousy and alter intimacy dynamics in ways distinct from previous digital distractions. As future technologies deepen AI's physical presence in daily life, society faces an ongoing challenge in balancing communication aids that supercharge relationships against those that risk acting as persistent barriers to genuine connection. Bloomberg Television · 10h ago
- David Cameron Sees Hope in Alzheimer’s ResearchFormer UK Prime Minister David Cameron and Senator Andy Kim recently joined the premiere of the "Ending Alzheimer's" podcast to discuss the accelerating global shift from viewing dementia as an inevitable aging process to a treatable disease with 190 active drug trials. The dialogue highlights breakthroughs in therapies targeting amyloid plaques and the imminent availability of cost-effective blood tests, while emphasizing the urgent need for governments to adopt pandemic-style recruitment strategies to address diagnosis gaps and high treatment costs. Despite these scientific advances, the event underscores persistent societal challenges, including the heavy financial burden on families and the necessity for expanded philanthropic support to fund basic research and NHS licensing. Bloomberg Television · 10h ago
- Ukraine Peace Push Turns to NATO and DonbasAmerican envoys Steve Witkoff and Jared Kushner presented a proposed peace framework to President Zelenskyy that trades potential NATO membership for Ukrainian concessions of the Donbas region, a move Zelenskyy rejected as requiring a public referendum despite European skepticism about the territory's size. While the US simultaneously shifts its Middle East strategy toward smaller, diffuse allied installations to mitigate Iranian threats, operational friction persists as Ukraine claims SpaceX Starlink outages are hindering its military momentum during a fifth-year conflict characterized by grinding attrition. The convergence of these diplomatic pressures and battlefield realities highlights the complex challenge of balancing immediate security guarantees with long-term sovereignty and global strategic realignment. Bloomberg Television · 10h ago
- “Bigger Than a Business Story”: Nvidia ShakeupFollowing allegations that an individual linked to Chinese intelligence engaged in an inappropriate relationship with former NVIDIA CEO Jensen Huang, the incident has sparked intense scrutiny regarding national security, intellectual property theft, and the administration's enforcement of export controls. While intelligence officials reportedly flagged the spy risk months in advance, the lack of a comprehensive Justice Department investigation and reports of empty U.S. embassies have led experts to question the efficacy of current foreign policy mechanisms and the administration's responsiveness to congressional pressure. Concurrently, the Trump administration's controversial tariff policies on Canada have drawn sharp criticism for violating trade agreements and burdening U.S. manufacturers, creating a complex geopolitical landscape where domestic political calculations intersect with eroding diplomatic standing among democratic allies. Bloomberg Television · 11h ago
- Nvidia’s Leadership Shakeup Tests AI Chip GiantFollowing CEO Jensen Huang's resignation due to an admitted affair, NVIDIA's board appointed interim CEO Colette Kress and permanent chairman Harvey Jones to stabilize governance and reassure investors. While Kress prepares to address market confidence during the upcoming earnings call, the leadership vacuum has created a strategic opening for competitors like Broadcom and AMD to capture attention in the AI sector. This sudden transition highlights broader industry concerns regarding the risks of relying on singular founders and exposes gaps in corporate oversight that necessitated the immediate appointment of new leadership. Bloomberg Television · 11h ago
- The Billion-Dollar Business of Virtual Public SchoolsFollowing the pandemic, virtual schooling in the United States has evolved into a primary educational choice, with Texas leading a rapid expansion dominated by the for-profit operator Stride, which controls 56% of the state's virtual schools and secured over $1 billion in taxpayer funds. New 2025 legislation has decoupled funding from student attendance and granted virtual institutions parity with brick-and-mortar schools, creating financial incentives that favor enrollment growth despite the state's largest virtual school reporting 14,000 truant students and reading proficiency rates as low as 26%. This legislative shift underscores a systemic divergence where major institutional investors and company profits continue to rise even as academic outcomes remain significantly below state averages. Bloomberg Television · 13h ago
- Jensen OUT as Nvidia CEO: "Spy" Scandal, Export Restrictions, Market ImpactFollowing allegations of an extramarital affair with a business partner linked to potential Chinese espionage, NVIDIA board members removed CEO Jensen Huang after a 33-year tenure, installing the CFO as interim leader while an investigation into the classified leak continues. This governance shift triggered a 15% stock decline and raised concerns that losing Huang's product vision could slow U.S. AI velocity while enabling legislative efforts to enforce strict government control over semiconductor hardware. Concurrently, the instability has heightened scrutiny on the broader AI sector, including a high-stakes IPO from rival Anthropic that aims to monetize rapid self-improving models despite safety contradictions and market volatility. All-In Podcast · 21h ago
- Secretary Mullin and Secretary Duffy Brief Members of the Press on the FAA Ground StopA nationwide air traffic control failure caused by overloaded legacy 1980s hardware forced the FAA to ground over 3,500 aircraft from 3:36 p.m. to 8:15 p.m. Eastern Time, though all flights landed safely without casualties. President Trump, citing the incident as a critical national security risk caused by aging infrastructure, has declared a national emergency to secure $50 billion in congressional funding for a complete system overhaul. While investigators have ruled out cyber attacks, the event has accelerated calls for modernization as the agency manages a gradual return to full operational capacity for the upcoming Thanksgiving travel period. The White House · 21h ago
- All Airports Are Ground Stopped Until Further Notice: FAAThe Federal Aviation Administration imposed a nationwide ground stop on U.S. airports following a critical telecommunication outage that halted all takeoffs while federal officials confirmed no evidence of a cyber attack or terrorism threat. Although the White House launched a whole-of-government investigation into whether the failure stems from legacy infrastructure or recent AI upgrades, the disruption has triggered significant market volatility, stranded passengers, and renewed political pressure for $30 billion in air traffic control modernization funding. Amidst the aviation paralysis, a SpaceX Starship launch proceeded successfully with stage separation, though the mission failed to catch the booster on the launch tower. Bloomberg Television · 1d ago
- Nvidia’s Board CEO Hunt, Stocks Finish Week Higher, Retail in FocusAmid a significant sector rotation driven by NVIDIA's sudden leadership crisis and a 13% weekly stock drop, investors shifted capital from high-beta technology to defensive energy and consumer staples while the broader S&P 500 declined only marginally. This market volatility coincided with hawkish Federal Reserve commentary suggesting further rate hikes and a surging 42% federal budget deficit that experts warn exacerbates inflationary pressures. Simultaneously, corporate disruptions including a major Microsoft outage and geopolitical oil price spikes underscored emerging supply chain fragilities even as the AI sector anticipated the upcoming Nvidia earnings and Anthropic's potential IPO. Bloomberg Television · 1d ago
- LaHood Says Antiquated FAA System Likely FailedSecretary of Transportation Duffy has unilaterally ordered a nationwide FAA ground stop from Virginia to manage a system shutdown that is expected to delay flights for at least 48 hours. Former Secretary Ray LaHood attributes the crisis to antiquated infrastructure rather than recent modernization efforts, characterizing the event as a national calamity that impacts major sectors including travel and sports. While airport staff across the country have been recalled to handle the emergency and ensure safe landings for aircraft still in flight, travelers are being advised to secure lodging and alternative transportation options. Bloomberg Television · 1d ago
- SpaceX Starship Launches on Flight TestSpaceX's Starship Flight 15 successfully achieved separation and reached spaceflight conditions despite scrubbing the planned tower catch of the Super Heavy booster, which ultimately performed an offshore splashdown in the Gulf of Mexico. Following the vehicle's lift-off with nominal engine performance and a hot staging event, the upper stage operated six Raptor engines for four and a half minutes before the mission's financial impact saw shares dip due to the incomplete booster recovery. While the booster's landing was marked by a sonic boom and on-site reports of an explosion, SpaceX plans to attempt catching the spacecraft stage via the tower chopsticks system approximately 23 hours post-launch as part of its ongoing development for lunar and Mars missions. Bloomberg Television · 1d ago
- Ground Stop Fix Will 'Take Some Time,' Mullin SaysSecretary of Homeland Security Mark Wayne Mullen declared a nationwide ground stop caused by a severe telecommunication outage while confirming that no nefarious acts or 9/11-like attacks are currently indicated. An all-of-government investigation involving the FAA, CISA, and the White House is actively examining causes ranging from routine technical failures to potential cyber intrusions or AI errors linked to new traffic control systems. Although flights currently in the air remain authorized to land, officials warn that resolving the crisis and restoring full communications will require significant time beyond the initially circulating estimates. Bloomberg Television · 1d ago
- Jensen Huang Scandal Fallout GrowsFollowing Jensen Huang's resignation amid ethical misconduct and potential legal scrutiny, NVIDIA's stock plummeted while the board considers ARM CEO Rene Haas as a successor, triggering geopolitical uncertainty in South Korea and marking the sector's worst weekly performance in over 18 months. Simultaneously, a massive Microsoft cloud outage exposed systemic fragilities in global infrastructure, yet analysts maintain bullish outlooks for the AI trade by emphasizing diversified semiconductor ecosystems and robust corporate balance sheets. Despite near-term volatility from these leadership crises and operational failures, major institutions like Goldman Sachs continue to predict S&P 500 gains driven by hyperscaler demand and upcoming catalysts such as the Anthropix IPO. Bloomberg Television · 1d ago
- Centers for Disease Control and Prevention Director Erica Schwartz | Future of Health Summit 2026CDC Director Dr. Mandy Schwartz addresses mounting measles outbreaks threatening US elimination status by coordinating over $100 million in federal support while simultaneously prioritizing the restoration of public trust through transparent dialogue and a strategic 2027 hiring plan. Despite ongoing leadership tensions with Secretary Robert Kennedy, the agency is deploying advanced surveillance tools to monitor domestic respiratory trends and managing a high-fatality Ebola crisis in the Democratic Republic of Congo with improved contact tracing. These coordinated efforts aim to stabilize internal institutional morale and guide evidence-based policy decisions regarding vaccination mandates and bio-threat detection across global and local fronts. Milken Institute · 1d ago
- Inside Jensen Huang’s Last Hours as Nvidia CEONVIDIA's board forced CEO Jensen Huang to resign following a confirmed internal policy violation involving a workplace affair, overriding his attempts to retain his position through personal apologies. While Huang faces immediate legal scrutiny and potential Congressional testimony, the company's leadership transition is being managed by CFO Colette Kress amid concerns over replicating the late CEO's critical global supply chain relationships. Despite the loss of Huang's charismatic frontman role, market analysts maintain a bullish outlook on NVIDIA's future, arguing that the firm's dominance relies on its engineering team's technical superiority rather than individual leadership. Bloomberg Television · 1d ago
- Stocks End Week Higher Amid Tech Turmoil | Closing BellDespite a mixed market close driven by a 1.7% technology sector decline and NVIDIA's 13% weekly drop, energy stocks rallied on oil price rebounds and financials posted gains. Individual performers highlighted extreme volatility, ranging from Modine's 27% surge on acquisition rumors to Virgin Galactic's 31% plunge following a flight delay, while an unprecedented nationwide FAA ground stop disrupted air travel and weighed on airline equities. Macroeconomic outlooks further complicated the landscape as Boston Fed President Susan Collins signaled potential rate hikes to combat persistent inflation, even as the Federal Reserve prepares for an upcoming meeting focused on longer-term issues. Bloomberg Television · 1d ago
- How Will Higher-than-Expected Inflation Data Impact the Fed's Next Rate Decisions?Recent CPI data exceeding 0.3% has compelled the Federal Reserve to consider 50 basis point rate hikes, forcing markets to unwind approximately 50 basis points of pricing despite oil's limited direct influence on the broader sell-off. While yields are unlikely to revisit October's 5.3% peak due to self-balancing mechanisms linked to AI capital expenditure, investors are navigating volatility through convexity selling and heightened geopolitical risks. Current strategy favors maintaining exposure to mega-cap technology while utilizing out-of-the-money put options to hedge against funding cost pressures on leveraged corporations. Goldman Sachs · 1d ago
- Lutnick Under Fire in Nvidia CrisisU.S. House and Senate committees have scheduled closed-door testimonies from NVIDIA CEO Jensen Huang and Commerce Secretary Howard Lutnick regarding alleged illicit chip transfers to China that threaten national security. As bipartisan anger intensifies over the scandal, potential leadership changes at NVIDIA and market declines in semiconductor stocks highlight the escalating geopolitical and corporate fallout. Experts warn that unauthorized technology exports could accelerate China's AI and quantum capabilities, complicating upcoming diplomatic negotiations while raising domestic political stakes for the administration. Bloomberg Television · 1d ago
Earnings Releases
By sector →- TPSTNov 13, 5:27 PMTempest Therapeutics reported a net loss of $3.6 million for the third quarter of 2026, with cash and cash equivalents declining to $0.9 million from $7.7 million at the end of 2025. The company secured exclusive licensing rights to Senlang's CD7-targeted lentiviral in vivo CAR-T platform and its lead candidate TPST-4903, while also advancing its next-generation candidate TPST-4003. To support operations, Tempest completed a private placement raising approximately $2.5 million and entered into an equity line of credit with Lincoln Park Capital Fund for up to $50.0 million. Additionally, the Board of Directors was strengthened by the appointments of Nancy Freda-Smith and John W. Frederick, though the company noted substantial doubt regarding its ability to continue as a going concern due to limited cash reserves.Healthcare
- BYSINov 13, 5:27 PMBeyondSpring Inc. reported a net loss of $2.1 million for the third quarter ended September 30, 2026, driven by increased research and development and general and administrative expenses. The company received FDA Fast Track designation for its lead candidate Plinabulin combined with docetaxel in patients with post-immunotherapy non-squamous non-small cell lung cancer lacking actionable genomic alterations. A strategic transaction with Biolin Investment Limited was completed to fund approximately half of the DUBLIN-4 Phase 3 trial's patient enrollment in China, providing BeyondSpring with access to the resulting clinical data. As of September 30, 2026, the company held $0.6 million in cash, cash equivalents, and short-term investments.Healthcare
- BCICNov 13, 5:26 PMBCP Investment Corporation reported third-quarter 2026 net investment income of $4.6 million, or $0.37 per share, with a net asset value of $162.7 million as of September 30, 2026. The company announced a merger agreement to acquire Investcorp Credit Management BDC, Inc. at 90% of ICMB's closing net asset value, a transaction expected to be accretive to shareholders. Non-accrual debt investments declined to 10, representing 2.8% of the portfolio at fair value, while the company increased its KeyBank Credit Facility capacity to $150 million and issued $10 million in additional notes due 2029. Additionally, BCP declared monthly base distributions of $0.09 per share for January, February, and March 2027.Financial Services
- CINGNov 13, 5:19 PMCingulate Inc. reported a net loss of $7.7 million for the third quarter of 2026, driven primarily by increased selling, general, and administrative expenses related to commercial readiness. The company has substantially completed manufacturing work to address FDA requests for its CTx-1301 ADHD drug application and expects to resubmit the new drug application between December 2026 and January 2027. As of September 30, 2026, Cingulate held approximately $23.2 million in cash and cash equivalents, which is projected to fund operations through mid-2027.Healthcare
- CTNTNov 13, 5:16 PMCheetah Net Supply Chain Service Inc. reported total revenue of $3.56 million for the third quarter of 2026, an 883% increase from the prior year period, driven primarily by its international trading segment following the May 2026 acquisition of Super International Trading Limited. The company recorded a net loss from continuing operations of $2.55 million for the quarter, a 93.8% increase compared to the same period in 2025, largely due to a $2.78 million loss from changes in the fair value of acquisition-related contingent consideration. For the nine months ended September 30, 2026, the company posted a net loss of $3.09 million while maintaining a cash and cash equivalent balance of approximately $14.5 million and a working capital balance of $87.1 million.Consumer Cyclical
- WFCFNov 13, 5:14 PMWhere Food Comes From, Inc. reported third-quarter 2026 total revenue of $7.3 million, a 4% increase from the prior year, driven by a 6% rise in verification and certification services to $5.9 million. Gross margins improved to 42.1% from 38.3% in the same period last year, resulting in operating income of $1.0 million, a 68% year-over-year increase. Net income for the quarter was $825,000, or $0.17 per diluted share, compared to $1.1 million in the prior year, as the previous period included a $946,000 gain on the sale of assets. Over the nine-month period ended September 30, 2026, the company generated $2.8 million in cash from operations and returned $268,000 to shareholders through stock buybacks.Technology
- BBGINov 13, 5:06 PMBeasley Broadcast Group reported third-quarter 2026 net revenue of $42.8 million, a 16.1% decrease from the prior year period, driven by weakness in traditional advertising markets. The company posted a net loss of $12.1 million for the quarter, though it achieved a 32% operating margin in its digital segment, up from 21% in the previous year. To strengthen its balance sheet, the company raised $4.6 million through equity offerings and subsequently sold two radio stations and two real estate parcels for over $10 million. Structural cost reductions helped limit the decline in operating expenses, while same-station digital revenue increased 4.4% on a year-to-date basis.Communication Services
- HITNov 13, 5:05 PMHealth In Tech reported a net loss of $7.1 million for the third quarter of 2026, driven by a $5.3 million provision for credit losses, compared to a net income of $0.5 million in the same period the prior year. The company's contracted revenue totaled $32.7 million for the first nine months of 2026, while pipeline revenue reached $156.4 million as of October 30, 2026. Distribution partners grew 15.9% year over year to 984, and the company revised its full-year 2026 revenue outlook to approximately $30 million. Sanjay Shrestha assumed the role of Chief Executive Officer in October 2026 to lead commercial execution and strategic growth initiatives.Technology
- XAIRNov 13, 5:00 PMBeyond Air reported a record quarterly revenue of $2.3 million for the period ended September 30, 2026, marking a 28% year-over-year increase. The company reaffirmed its full-year 2026 revenue guidance of $8 million and its 2027 guidance of $16 million to $18 million, contingent on FDA approval for its second-generation LungFit PH system. During the quarter, the company incurred a net loss of $7.8 million, or $3.76 per share, while maintaining $18.5 million in cash and equivalents. Additionally, Beyond Air announced the sale of its controlling interest in NeuroNOS Israel Ltd. and received FDA Breakthrough Device Designation for its LungFit GO product.Healthcare
- EVFMNov 13, 4:59 PMEvofem Biosciences reported net sales of $4.6 million for the third quarter of 2026, a decrease from $5.0 million in the prior year period, primarily due to lower ex-factory sales of PHEXX. The company generated $0.7 million in operating income and $0.9 million in net income attributable to common stockholders for the quarter, contrasting with a net loss in the same period of 2025. Strategic milestones achieved since July 2026 include contracting a second manufacturer for PHEXX production, shipping the 500,000th box of PHEXX, and adding a fifth site to an NIH-funded Phase 4 clinical trial for SOLOSEC. As of September 30, 2026, restricted cash and cash equivalents stood at $0.3 million, reflecting the company's ongoing liquidity position.Healthcare
- SRGNov 13, 4:51 PMSeritage Growth Properties reported a net loss of $36.2 million for the nine months ended September 30, 2026, driven by a $15.2 million impairment charge on a consolidated property and a $5.2 million impairment on an unconsolidated entity. During the third quarter, the company generated $3.0 million in gross proceeds from asset sales and received $8.9 million in distributions from an unconsolidated entity. As of September 30, 2026, the company held $45.4 million in cash and had $10.0 million available under its new revolving loan facility, which was established in July 2026 to refinance a prior term loan. The company's portfolio consists of eight properties with a total of approximately 0.7 million square feet of gross leasable area and 133 acres of land.Real Estate
- CNSYNov 13, 4:51 PMCerenome, Inc. reported third-quarter 2026 financial results showing $0.7 million in net diagnostic revenue and an operating loss of $7.5 million. The company expanded its payer coverage to approximately 190 million lives and launched CNSide molecular profiling tests for solid tumors and hematologic malignancies in October. Clinically, enrollment was completed in the Phase 2 ReSPECT-GBM trial for recurrent glioblastoma, while interim data from the ReSPECT-LM multi-dose study demonstrated safety with no dose-limiting toxicities. As of September 30, 2026, the company held $4.9 million in cash and investments, having recently secured a senior secured financing facility and raised additional equity.Healthcare
- NYCNov 13, 4:49 PMAmerican Strategic Investment Co. reported a net loss of $6.7 million for the third quarter of 2026, a significant decline from the $35.8 million net income recorded in the same period of 2025 due to the absence of a prior-year property disposition gain. Revenue for the quarter fell to $7.1 million from $12.3 million in 2025, primarily driven by the sale of 1140 Avenue of the Americas in the previous year. The company's portfolio, now consisting of five properties with a 74.0% occupancy rate, generated $3.5 million in cash net operating income and maintained a weighted-average remaining lease term of 6.0 years. Following the quarter, the company secured an extension and expansion lease with the State of New York at 123 William Street, increasing pro-forma occupancy at that location to approximately 75%.Real Estate
- FEMYNov 13, 4:47 PMFemasys Inc. announced a $30 million private placement in mid-August 2026 to fund U.S. commercial team expansion and the FemBloc pivotal trial. For the quarter ended September 30, 2026, U.S. sales rose slightly to $347,039, while total sales declined 44.5% to $404,597 due to timing of international distributor orders. The company reported a net loss of $4,564,815 for the quarter and $8,187,810 for the nine-month period, with cash and cash equivalents reaching approximately $23.9 million by September 30.Healthcare
- NXPLNov 13, 4:47 PMNextPlat Corp reported third-quarter 2026 consolidated revenue of approximately $10.5 million, a decrease from $13.8 million in the prior year period, driven by lower reimbursement rates and reduced retail prescription volumes. Despite the revenue decline, the company achieved a consolidated gross margin of 35.0%, a significant improvement from 19.9% in the same period last year, largely due to a 300% increase in pharmacy contract revenue. Net loss attributable to common stockholders narrowed by 66% to approximately $0.7 million, or $0.28 per diluted share, compared to $2.2 million in the prior year. The company ended the quarter with $11.2 million in cash and noted a 72% year-over-year growth in higher-margin 340B prescription volumes.Technology
- Nov 13, 4:41 PMThe Fidelity Private Credit Fund targets senior secured loans to private equity-owned middle-market companies, maintaining a weighted average loan-to-value of 39% and net leverage of 4.7 times as of September 30, 2026. The fund's investment strategy emphasizes disciplined underwriting and strong documentation to navigate an environment characterized by rising interest rates and increased credit dispersion among borrowers. Performance data indicates a year-to-date total net return of 4.52% for Class I shares, with a distribution rate of 9.36% calculated on the net asset value. The portfolio is heavily concentrated in floating-rate investments at 99.8%, with top holdings including Project Fractal in aerospace, Project METIS in healthcare services, and Project Sentinel in industrial distribution.
- AIRTNov 13, 4:35 PMAir T, Inc. reported second-quarter fiscal 2027 revenues of $146.9 million, a 129% increase from the prior year, driven largely by the inclusion of Regional Express Holdings Pty Ltd acquired in December 2025. The company posted an operating loss of $11.8 million and a net loss per share of $7.48, contrasting with the prior year's operating income and net income per share. Adjusted EBITDA declined to $4.4 million from $7.9 million in the previous year, impacted by significant fuel cost increases and unscheduled engine removals at the Regional Airline segment. Despite challenges in the newly acquired Rex unit, other segments such as Overnight Air Cargo and Ground Support Equipment contributed positively to the quarter's financial performance.Industrials
- CLDINov 13, 4:35 PMCalidi Biotherapeutics reported a net loss of $3.6 million for the third quarter of 2026, a significant improvement from the $10.8 million loss in the same period of 2025. The company advanced its lead candidate CLD-401, presenting preclinical data at the ESMO Congress 2026 that demonstrated complete tumor eradication in 80% of mice in breast cancer models. General and administrative expenses decreased by 39% to $1.6 million as the firm executed a restructuring plan to extend its cash runway. Additionally, Calidi raised $1.2 million through an at-the-market registered direct offering and ended the quarter with $3.9 million in cash.Healthcare
- NWTGNov 13, 4:31 PMNewton Golf Company reported a net loss of $1.2 million for the third quarter of 2026, driven by a 47% decline in net sales to $1.4 million due to reduced marketing activity. The company expanded its 2.0 shaft rollout with over 80 professional golfers using its products and grew its fitter network to approximately 301 accounts. Following the quarter, Newton raised approximately $3.0 million through equity financings and converted $1.0 million of debt into equity, resulting in a pro forma stockholders' equity of $5.2 million. Despite these liquidity improvements, the company faces Nasdaq compliance concerns regarding its minimum equity requirement and anticipates needing additional financing to continue operations.Consumer Cyclical
- PEDNov 13, 4:31 PMPEDEVCO Corp. reported a net loss of $9.2 million for the third quarter of 2026, driven by a $16.6 million net loss on derivative contracts that offset higher operating income from an expanded asset base. Average daily production surged 298% year-over-year to 5,850 barrels of oil equivalent per day following the October 2025 merger with Juniper Capital Advisors, while revenue increased 411% to $35.5 million. Adjusted EBITDA rose 239% to $14.7 million, reflecting increased production volumes and a 31% rise in the average realized oil price to $83.81 per barrel. The company updated its full-year 2026 net capital expenditure guidance to a range of $37 million to $42 million and reiterated its Adjusted EBITDA guidance of $60 million to $70 million.Energy
- VUZINov 13, 4:30 PMVuzix Corporation reported third-quarter 2026 total revenues of $0.7 million, a 38% decrease from the same period in 2025, driven by a 45% decline in product sales. The company recorded a net loss of $8.4 million, or $0.10 per share, compared to a $7.4 million loss in the prior year quarter. Strategic progress includes the shipment of evaluation samples for the Causeway optical interconnect platform to over 10 companies and the delivery of the SHRIKE Defense Display Platform for customer evaluation. Additionally, Vuzix secured nearly $1.0 million in new OEM defense orders and completed facility upgrades at its Rochester waveguide manufacturing site.Technology
- NVVENov 13, 4:30 PMNuvve Holding Corp. reported third-quarter 2026 total revenues of $1.09 million, a 31.9% decrease from the same period in 2025, driven by lower product sales and service revenue. The company recorded a net loss of $4.7 million for the quarter, with gross profit margins declining to 24.0% from 52.0% in the prior year due to higher warranty costs and project write-downs. Despite the revenue decline, Nuvve raised $0.97 million in gross proceeds through debt and equity instruments to support operations, while megawatts under management increased by 5.7% to 29.9 megawatts.Consumer Cyclical
- INDPNov 13, 4:30 PMIndaptus Therapeutics reported a net loss of $1.0 million for the third quarter of 2026, a significant decrease from $3.0 million in the same period of 2025, driven by reduced research and development and general administrative expenses. The company completed a private placement in September 2026, raising approximately $24.0 million in gross proceeds to fund working capital and early-stage research into a neurotechnology device for sleep-related conditions. As of September 30, 2026, Indaptus held $30.6 million in cash, cash equivalents, and short-term investments, providing sufficient liquidity to support its anticipated operating expenses. The company also announced a strategic shift away from its Decoy20 clinical program to focus on new opportunities with long-term potential.Healthcare
- IRLANov 13, 4:30 PMIRulya Therapeutics Inc., formerly Quince Therapeutics, reported a net loss of $27.7 million for the third quarter ended September 30, 2026, while maintaining a cash position of $105.2 million expected to fund operations through 2028. The company relaunched with a new name and ticker symbol IRLA, appointing a new leadership team and board of directors to focus on its lead candidate, LAM-001. Clinical progress includes a fully enrolled Phase 2 trial for bronchiolitis obliterans syndrome (BOS) with data anticipated in early 2027, an ongoing Phase 2b trial for pulmonary hypertension associated with interstitial lung disease (PH-ILD), and a planned Phase 2 study for sarcoidosis-associated pulmonary hypertension (SAPH) to begin in late 2026.Healthcare
- BOCNov 13, 4:29 PMBoston Omaha Corporation reported a net loss attributable to common stockholders of $192,000 for the third quarter of 2026, compared to a loss of $2.588 million in the same period the previous year. Total revenues for the quarter reached $22.178 million, driven by billboard rentals and broadband services, while net other expense was recorded at $3.611 million due primarily to fair value changes in investment funds. The company repurchased 457,308 shares of its Class A common stock for $6.4 million during the quarter and subsequently increased its share repurchase program authorization from $30 million to $85 million. As of September 30, 2026, the company held $29.743 million in unrestricted cash and investments with a book value per share of $16.64.Communication Services
- ANVSNov 13, 4:24 PMAnnovis Bio, Inc. reported third-quarter 2026 financial results showing cash and cash equivalents of $2.8 million and a net loss of $9.5 million. The company raised $21.0 million in gross proceeds through an underwritten public offering to fund operations through the March 2027 data readout for its Phase 3 DUET-AD Alzheimer's study. Clinical progress includes full enrollment of 862 patients in the DUET-AD trial and 326 patients in the Parkinson's open-label extension study. Upcoming milestones include the last patient visit for the 6-month treatment period on December 31, 2026, and a planned database lock on February 8, 2027.Healthcare
- ASTCNov 13, 4:20 PMAstrotech Corporation reported a net loss of $2.948 million for the first quarter of fiscal year 2027, ending September 30, 2026, compared to a loss of $3.465 million in the same period the prior year. Total operating expenses decreased by 15.7% to $3.1 million, driven primarily by a reduction in research and development costs, while revenue declined slightly to $274,000. As of the quarter's end, the company maintained $11.6 million in working capital and had deployed its TRACER 1000 technology in approximately 38 locations across 17 countries. Additionally, Astrotech submitted a proposal to NASA under the NextSTEP-3 LEIA program to advance its Mobile Power System for lunar infrastructure applications.Industrials
- GXAINov 13, 4:17 PMGaxos.ai Inc. reported third-quarter 2026 consolidated revenue of approximately $2.81 million, representing a 14.5% increase from the second quarter and a 464.9% increase from the same period in 2025. During the quarter, advertising and marketing expenses decreased by 16.7% to $2.62 million, resulting in an improved revenue generation of $1.08 per advertising dollar, a 38% improvement over the previous quarter. The company held cash and short-term investments of $13.30 million as of September 30, 2026, and issued 3,007,654 shares of common stock following warrant exercises. Gaxos plans to focus on increasing recurring revenue, improving customer acquisition efficiency, and scaling products with favorable contribution economics for the remainder of 2026.Communication Services
- FIEENov 13, 4:16 PMFiEE, Inc. reported a 382.1% year-over-year revenue increase to approximately $9.6 million for the nine months ended September 30, 2026, driven by its strategic transition to SaaS solutions and phygital art advisory services. The company achieved a net income of $3.6 million for the period, marking a significant turnaround from a net loss of $1.3 million in the same timeframe the previous year. Revenue growth was primarily fueled by SaaS-MCN digital services, software services, and new phygital art advisory offerings, which generated $3.5 million in revenue compared to zero in 2025. Additionally, the company onboarded 939 customers for its SaaS-MCN services and secured $4.1 million in contracts for software services as of September 30, 2026.Technology
- MEDSNov 13, 4:15 PMDataMEDS AI reported a 50% sequential revenue increase to $2.7 million for the third quarter of 2026, driven primarily by growth in its Corexa Pharmacy drug dispensing operations. The company achieved a net profit of $10.535 million, resulting in a net profit per share of $2.72, a significant turnaround from the net loss recorded in the same period the previous year. Key business developments included the launch of the Health Lives Here mobile app, an exclusive license for the REBOOT GLP-1 patient management platform, and the acquisition of Helomics cancer diagnostics laboratory. Additionally, the company regained full compliance with Nasdaq listing standards and secured a memorandum of understanding with an HMO to deploy its mobile application to over 25,000 members.Consumer Defensive
- AVEXNov 13, 4:15 PMAEVEX Corp. reported third-quarter 2026 total revenue of $189.7 million, a 56.5% increase from the prior year period, driven primarily by growth in its Airborne Systems segment and the recent acquisition of BlackSea Technologies. The company posted a net loss of $16.8 million for the quarter, contrasting with a net income of $9.9 million in the same period last year, while Adjusted EBITDA rose to $30.8 million. Following the establishment of Maritime Systems as a new reportable segment, AEVEX raised its full-year 2026 revenue outlook to a range of $820.0 million to $840.0 million and Adjusted EBITDA guidance to $128.0 million to $132.0 million.Industrials
- ECTMNov 13, 4:14 PMECA Marcellus Trust I announced a quarterly distribution of $0.021 per unit for the period ended September 30, 2026, payable on or before November 30, 2026, to holders of record as of November 23, 2026. The trustee is withholding approximately $90,000 from this quarter's distribution to build a cash reserve toward a target of $3.8 million, which is intended to cover future known, anticipated, or contingent expenses. The trust holds royalty interests in natural gas properties in the Marcellus Shale formation in Greene County, Pennsylvania, and its distributions fluctuate based on production proceeds, commodity prices, and administrative costs. Non-U.S. persons may be subject to withholding taxes on income effectively connected to a U.S. trade or business or on fixed, determinable, annual, periodic income from U.S. sources.Energy
- ICMBNov 13, 4:11 PMInvestcorp Credit Management BDC, Inc. reported a net asset value per share of $3.02 as of September 30, 2026, representing a decrease of $0.42 from the previous quarter. The company recorded a net investment loss before taxes of $1.8 million and a total net decrease in net assets from operations of $4.8 million for the three-month period. During the quarter, the investment adviser waived all management fees and $0.2 million of previously accrued incentive fees, while the weighted average yield on debt investments fell to 9.53%. Subsequent to the quarter end, the company received $11.5 million in repayments and repaid $10.0 million of outstanding borrowings under its revolving credit facility.Financial Services
- ROLRNov 13, 4:10 PMHigh Roller Technologies reported a net loss of $2.8 million for the third quarter of 2026, driven by a 51% decline in net revenues to $2.4 million as the company exited certain online casino markets. Despite lower revenue, the company maintained a strong liquidity position with $13.4 million in cash and no outstanding borrowings at the end of the quarter. The firm commercially launched its ROLR prediction markets platform on October 21, 2026, and released its iOS application in November, aiming to establish prediction markets as a primary growth driver in 2027.Consumer Cyclical
- BYFCNov 13, 4:10 PMBroadway Financial Corporation reported net income attributable to common stockholders of $392 thousand for the third quarter of 2026, a significant improvement from the $24.6 million net loss recorded in the same period of 2025. During the first nine months of 2026, the company achieved consolidated net income of $1.0 million, driven by an 11.4% increase in net loans and a 21.0% rise in total deposits. The bank maintained stable credit quality with non-accrual loans representing 1.20% of gross loans and reported a strong Community Bank Leverage Ratio of 12.83% as of September 30, 2026.Financial Services
- FFRNov 13, 4:10 PMFF EAI Robotics Ecosystem Inc. completed the acquisition of Faraday Future's robotics business on October 23, 2026, transforming into a pure-play humanoid and bionic Physical AI robotics company. For the nine months ended September 30, 2026, the acquired robotics business generated approximately $2.3 million in standalone revenue with a gross margin of 26%, entering the company with no outstanding debt. The company has advanced its Four-Core Full-Stack AI ecosystem, introducing the FF OmniMind brain platform which ranked first on the RoboColiseum benchmark, and achieved a record 351 robot shipments in October. Looking ahead, FFR plans to launch a 100-city robotics education initiative, introduce its Physical Cloud technology platform during CES, and begin domestic factory production in the first quarter of 2027.Technology
- VTGNNov 13, 4:08 PMVistagen Therapeutics reported a net loss of $10.7 million for the second quarter of fiscal year 2027, ending September 30, 2026, with cash and marketable securities totaling $20.0 million. The company received constructive feedback from the FDA regarding its Phase 3 development plan for fasedienol in social anxiety disorder, which will now focus on overall treatment rather than just acute management. Preliminary data from the open-label extension of the PALISADE-4 study showed clinically relevant improvements in social anxiety over four months. Additionally, Vistagen appointed Douglas J. Williamson, MD, to its board and implemented cost-management initiatives to extend its operating runway into 2027.Healthcare
- INBXNov 13, 4:08 PMInhibrx Biosciences reported a net loss of $38.7 million for the third quarter of 2026, driven by $26.0 million in research and development expenses and $7.8 million in general and administrative costs. The company recognized $2.0 million in revenue from a non-exclusive license agreement with Pfizer, while cash and cash equivalents increased to $199.5 million as of September 30, 2026. Clinical milestones include upcoming data presentations for ozekibart in Ewing sarcoma and the ongoing enrollment of ordastobart in head and neck squamous cell carcinoma. Additionally, the company is advancing commercial readiness activities for ozekibart in chondrosarcoma while preparing for a potential Biologics License Application.Healthcare
- OPRXNov 13, 4:06 PMOptimizeRx reported third-quarter 2026 revenue of $21.6 million, a 17% decrease from the prior year, while achieving a net income of $1.2 million and adjusted EBITDA of $6.3 million. The company updated its full-year 2026 revenue guidance to a range of $87 million to $93 million, though adjusted EBITDA guidance remains unchanged at $21 million to $25 million. Since June 30, 2026, OptimizeRx repaid $9.3 million in debt principal, reducing its outstanding principal balance to $10.4 million. Management cited margin expansion and cost management as drivers for the 23% year-over-year increase in adjusted EBITDA despite the revenue decline.Healthcare
- BJDXNov 13, 4:05 PMBluejay Diagnostics completed enrollment in its SYMON-II clinical validation study with 777 evaluable patients, exceeding the original target of 750. The company established an alternative manufacturing facility ahead of a contractual deadline and advanced U.S. commercial infrastructure through new distribution agreements. As of September 30, 2026, the company held $7.38 million in cash and projects these resources will sustain operations through the second quarter of 2027. Bluejay aims to submit an FDA 510(k) application for its Symphony IL-6 test during the first half of 2027.Healthcare
- TXMDNov 13, 4:05 PMTherapeuticsMD, Inc. reported net income from continuing operations of $501 thousand, or $0.04 per share, for the third quarter of 2026, an increase from $50 thousand in the same period of 2025. License revenues rose to $1.3 million, driven by a $365 thousand milestone payment from Knight related to IMVEXXY sales for the year ended December 31, 2025. Total operating expenses increased by 5.6% to $1.7 million, primarily due to higher legal and professional fees. As of September 30, 2026, the company held $10.4 million in cash and cash equivalents while continuing to evaluate strategic alternatives such as a potential acquisition or merger.Healthcare
- CRISNov 13, 4:05 PMCuris, Inc. reported a net loss of $8.1 million for the third quarter of 2026, with no revenue generated due to the prior sale of Erivedge royalties. The company is currently enrolling patients in two ongoing studies, the TakeAim CLL study and the TakeAim Lymphoma study, which evaluate emavusertib in combination with BTK inhibitors. Clinical data from the TakeAim Lymphoma study showed objective response rates of 100% for BTK-naïve patients and 33% for BTKi-experienced patients as of July 2026. Financially, Curis held $5.0 million in cash and cash equivalents as of September 30, 2026, and expects its existing resources combined with recent private placement proceeds to fund operations into the first quarter of 2027.Healthcare
- SEVNov 13, 4:05 PMAptera Motors reported a GAAP net loss of $14.0 million for the third quarter of 2026 and $35.0 million for the first nine months of the year. The company raised approximately $6.0 million in gross proceeds during the quarter through a warrant inducement transaction and entered a strategic partnership with Shanghai Launch Automotive Technology to support manufacturing. As of September 30, 2026, Aptera held $9.2 million in cash and cash equivalents, including $4.1 million in refundable reservation fees, while maintaining over 49,000 vehicle reservations. Management estimates a need for approximately $25 million to reach start of production and $65 million to achieve a production rate of 500 vehicles per month.Consumer Cyclical
- ENVBNov 13, 4:05 PMEnveric Biosciences reported a net loss of $2.5 million for the third quarter ended September 30, 2026, with cash-on-hand totaling $5.6 million. The company advanced final IND-enabling activities for its lead candidate EB-003, a non-hallucinogenic neuroplastogenic therapeutic, supported by preclinical data showing brain penetration and a distinct activity profile compared to DMT. Recent in vitro studies confirmed favorable absorption and metabolic properties with a reduced potential for drug-drug interactions, while independent assays reinforced the compound's predicted non-hallucinogenic profile. Additionally, Enveric secured a U.S. patent allowance for next-generation non-hallucinogenic mescaline derivatives in its EVM401 series.Healthcare
- TRXBNov 13, 4:04 PMTRexBio reported a net loss of $13.2 million for the third quarter of 2026, driven by increased research and development expenses related to its TRB-061 and TRB-071 programs. The company announced positive Phase 1a results for TRB-061, an investigational TNFR2 agonist for atopic dermatitis, which demonstrated proof of mechanism and safety in healthy volunteers. TRexBio completed a $133.5 million initial public offering in October 2026, extending its cash runway into the second half of 2029. Topline data for the Phase 1b trial of TRB-061 is expected in mid-2027, while a Phase 1 trial for the CD30 agonist TRB-071 is anticipated to begin in the first half of 2027.Healthcare
- WSBFNov 13, 4:00 PMWaterstone Financial, Inc. reported net income of $6.2 million, or $0.36 per diluted share, for the quarter ended September 30, 2026, a decrease from $7.9 million in the same period of 2025. The Community Banking segment achieved record quarterly net interest income of $16.0 million, driven by a reduction in the average cost of funds, while the Mortgage Banking segment recorded a pre-tax loss of $754,000 due to elevated mortgage rates and compressed sales margins. Consolidated return on average assets for the quarter was 1.09%, and book value per share declined to $19.29, primarily due to accumulated other comprehensive losses from rising treasury rates. Total dividends declared for the quarter amounted to $0.17 per common share.Financial Services
- Nov 13, 3:04 PMImricor Medical Systems commenced its U.S. commercial launch in the third quarter of 2026, securing its first two hospital customers, Rady Children's Hospital–San Diego and Children's Medical Center Dallas, for its NorthStar interventional MR system. The company reported revenue of US$188k, a 437% increase from the prior period, driven by initial sales and installations while maintaining a cash balance of US$62.1m. Regulatory progress included FDA 510(k) clearances for pediatric label expansions on NorthStar and the Vision-MR Diagnostic Catheter, as well as the acceptance of the manufacturing module for the Vision-MR Ablation Catheter PMA application. Additionally, Imricor established a strategic partnership with Philips to issue a Third Party Product Compatibility Declaration, enabling NorthStar to operate on the Philips MR installed base and launching a joint turnkey iMR lab solution.
- DBHLNov 13, 3:03 PMDeep Isolation Nuclear, Inc. reported consolidated revenue of $1.8 million and a net loss of $3.8 million for the third quarter of 2026. The company advanced its Commercialization Pilot near Cameron, Texas, by securing a drilling permit from the Texas Railroad Commission and initiating well pad construction. Operational progress included selection as the sole industrial partner on three U.S. Department of Energy grants for artificial intelligence-enabled nuclear waste repository analysis. As of September 30, 2026, the company held $16.5 million in available cash with 57.77 million common shares outstanding.
- NTWKNov 13, 2:39 PMNETSOL Technologies reported fiscal first quarter 2027 revenue of $16.4 million, representing a 9.3% increase from the prior-year period. The company achieved a gross margin of 50.5%, an expansion of over 1,100 basis points, driven by revenue mix changes and the capitalization of $1.0 million in software development costs. GAAP net income attributable to NETSOL turned positive at $0.16 million, or $0.01 per diluted share, compared to a net loss of $2.36 million in the same period last year. Additionally, adjusted EBITDA attributable to NETSOL improved to $0.48 million from a negative $1.66 million in the prior year, while cash and cash equivalents stood at $19.7 million as of September 30, 2026.Technology
- INUVNov 13, 2:29 PMInuvo reported a 70% year-over-year decline in net revenue to $6.8 million for the third quarter of 2026, driven by an 80% drop in Legacy Search revenue and a 24% decrease in Audience Modeling revenue. The company recorded a net loss of $5.0 million, or $0.28 per share, with operating expenses totaling $7.8 million that included a $2.4 million non-cash impairment charge. Despite the revenue contraction, Inuvo highlighted a stabilizing Legacy Search segment and an expanding sales pipeline for its IntentKey privacy-first AI solutions across automotive, travel, healthcare, and financial sectors. Management expects fourth-quarter Audience Modeling revenue to increase supported by the growing pipeline, while Legacy Search revenue and margins are projected to remain consistent with the third quarter.Communication Services
- Nov 13, 1:36 PMVaragon Capital Corporation reported a net asset value of $8.93 per share and net investment income of $0.23 per share for the third quarter of 2026, resulting in an annualized yield of 10.2%. The company declared a fourth-quarter distribution of $0.23 per share, maintaining the same rate as the previous quarter, while total investments at fair value stood at $819 million across 121 portfolio companies. Credit quality remained robust with approximately 90% of investments rated as low risk, although three portfolio companies were placed on non-accrual status by the end of the period.
- INBPNov 13, 12:12 PMIntegrated BioPharma, Inc. reported revenue of $9.9 million for the quarter ended September 30, 2026, a 22% decrease from the $12.7 million recorded in the same period of 2025. The company posted an operating loss of $1.0 million and a net loss of approximately $0.7 million, or $0.02 per share, compared to an operating income of $0.2 million and net income of $0.1 million in the prior year quarter. Revenue concentration remained high, with the two largest customers in the Contract Manufacturing Segment accounting for approximately 88% of total revenue in the current quarter.Consumer Defensive
- DYAINov 13, 11:57 AMDyadic International, Inc. reported a net loss of $1,357,041 for the third quarter ended September 30, 2026, driven by a 61.4% decline in total revenue to $449,101. The company achieved a significant milestone by recording its first direct commercial product sales of recombinant transferrin and DNase I, while also expanding distribution through Integrated Biotherapeutics. Strategic partnerships advanced with Proliant promoting AlbuFree DX and Inzymes commercializing a second chymosin product, alongside continued progress on the C1 biopharmaceutical platform for vaccine and antibody development. As of September 30, 2026, the company held $6,046,083 in cash and equivalents, reflecting a decrease from the previous year-end balance.Healthcare
- INLXNov 13, 11:15 AMIntellinetics, Inc. reported a narrowed GAAP net loss of $239,163 for the third quarter of 2026, compared to a loss of $369,765 in the same period the previous year. Total revenue for the quarter increased 0.7% year-over-year to $4.03 million, driven by growth in Software as a Service and storage services, while professional services revenue declined. The company achieved positive Adjusted EBITDA of $144,821, marking a sequential improvement of approximately $516,000 from the second quarter. For the nine-month period ended September 30, 2026, the company recorded a net loss of $2.5 million and total revenue of $11.88 million, with management revising its full-year SaaS growth outlook to single-digit year-over-year increases.Technology
- UWHRNov 13, 10:02 AMUwharrie Capital Corp reported total assets of $1.23 billion as of September 30, 2026, representing a $15 million increase from the prior year. Net income for the nine-month period ended September 30, 2026, reached $10 million, an increase of nearly 21% compared to the same period in 2025. The company's loan portfolio grew by $27 million to $709 million, supported by a $14 million year-over-year increase in core deposits. In response to this financial progress, the Board of Directors declared a 3% stock dividend payable on November 23, 2026, to shareholders of record as of November 5, 2026.
- MOBXNov 13, 9:50 AMMobix Labs reported preliminary fourth-quarter revenue of approximately $1.81 million, a 129% sequential increase that exceeded its guidance range. The company's gross margin expanded significantly to 44.5% from 12.9% in the prior quarter, while the GAAP operating loss narrowed by 11% to $6.56 million. Balance sheet improvements included a 21% reduction in total liabilities and a $5.2 million increase in stockholders' equity compared to the previous year. Management anticipates continued revenue growth as the company addresses working capital constraints and builds on its operational recovery.Technology
- BCGNov 13, 9:29 AMBinah Capital Group reported third-quarter 2026 results showing a 5.0% year-over-year increase in assets under management to $31.4 billion. Total revenue for the quarter rose 9.4% to $50.6 million, while GAAP net income increased 44.4% to $2.6 million. The company also reported EBITDA growth of 74.1% to $4.7 million and Adjusted EBITDA of $4.9 million. As of September 30, 2026, Binah held $13.2 million in cash and cash equivalents against $16.7 million in outstanding long-term debt.Financial Services
- ALOYNov 13, 9:28 AMREalloys Inc. reported a net loss of $30.5 million for the third quarter of 2026, driven primarily by $25.3 million in non-cash stock-based compensation, while net revenues increased to $0.4 million. The company executed a non-binding term sheet with the U.S. Army to establish a heavy rare earth processing facility at Tooele Army Depot, targeting commissioning in early 2028 with a capacity of 50 tonnes of dysprosium and terbium oxide annually. REalloys aims to achieve initial U.S.-based production of approximately 3,000 tonnes of sintered NdFeB magnets by 2030, supported by a planned $10 million investment in research and development through 2027. As of September 30, 2026, the company maintained a cash balance of $116.2 million and a virtually debt-free balance sheet.Basic Materials
- LFWDNov 13, 9:25 AMLifeward reported third-quarter 2026 revenue of $5.4 million, a 12% decrease from the prior year, driven by an 18% year-over-year increase in AlterG revenue to $3.6 million offset by lower ReWalk sales during its transition to a channel-partner distribution model. The company posted a net loss of $5.1 million, or $1.32 per share, compared to a net loss of $3.2 million in the same period last year, with gross margin declining to 27.4% due to foreign exchange fluctuations and acquisition-related expenses. Lifeward is advancing its strategic shift for ReWalk to expand patient access through established distributors while maintaining coverage under Medicare and major insurance plans. Additionally, the company strengthened its clinical evidence base with two new peer-reviewed studies and continues to develop AI-enabled rehabilitation technologies alongside its Protein Oral Delivery platform.Healthcare
- CTGONov 13, 9:00 AMContango Silver & Gold reported a net loss of $23.0 million for the third quarter of 2026, driven primarily by increased exploration expenditures and lower income from its Peak Gold Joint Venture. The company's Manh Choh mine transitioned from the north pit to the south pit, resulting in reduced gold production for the quarter but improved mill recovery rates to 86.5%. Contango received a $6 million cash distribution from the JV in October and expects to complete its 2026 production guidance of 40,000 gold equivalent ounces with the fourth campaign. Additionally, the company advanced permitting and drilling at its Kitsault Valley, Johnson Tract, and Lucky Shot projects while repaying debt and eliminating most hedge delivery obligations.Basic Materials
- RMIXNov 13, 8:36 AMSuncrete, Inc. reported third-quarter 2026 revenue of $141.0 million, representing a 163% increase compared to the same period in 2025 and a 45% rise from the second quarter of 2026. The company achieved an Adjusted EBITDA of $22.4 million and a Supplemental Adjusted EBITDA of $23.3 million, while total ready-mix concrete yards delivered increased by 32% quarter-over-quarter. Despite the revenue growth, the company reported a net loss of $78,000 for the quarter, contrasting with a net loss of $37.1 million in the previous quarter. Suncrete has revised its full-year 2026 outlook to project revenue between $408.0 million and $434.0 million and Adjusted EBITDA between $60.0 million and $64.0 million.Basic Materials
- MTVANov 13, 8:35 AMMetaVia Inc. reported a net loss of $4.6 million for the third quarter of 2026, driven by increased research and development expenses related to its lead candidate DA-1726. The company announced positive interim data from a Phase 1 study showing a 68.1% placebo-adjusted reduction in liver fat and 13.5% weight loss, supporting plans for a Phase 2 trial in MetALD and ALD expected to begin in late 2027. Additionally, MetaVia appointed Sarah Browne, M.D., as Chief Medical Officer to lead clinical development while advancing its second candidate, vanoglipel, in combination with resmetirom for MASH.Healthcare
- XBIONov 13, 8:35 AMXenetic Biosciences reported a net loss of approximately $1.7 million for the third quarter of 2026, driven by a 138% increase in general and administrative expenses related to a proposed share exchange transaction. The company entered into a definitive agreement to acquire Santersus AG in an all-stock deal expected to close in early 2027, creating a Nasdaq-listed entity named Santersus Bio, Inc. focused on targeting neutrophil extracellular traps across multiple therapeutic areas. Strategic highlights include the initiation of a Phase I clinical study combining Xenetic's DNase I technology with CAR T-cell therapy for large B-cell lymphoma and the advancement of preclinical research demonstrating DNase I's ability to enhance antitumor activity.Healthcare
- SGRPNov 13, 8:33 AMSPAR Group, Inc. reported a net income of $50,000 for the third quarter of fiscal 2026, marking the second consecutive quarter of profitability despite a 19.0% year-over-year decline in net revenues to $33.5 million. Gross margins expanded to 18.9% driven by a shift toward higher-quality services, while selling, general, and administrative expenses decreased by 39.0% to $5.6 million due to cost reduction initiatives. The company generated $1.4 million in Adjusted EBITDA for the quarter and $4.3 million for the nine-month period, ending the quarter with $4.7 million in cash and cash equivalents. Additionally, SPAR Group announced a new three-year services agreement with a national retailer to begin in 2027 and adjusted its full-year 2026 revenue guidance to a range of $125 million to $130 million.Industrials
- BKYINov 13, 8:30 AMBIO-key International reported a 39% year-over-year increase in Q3 2026 software license fee revenue to $1.3 million, marking its third consecutive quarter of double-digit growth driven by momentum in the Middle East and Europe. The company's total revenue for the quarter was $1.48 million, while its gross margin improved to 90% and net loss narrowed to $886,000 compared to the prior year period. During the quarter, BIO-key retired its remaining note payable, leaving the company effectively debt-free, and working capital increased to $3.1 million. Looking ahead, the company anticipates a strong finish to 2026 and a robust start to 2027 supported by new government contracts and expanding deployments.Industrials
- QUCYNov 13, 8:18 AMQuantum Cyber N.V. reported its first revenue of approximately $966,833 for the third quarter of 2026, generated by its precision metal stamping operations at the Bridgeport, Connecticut facility. The company secured an $8.0 million funding commitment from CEO David Lazar to support the expansion of its autonomous defense manufacturing capabilities and the development of its Project LightShift quantum antenna technology. Additionally, the company resolved a legacy legal claim with Boustead Securities for $250,000 and expanded the licensed field of use for its quantum antenna to include unmanned surface and underwater vehicles. Shareholders' equity increased significantly to approximately $16.2 million by September 30, 2026, driven by $15.2 million in proceeds from warrant exercises and $6.0 million from preferred share issuances.Healthcare
- AARDNov 13, 8:18 AMAardvark Therapeutics received FDA approval to lift the clinical hold on its investigational drug ARD-101 for treating hyperphagia in Prader-Willi Syndrome, allowing the company to proceed with an open-label trial at a dose of 200 mg twice daily. The company plans to meet with the FDA in the first quarter of 2027 to finalize its clinical development strategy and expects to resume clinical activities in PWS during 2027. Financial results for the third quarter of 2026 showed a net loss of $19.2 million, with the company maintaining $60.3 million in cash and short-term investments to fund operations through 2027.Healthcare
- CNVSNov 13, 8:15 AMCineverse reported second-quarter fiscal 2027 revenue of $26.0 million, representing a 110% increase from the prior year quarter, driven primarily by technology and media services streams which now account for 55% of total revenue. The company achieved a net income of $3.2 million, or $0.11 per diluted share, marking a significant turnaround from a $5.7 million net loss in the same period last year, while Adjusted EBITDA rose to $1.7 million for the third consecutive positive quarter. Operational progress included the full integration of Giant Worldwide and IndiCue, resulting in a consolidated product portfolio on the Matchpoint platform and a 300 basis point sequential improvement in direct operating margin. Cineverse reaffirmed its full-year fiscal 2027 guidance of $115 to $120 million in revenue and $10 to $20 million in Adjusted EBITDA, citing strong momentum in advertising technology and content distribution.Communication Services
- BFRINov 13, 8:10 AMBiofrontera Inc. reported net product revenue of $9.1 million for the third quarter of 2026, representing a 29.8% increase from the prior-year period. The company achieved a gross margin of 74.4% and a net loss of $6.4 million, or $0.42 per share, during the quarter. Key developments included FDA approval of Ameluz for superficial basal cell carcinoma and a U.S. Customs ruling allowing the import of the redesigned XL-C lamp. For the nine months ended September 30, 2026, revenue grew 26.6% to $31.2 million while the net loss narrowed to $11.8 million.Healthcare
- OWLTNov 13, 8:05 AMOwlet reported third-quarter 2026 revenue of $30.4 million, a 4.9% decrease from the prior year, driven by lower hardware sales but offset by a 140% increase in subscription revenue to $3.6 million. The company achieved a gross margin of 53.8% and reported a net income of $1.4 million for the quarter. However, Owlet withdrew its full-year 2026 financial outlook following a safety incident involving exposed camera cables, which necessitates a free replacement program for all camera owners. Anticipated remediation expenses, potential retailer returns, and near-term demand uncertainty are expected to impact the fourth quarter results.Healthcare
- PDSBNov 13, 8:05 AMPDS Biotechnology Corporation reported a net loss of $7.6 million, or $0.11 per share, for the third quarter ended September 30, 2026, compared to a $9.0 million loss in the same period the previous year. The company announced the initial closing of a PIPE financing of up to $22.3 million led by Nant Capital, LLC, which included the appointment of Dr. Patrick Soon-Shiong and James Banaag to its Board of Directors. During the quarter, research and development expenses decreased to $2.1 million from $4.6 million in the prior year period, primarily due to reduced clinical trial costs. As of September 30, 2026, the company held $15.2 million in cash and cash equivalents while continuing to prioritize its lead program, PDS0301, and advancing its Versamune cancer vaccine platform.Healthcare
- PAVMNov 13, 8:05 AMPAVmed reported preliminary third-quarter 2026 financial results showing operating expenses of approximately $6.8 million and a non-GAAP adjusted net loss of $1.2 million. Its subsidiary Lucid Diagnostics began receiving Medicare payments for its EsoGuard test in October and recognized $1.2 million in revenue for the quarter. Veris Health achieved a design freeze for its implantable physiological monitor and initiated a 90-day GLP animal study ahead of an expected early 2027 FDA submission. Additionally, PAVmed engaged with the FDA regarding its PortIO and Octeris products, with Octeris preparing to submit an initial pre-submission package.Healthcare
- FBIONov 13, 8:05 AMFortress Biotech reported third-quarter 2026 net revenue of $19.2 million, representing a 9% increase from the prior year period, driven primarily by $18.9 million in product revenue. The company fully repaid its $15.0 million senior secured credit facility with Oaktree in September 2026, leaving it with no outstanding debt at the parent level. Key corporate developments included the in-licensing of FB-607 for irritable bowel syndrome, the approval of anselamimab in Japan for amyloidosis, and a $130 million Series B financing for partner Crystalys Therapeutics. Financial results for the quarter showed a net loss attributable to common stockholders of $7.9 million, while consolidated cash and cash equivalents rose to $152.2 million.Healthcare
- BNTCNov 13, 8:02 AMBenitec Biopharma reported positive interim clinical results for its BB-301 therapy in a Phase 1b/2a study for Oculopharyngeal Muscular Dystrophy, showing a 100% responder rate across all patients in Cohort 1 and Cohort 2 with no serious adverse events. The company announced a net loss of $12.9 million for the first quarter ended September 30, 2026, while maintaining approximately $176.5 million in cash and cash equivalents. Benitec plans to finalize the design for its pivotal BB-301 trial in the first quarter of 2027, with the study on track to begin in mid-2027. Additionally, the company intends to transition its fiscal year-end from June 30 to December 31, presenting operational guidance on a calendar-year basis and financial guidance on a fiscal-year basis.Healthcare
- IMUXNov 13, 8:00 AMImmunic, Inc. reported a net loss of $42.3 million for the third quarter of 2026, driven by increased research and development and general and administrative expenses. The company's Phase 3 ENSURE-1 and ENSURE-2 trials for vidofludimus calcium in relapsing multiple sclerosis remain on track to report top-line data in December 2026. Immunic is also initiating a Phase 3 PROTECT-MS trial for progressive multiple sclerosis, with the first patient enrollment expected in the first half of 2027. To support regulatory and commercial readiness, the company appointed a Chief Data and Digital Officer and a Chief People Officer during the quarter.Healthcare
- HURANov 13, 7:50 AMTuHURA Biosciences reported third-quarter 2026 financial results showing $1.9 million in cash and cash equivalents alongside $3.7 million in research and development expenses. The company announced preliminary data from its IFx-2.0 and Keytruda study in metastatic Merkel cell carcinoma patients, demonstrating major objective tumor responses in the first three subjects. TuHURA also received FDA clearance to initiate a Phase 1b trial for its VISTA-inhibiting antibody TBS-2025 in relapsed or refractory acute myeloid leukemia and secured new patents for its VISTA inhibitor and Delta Opioid Receptor technology. To support these initiatives, the company accessed $5.6 million in non-dilutive financing from its Parkview credit facility during the quarter.Healthcare
- NDLSNov 13, 7:45 AMNoodles & Company reported a 9.5% increase in system-wide comparable restaurant sales for the third quarter of 2026, driven by a 10.7% rise at company-owned locations and a 4.9% rise at franchise locations. The company posted a net loss of $2.1 million for the quarter, a significant improvement from the $9.2 million loss recorded in the same period of 2025, while operating margin expanded to 0.1% from (5.2)%. Restaurant contribution margin improved to 16.7% and Adjusted EBITDA increased by 34.3% to $8.7 million. Management has tightened its full-year 2026 guidance, projecting total revenue between $485 million and $495 million and Adjusted EBITDA between $35 million and $37 million.Consumer Cyclical
- DGXXNov 13, 7:45 AMDigi Power X Inc. reported third-quarter 2026 revenue of $12.25 million, representing an 85% increase from the previous quarter and a 50% year-over-year rise. AI-related revenue reached $5.66 million, accounting for 46% of total revenue, driven by a 400% surge in GPU rental income and the launch of the NeoCloudz Token Factory. The company ended the quarter with $119.6 million in cash and digital currencies, no outstanding borrowings, and a net income of $1.0 million. Looking ahead, Digi Power X anticipates an annualized revenue run-rate of $250 million to $300 million by the end of Q3 2027, supported by the upcoming billing for its Columbiana Phase 1 colocation facility and a planned $200 million debt financing.Utilities
- MISTNov 13, 7:36 AMMilestone Pharmaceuticals reported third-quarter 2026 net product revenue of $1.0 million for its FDA-approved drug CARDAMYST, representing a 73% increase from the previous quarter. To extend its cash runway into late 2028, the company implemented cost-efficiency measures that reduce operating expenses by approximately 30%, including bringing its sales force in-house and reducing its headquarters workforce. Consequently, Chief Financial Officer Amit Hasija and Chief Medical Officer Dr. David Bharucha have departed the leadership team, while the company maintains full funding for its Phase 3 AFib-RVR trial with data expected in the second half of 2028. As of September 30, 2026, the company held $145.4 million in cash and equivalents, providing sufficient resources to cover operations well beyond the anticipated Phase 3 readout.Healthcare
- XTIANov 13, 7:30 AMXTI Aerospace reported third-quarter 2026 revenue of $35.3 million, representing an 8.8% sequential increase and a 46.1% rise compared to the prior year's proforma revenue. The company achieved an adjusted EBITDA of $1.6 million, a significant improvement from a negative $4.9 million in the second quarter, driven by cost realignment initiatives and tariff recovery benefits. Management has completed its strategic pivot to focus exclusively on the Drone Nerds business, discontinuing the XTI aircraft operations while expanding its portfolio with new programs for pressure washing, airport detection, and first responders. Looking ahead, XTI Aerospace has reiterated its full-year 2026 revenue guidance of $125 million to $130 million and expects to transition to positive ongoing operating cash flows by the fourth quarter.Technology
- JBIONov 13, 7:20 AMJade Biosciences reported a net loss of $35.1 million for the third quarter ended September 30, 2026, driven by increased research and development and general and administrative expenses. The company holds $475.7 million in cash, cash equivalents, and investments, providing a runway into the fourth quarter of 2028. Key pipeline updates include the expected initiation of the Phase 3 EVERGREEN trial for JADE101 in the fourth quarter of 2026 and the planned start of the Phase 1 JADE301 trial in dermatomyositis during the same period. Additionally, the company expanded Brad Dahms' role to include Chief Business Officer responsibilities alongside his position as Chief Financial Officer.Healthcare
- TVRDNov 13, 7:05 AMTvardi Therapeutics reported a net loss of $6.1 million for the third quarter ended September 30, 2026, driven by increased research and development expenses related to its TTI-101 program. The company plans to advance its lead candidate TTI-109 into clinical trials for ulcerative colitis in 2027, pending Investigational New Drug clearance and additional funding. TTI-101 is currently being evaluated in a Phase 1b/2 study for hepatocellular carcinoma, with topline data expected in the early first quarter of 2027. As of September 30, 2026, Tvardi held $22.3 million in cash and cash equivalents, which is projected to fund operations through the third quarter of 2027.Healthcare
- PWCMNov 13, 7:00 AMPowerCompute reported a net income of $0.4 million for the third quarter of 2026, driven by a $6.7 million fair value gain on digital assets receivable as Bitcoin prices rose approximately 43% during the period. The company mined 23.9 Bitcoin, representing a 35.8% increase in production compared to the same quarter in 2025, while its mining margin improved to 50.7% from 29.0% in the previous quarter. Significant balance sheet improvements were achieved by repaying and terminating its Bitcoin-backed credit facility, which reduced secured debt by 94% to $1.25 million and eliminated pledged Bitcoin. Additionally, PowerCompute purchased 600 new Bitmain Antminer S21++ units for $1.0 million, which are expected to increase the company's active hashrate by approximately 10% by mid-December 2026.Financial Services
- SBCNov 13, 6:50 AMSBC Medical Group Holdings reported third-quarter 2026 total revenues of $59 million, representing a 35% year-over-year increase driven by service fee revisions and the consolidation of Waqoo. Net income attributable to the company rose 22% to $16 million, while Adjusted EBITDA surged 66% to $28 million, resulting in an Adjusted EBITDA margin of 47%. The company's clinic network expanded to 293 locations with 7.06 million patient visits over the trailing twelve months, and it held $198 million in cash and cash equivalents as of September 30, 2026.Industrials
- MXCNov 12, 5:28 PMMexco Energy Corporation reported a net income of $945,152, or $0.45 per diluted share, for the six months ended September 30, 2026, representing a 67% increase from the same period in the prior year. Operating revenues rose 21% to $4,102,157, driven primarily by a 43% increase in average oil prices despite a 23% decline in natural gas prices and a 7% drop in oil production. During this period, the company invested approximately $3.2 million in acquiring oil and gas royalty interests and plans to drill 55 horizontal wells and complete 20 others in the fiscal year ending March 31, 2027.Energy
- LGLNov 12, 5:27 PMThe LGL Group, Inc. reported total revenues of $1.464 million for the third quarter of 2026, representing a 32.1% increase from the same period in 2025. Net loss attributable to common stockholders was $45,000 for the quarter, a significant decline from the $772,000 net income recorded in 2025, primarily due to a reversal of a previously recorded uncertain tax position. The company's backlog in the Electronic Instruments segment grew substantially to $6.5 million as of September 30, 2026, up from $625,000 at the end of 2025. Cash and cash equivalents, along with marketable securities, increased to $87.0 million, driven largely by a rights offering that generated $41.5 million in net proceeds in July 2026.Technology
- BMTMNov 12, 5:27 PMBright Mountain Media, Inc. reported revenue of $11.6 million for the third quarter of 2026, a 17% decrease from the same period in 2025, while net loss narrowed to $3.0 million from $2.8 million. For the nine months ended September 30, 2026, revenue totaled $39.2 million, down 10% year-over-year, with the net loss improving by 26% to $7.5 million compared to $10.1 million in the prior period. Adjusted EBITDA increased to $1.5 million for the quarter and $3.6 million for the nine-month period, reflecting a 10% and 88% improvement respectively. The company's balance sheet showed total assets of $32.75 million and a stockholders' deficit of $84.09 million as of September 30, 2026.
- ROCNov 12, 5:21 PMRank One Computing Corporation reported record third-quarter 2026 revenue of $8.0 million, representing a 50% year-over-year increase and achieving its first quarterly net income of approximately $0.6 million. The company secured a historic $64.3 million federal contract with the Department of Justice for its ROC Evidence platform and a $5.1 million contract for ROC ABIS, while product revenue grew 24% to $5.7 million driven by strong performance in ROC SDK and ROC ABIS. Gross margin improved to 90% due to a favorable mix of high-margin software licensing, and the company completed the acquisition of Zuccaro Technical Consulting to expand its digital forensics capabilities.Technology
- AKTXNov 12, 5:21 PMAkari Therapeutics initiated GLP toxicology studies for its lead candidate AKTX-101, a TROP2-targeted antibody-drug conjugate utilizing the novel PH1 payload, to support a planned Phase 1 clinical trial in mid-2027. New preclinical data demonstrated that AKTX-101 exhibited significant tumor growth inhibition in urothelial cancer models resistant to existing therapies like Padcev and Trodelvy. The company reported third-quarter 2026 financial results showing $5.7 million in cash, a net loss of $4.8 million, and the full repayment of $0.7 million in convertible notes. Additionally, Akari strengthened its business development capabilities with the appointment of a new Chief Business Officer and expanded its intellectual property portfolio with a new patent application covering PH1's RNA splicing modulation mechanisms.Healthcare
- ITHUFNov 12, 5:21 PMiAnthus Capital Holdings reported fiscal third quarter 2026 revenue of $38.4 million, representing a sequential increase of $3.0 million from the previous quarter. The company achieved a gross profit of $16.7 million with a gross margin of 43.5%, while reporting a net loss of $13.2 million. Adjusted EBITDA for the quarter reached $5.2 million, an increase from $4.4 million in the second quarter and $2.5 million in the prior year's third quarter. Additionally, the company appointed Macias Gini & O'Connell LLP as its new independent registered public accounting firm effective November 12, 2026, following the resignation of PKF O'Connor Davies.
- ELTPNov 12, 5:20 PMElite Pharmaceuticals, Inc. reported consolidated revenues of $40.1 million for the second quarter of fiscal year 2027, representing a 10.4% increase from the prior year period. This growth was primarily driven by higher sales from the company's amphetamine and naltrexone product lines under the Elite label. The company recorded income from operations of $9.9 million and net income attributable to common shareholders of $17.3 million for the quarter. Management is scheduled to host a conference call on November 13, 2026, to discuss these financial results and recent business developments.Healthcare
- TBNNov 12, 5:18 PMTamboran Resources achieved first gas sales from its Shenandoah South Pilot Project in the Beetaloo Basin in September 2026, delivering 40 TJ/d to the Northern Territory Government under a fixed-price contract. Initial production tests on wells SS2-3H and SS2-5H confirmed average IP30 rates of 8.8 and 10.0 MMcf/d, while the SS2-2H ST1 well demonstrated a cleaned-up rate of 10.2 MMcf/d. The company reported US$1.8 million in gas sales revenue for the first quarter of fiscal year 2027, maintaining a pro forma cash balance of approximately US$180 million. Tamboran continues to advance its development strategy with ongoing drilling programs and strategic partnerships aimed at scaling production across its 2.8 million net prospective acres.Energy
- SLNDNov 12, 5:17 PMSouthland Holdings reported third-quarter 2026 revenue of $233.8 million, an increase from $213.3 million in the same period the prior year, driven by strong demand in its Civil and Transportation segments. The company achieved a gross profit of $20.6 million with an 8.8% margin, a significant improvement over the 0.9% margin recorded in the previous year, largely due to a $28.7 million settlement gain with Liberty Mutual. Net income attributable to stockholders reached $33.7 million, or $0.62 per diluted share, contrasting sharply with a net loss of $75.3 million in the prior year quarter. Additionally, Southland's backlog grew to $1.71 billion, reflecting continued execution of its strategic plan and operational improvements.Industrials
- LGVNNov 12, 5:11 PMLongeveron Inc. reported a net loss of $6.1 million for the third quarter ended September 30, 2026, driven by research and development expenses of $4.0 million and general and administrative costs of $3.3 million. The company's Phase 2b ELPIS II clinical trial for hypoplastic left heart syndrome did not meet its primary efficacy endpoint, prompting a request for a meeting with the FDA to determine future development steps. Concurrently, Longeveron is evaluating strategic alternatives, including potential partnerships, mergers, or sales, with Lucid Capital Markets retained as financial advisor to maximize stockholder value. The company implemented a 1-for-10 reverse stock split in August and currently holds $7.2 million in cash, which is expected to fund operations into the first quarter of 2027.Healthcare
- VGZNov 12, 5:10 PMVista Gold Corp. announced a consolidated net loss of $6.4 million, or $0.05 per share, for the quarter ended September 30, 2026, while maintaining cash reserves of $43.5 million with no debt. On September 20, 2026, the company entered into an arrangement agreement with Artemis Gold Inc. to be acquired via a court-approved plan of arrangement. Under the proposed terms, each Vista common share will be exchanged for 0.0966 of an Artemis common share, resulting in Vista shareholders collectively owning approximately 5% of the combined entity. The transaction aims to leverage Artemis's resources to advance the development of Vista's Mt Todd gold project while expanding the Blackwater operation.Basic Materials
- NNUPNov 12, 5:08 PMNocopi Technologies reported a 763% increase in third-quarter 2026 revenues to $3.329 million, driven by a renewed license agreement and sales from the acquired Polymeric business. The company achieved a net income of $1.397 million for the quarter, a significant turnaround from the net loss recorded in the same period of the previous year. Operating expenses rose to $0.982 million due to the inclusion of Polymeric's operations and elevated professional fees associated with the acquisition. As of September 30, 2026, the company maintained a strong balance sheet with $10.278 million in cash and investments and no outstanding debt.
- PALNov 12, 5:03 PMProficient Auto Logistics reported third-quarter 2026 total operating revenue of $149.0 million, a 30.3% increase from the prior year period, driven by the inclusion of Hansen & Adkins following its acquisition on August 13, 2026. The company delivered 839,036 units, representing a 38.6% year-over-year growth, though total operating income declined to a loss of $3.9 million compared to a $0.1 million loss in the previous year. Adjusted operating income for the quarter was $0.3 million, with the adjusted operating ratio rising to 99.8% due to elevated costs in insurance, wages, and fuel surcharge under-recovery. The integration of Hansen & Adkins is progressing on schedule, with the company now identifying a synergy opportunity range of $20 million to $30 million, significantly higher than the initial estimate.Industrials
- KIDZNov 12, 5:00 PMKIDZ AI Inc. reported a 40% sequential increase in third-quarter 2026 revenue, marking its first quarter-over-quarter growth in the year. The company achieved a gross margin of 65.9% and narrowed its net loss to $654,057, while strengthening its balance sheet with stockholders' equity rising 349% to $16.9 million. As of September 30, 2026, the firm maintained a net cash position of approximately $14.9 million, representing roughly 12 times its market capitalization. During the quarter, KIDZ AI repurchased 74,082 shares of Class B common stock at an average price of $3.36 per share.Consumer Defensive
- CWDNov 12, 5:00 PMCaliber reported a third quarter 2026 platform revenue of $3.8 million and a platform net loss of $4.3 million, resulting in a positive platform Adjusted EBITDA of $0.1 million for the second consecutive quarter. The company revised its full-year 2026 total platform revenue guidance down to a range of $15.0 million to $17.0 million due to tighter credit conditions, while reaffirming its profitability guidance. During the quarter, Caliber completed the tokenization of three additional real estate projects, bringing the total tokenized offerings to four with up to $110 million in combined offered equity. Additionally, the company held 229,203 LINK tokens valued at $3.3 million, which contributed a $1.6 million gain from changes in fair value.Financial Services
- MSGMNov 12, 5:00 PMMotorsport Games reported third-quarter 2026 revenues of $3.8 million, representing a 21.8% increase from the prior year period, driven by growth in Le Mans Ultimate downloadable content and RaceControl subscriptions. The company achieved its seventh consecutive quarter of profitability with net income of $0.7 million and expanded its gross profit margin to 88.0%. Le Mans Ultimate surpassed two million combined unit sales and set a new concurrent player record of 11,941 during a special event in October. Additionally, the company strengthened its balance sheet, ending the quarter with $5.4 million in cash and deferred revenue, while RaceControl subscription revenues grew by 186.2% over the nine-month period.Communication Services
- BGMSNov 12, 5:00 PMBio Green Med Solution, Inc. reported a net loss of $0.4 million for the third quarter ended September 30, 2026, narrowing from a $1.0 million loss in the prior-year period. The company's fire safety business generated $454,000 in product revenue, representing a significant increase from $81,000 in the same period last year, while general and administrative expenses decreased by 37% year over year. As of September 30, 2026, the company held $3.5 million in cash and cash equivalents, which management estimates will fund operations through the second quarter of 2027. Additionally, the company announced that its Form S-4 regarding a proposed business combination with Future NRG Sdn. Bhd. was declared effective in October, with a shareholder special meeting planned for November 2026.Industrials
- DIODNov 12, 5:00 PMDiodes, Inc. reported record third-quarter 2026 revenue of $532.6 million, representing a 36% year-over-year increase and a 20% sequential rise. The company achieved a gross margin of 36.1%, driven by strong demand in automotive, industrial, and AI-related computing sectors, alongside capacity expansion and product mix improvements. Management projects fourth-quarter revenue to reach approximately $550 million with a non-GAAP gross margin of 37%, aiming to exceed its three-year financial goals.Technology
- PRSONov 12, 4:58 PMPeraso Inc. reported third-quarter 2026 total net revenue of $0.3 million, a significant decline from $1.3 million in the prior quarter and $3.2 million in the same period last year, driven by reduced shipments to fixed wireless access customers. The company posted a GAAP net loss of $2.7 million, or $0.18 per share, while achieving a gross margin of 78.5% due to a favorable product mix and a one-time inventory accrual reversal. Management noted early signs of renewed demand in the fourth quarter, highlighted by a production order exceeding $2 million received in October, and announced a private placement with Nant Capital that raised approximately $10 million to support strategic initiatives in defense and drone communications.Technology
- SPRUNov 12, 4:52 PMSpruce Power reported a net income of $6.0 million for the third quarter of 2026, marking a significant turnaround from a net loss of $0.9 million in the same period the previous year. Operating EBITDA increased by 3% year-over-year to $27.0 million, driven by a 23% reduction in SG&A expenses resulting from streamlining efforts and labor savings initiatives. The company ended the quarter with $87.3 million in cash and cash equivalents, reduced its outstanding debt principal by $21.9 million, and finalized a non-binding term sheet to refinance key facilities extending their maturity to January 2027.Technology
- NSPRNov 12, 4:45 PMInspireMD, Inc. reported a net loss of $9.76 million for the third quarter of 2026, driven by a decline in total revenue to $2.24 million due to a voluntary U.S. recall of its CGuard Prime delivery system. The company received FDA approval for its CGuard Prime TransCarotid Stent System for TCAR procedures, which is expected to expand its addressable market by over 35,000 annual procedures and commence U.S. sales in the fourth quarter of 2026. International revenue grew by 9.1% to $2.21 million, offsetting the loss of U.S. sales, while the company continues to advance its SwitchGuard neuroprotection system and plans to submit a PMA supplement for an enhanced CAS delivery system in December 2026.Healthcare
- ALMUNov 12, 4:45 PMAeluma, Inc. reported a net loss of $3.8 million for the first quarter of fiscal 2027, with revenue declining to $0.6 million from $1.4 million in the prior year period. The company finalized a purchase agreement with Aixtron to acquire a new 200 mm capable MOCVD system, aiming to expand manufacturing capacity for non-indium-phosphide photonics. Aeluma continues to advance technology readiness for the AI datacom market through the development of high-speed photodetectors and quantum dot lasers while engaging with customers for potential high-volume demand. Additionally, the company is in negotiations with the U.S. Department of Commerce for up to $30 million in CHIPS R&D funding to support the commercialization of photonics for AI and advanced computing.Technology
- STRONov 12, 4:45 PMSutro Biopharma reported third-quarter 2026 financial results showing $9.1 million in revenue and a net loss of $31.5 million, while maintaining a cash balance of $142.2 million expected to fund operations through the first half of 2028. The company advanced its STRO-004 ADC program with encouraging early clinical data and initiated dosing for the STRO-006 ITGB6-targeting ADC, with both programs scheduled for further clinical updates in 2027. Additionally, the STRO-227 dual-payload ADC is set to enter clinical trials in early 2027, and a collaboration with Astellas triggered a $10 million milestone payment following the dosing of a second dual-payload program.Healthcare
- SPRONov 12, 4:43 PMSpero Therapeutics announced its third-quarter 2026 financial results, reporting a net loss of $44.3 million and research and development expenses of $38.2 million, which included a $35 million upfront payment for the in-licensing of SP001 from Innovent Biologics. The company secured $105 million in non-recourse financing in July 2026, bringing its cash and cash equivalents to $107.9 million as of September 30, 2026, sufficient to fund operations into the second half of 2029. SP001, a third-generation anti-CD40L antibody, is advancing toward a Phase 2 study in IgG4-related disease scheduled for the second quarter of 2027. Spero has also strengthened its leadership team with new appointments for Chief Medical Officer, Chief Regulatory and Quality Officer, and a new Board member to support its clinical development strategy.Healthcare
- LSFNov 12, 4:42 PMLaird Superfood reported third-quarter 2026 net sales of $42.0 million, representing a 225% increase from the prior year period, driven by the integration of Navitas Organics and Terrasoul Superfoods. The company achieved a net income of $1.7 million and an Adjusted EBITDA of $2.1 million, while e-commerce sales grew 268% to account for 54% of total revenue. For the full fiscal year 2026, the company maintains a revenue guidance range of $135 million to $140 million and an Adjusted EBITDA range of $5 million to $6 million. As of September 30, 2026, Laird Superfood held $17.3 million in cash with no outstanding debt.Consumer Defensive
- BATLNov 12, 4:41 PMBattalion Oil Corporation reported third quarter 2026 sales volumes of 11,359 barrels of oil equivalent per day, with average daily production of 4,915 net barrels of oil. The company generated $45.6 million in operating revenue, driven by a $5.13 per Boe increase in average realized prices, while reporting a net loss of $41.1 million largely due to $44.8 million in net losses on derivative contracts. Financial highlights include $92.1 million in cash and cash equivalents, a reduction in net debt to $70.4 million, and the commencement of drilling operations under a joint exploration agreement ahead of schedule. Additionally, the company executed a midstream transaction to transition crude transportation from trucking to pipeline and appointed John Juneau to its board of directors.Energy
- DMACNov 12, 4:40 PMDiaMedica Therapeutics reported a net loss of $11.3 million for the third quarter of 2026, with total cash, cash equivalents, and short-term investments standing at $34.9 million as of September 30, 2026. The company completed enrollment in the first two cohorts of its Phase 2 trial for early-onset fetal growth restriction and surpassed the 200-participant threshold for its ReMEDy2 acute ischemic stroke trial. Regulatory progress includes conditional authorization from the European Medicines Agency and Health Canada for early-onset preeclampsia studies, while the company continues to address FDA feedback regarding nonclinical reproductive toxicity data for a U.S. Investigational New Drug application. Management anticipates the ReMEDy2 interim analysis to be completed in the first quarter of 2027 and expects current cash reserves to fund operations through the fourth quarter of 2027.Healthcare
- DDSNov 12, 4:39 PMDillard's, Inc. reported net income of $130.9 million for the third quarter ended October 31, 2026, representing a 1% increase in total retail sales compared to the prior year period. For the 39 weeks ended October 31, 2026, the company achieved net income of $479.1 million, driven by a 2% increase in total retail sales and significant non-operating gains from tariff refunds and a litigation settlement. The retailer maintained a retail gross margin of 45.3% for the quarter and 44.0% for the year-to-date period, while operating expenses rose due to higher payroll costs. Additionally, Dillard's announced the closure of its Boynton Beach Mall Clearance Center in January 2027 and operates 272 stores across 30 states.Consumer Cyclical
- GEMINov 12, 4:35 PMGemini Space Station, Inc. reported third-quarter 2026 total revenue of $40.9 million, a 19% decrease from the prior year, driven by a 73% decline in platform spot trading volume. Total operating expenses fell 30% year-over-year to $119.9 million, resulting in a net loss of $58.6 million, which represents a 63% improvement over the same period in 2025. Services revenue and interest income accounted for 59% of net revenue, while exchange revenue dropped 47% to $13.4 million due to reduced retail trading activity. The company maintained disciplined cost management with lower compensation and marketing spend, despite a 38% increase in transaction losses primarily attributed to credit card charge-offs.Financial Services
- WHKNov 12, 4:34 PMWhiteHawk Minerals Corp. reported third-quarter 2026 net production of 71.3 million cubic feet equivalent per day, representing a 10% year-over-year increase. The company announced the signing of 13 acquisitions totaling $45.5 million in core Appalachian and Haynesville mineral interests, which are expected to generate approximately $5.6 million in incremental cash flow in 2027. For the quarter, WhiteHawk declared a quarterly dividend of $0.50 per share, achieved net income of $6.9 million, and reported adjusted EBITDA of $21.1 million.Energy
- CVNov 12, 4:34 PMCapsoVision reported third-quarter 2026 revenue of $3.6 million, a slight increase from $3.5 million in the same period of 2025, while net loss narrowed to $7.3 million from $7.9 million. The company received FDA clearance for its AI Highlights tool in September 2026 and launched it commercially in November, alongside completing enrollment for its CapsoCam Colon study with an expected FDA submission by year-end. Financial results reflected a gross margin decline to 49% due to higher material costs and inventory charges, though operating expenses decreased to $9.1 million. To support its operations and development pipeline, CapsoVision raised approximately $19.5 million in net proceeds through a registered direct offering and an at-the-market program during the quarter.Healthcare
- UPXINov 12, 4:31 PMUpexi, Inc. reported fiscal first quarter 2027 net income of $89.1 million, or $0.68 per diluted share, driven primarily by $102.0 million in unrealized gains on digital assets. Total revenue for the quarter reached $3.5 million, with digital asset revenue accounting for $3.1 million and product revenue declining to $0.4 million as the company shifted away from legacy consumer product lines. The company strengthened its balance sheet by increasing its Solana treasury to approximately 2.35 million SOL and raising cash on hand to $6.4 million, while also reducing the interest rate on its BitGo borrowings from 11.5% to 7.5%. Stockholders' equity improved significantly to $49.2 million as of September 30, 2026, reversing a deficit of $53.8 million recorded at the end of the previous quarter.Communication Services
- SPCENov 12, 4:31 PMVirgin Galactic reported a net loss of $59 million for the third quarter of 2026, driven by $59 million in operating expenses and revenue of $0.4 million. The company holds $184 million in cash and marketable securities as of September 30, 2026, while its first commercial spaceflight is expected in early 2027. Operational updates include the completion of a rocket motor production facility in Arizona and the opening of limited bookings for spaceflight expeditions at $850,000 per seat. Additionally, Virgin Galactic projects a high-cadence launch hangar opening in late 2028 to increase annual spaceflight capacity to 150.Industrials
- PROPNov 12, 4:30 PMPrairie Operating Co. reported third-quarter 2026 sales volumes of 2.4 million barrels of oil equivalent, representing a 21% increase from the prior quarter and driving revenue to $129.5 million. The company generated $65.3 million in Adjusted EBITDA, a 92% quarter-over-quarter increase, while reducing lease operating expenses per barrel of oil equivalent by 17%. Year-to-date through September 30, 2026, total revenue reached $311.8 million, an increase of approximately 97% compared to the same period in 2025. Production reached approximately 32,287 barrels of oil equivalent per day by early October, following the online status of the Burnett and Castor development pads.Energy
- AEMDNov 12, 4:30 PMAethlon Medical, Inc. reported a net loss of $2.62 million for the second quarter ended September 30, 2026, with operating expenses rising 77.2% to $2.7 million primarily due to professional fees associated with a proposed merger. On September 17, 2026, the company entered into a merger agreement with North Immunology, Inc., under which the combined entity will operate as North Immunology and shareholders will receive contingent value rights tied to the legacy Hemopurifier business. During the quarter, the company treated its second patient in the final dosing cohort of its Phase 1 oncology study in Australia and implemented workforce reductions to align with the merger timeline. As of September 30, 2026, the company held approximately $6.5 million in cash and cash equivalents.Healthcare
- LGCYNov 12, 4:30 PMLegacy Education Inc. reported a record student population of 3,684 for the first quarter of fiscal 2027, representing a 5.4% increase from the prior year. The company achieved $20.0 million in revenue and $0.9 million in net income, while expanding its footprint with a new campus lease in Houston, Texas. Strategic investments in faculty, facilities, and new programs drove educational services expenses up by 13.0%, resulting in a lower net income margin compared to the previous year. Additionally, the company recorded an estimated $0.7 million legal settlement expense and maintained a strong balance sheet with $21.7 million in cash and minimal debt.Consumer Defensive
- PLNHNov 12, 4:28 PMPlanet 13 Holdings Inc. reported a net loss of $6.4 million and revenue of $23.1 million for the third quarter of 2026. The company achieved a gross profit margin of 56.2%, a significant increase from the prior year, driven by the exit from California wholesale operations and a reduction in inventory reserves. Adjusted EBITDA improved to a loss of $0.2 million, reflecting better cost control and higher gross margins despite lower tourist traffic in Nevada. Additionally, the company announced that its Form S-4 merger registration with Vireo Growth Inc. was declared effective, with a shareholder vote scheduled for December 10, 2026.
- VRCANov 12, 4:27 PMVerrica Pharmaceuticals reported third-quarter 2026 total revenue of $6.9 million, driven by a record $5.7 million in net product revenue from YCANTH, which represents an 11.9% increase over the previous quarter. The company completed enrollment in its first pivotal Phase 3 trial for common warts and achieved milestones to unlock an additional $15.0 million in non-dilutive growth capital, extending its cash runway into the fourth quarter of 2027. Additionally, Verrica announced it is exploring the development of its oncolytic peptide, VP-315, for the treatment of Gorlin syndrome, a rare genetic disease characterized by frequent basal cell carcinomas.Healthcare
- NKTRNov 12, 4:25 PMNektar Therapeutics reported a net loss of $55.7 million for the third quarter of 2026, driven by increased research and development expenses totaling $44.1 million as the company advances its lead candidate rezpegaldesleukin into Phase 3 trials for atopic dermatitis and alopecia areata. Revenue for the quarter declined to $9.4 million from $11.8 million in the same period the previous year, while cash and investments rose significantly to $952.9 million. The company has initiated all three global registrational trials for the ZENITH AD program and expects topline data in mid-2028, with a target Biologics License Application submission in 2029.Healthcare
- ARMPNov 12, 4:24 PMArmata Pharmaceuticals reported a net income of $54.9 million for the third quarter of 2026, driven primarily by a $69.6 million gain from changes in the fair value of its convertible loan. The company advanced preparations for its pivotal Phase 3 superiority study of AP-SA02, receiving FDA Breakthrough Therapy designation and securing an additional $3.7 million in non-dilutive funding from the U.S. Department of War. Operating expenses for the quarter totaled $10.5 million, while the company held $18.3 million in unrestricted cash and cash equivalents as of September 30, 2026.Healthcare
- FGINov 12, 4:24 PMFGI Industries reported third-quarter 2026 total revenue of $31.7 million, an 11.6% decrease from the prior year, driven by softness in housing and remodeling activity. The company posted a gross profit of $8.7 million with an expanded gross margin of 27.6%, while operating and net losses were recorded at $0.5 million and $0.9 million, respectively. Revenue declined across core categories including sanitaryware and shower systems, though the custom kitchen cabinetry segment grew by 32.8%. Consequently, FGI revised its full-year 2026 net revenue guidance downward to a range of $120-127 million and adjusted its operating and net income forecasts to reflect continued market challenges.Consumer Cyclical
- XOSNov 12, 4:23 PMXos, Inc. reported a third consecutive quarter of positive GAAP gross profit for the period ended September 30, 2026, with the nine-month GAAP gross margin expanding to 26.9% from 13.3% in the prior year. Revenue for the quarter increased 17.0% sequentially to $5.5 million on 33 units delivered, while operating expenses were reduced by 10.0% year-over-year to $25.8 million for the nine-month period. The company delivered its first Xos Hub units internationally to support Waymo's autonomous vehicle operations in London and now has over 1,000 units in the field. Xos revised its full-year 2026 outlook to project revenue between $25 million and $35 million and unit deliveries between 185 and 250 units.Consumer Cyclical
- ENSCNov 12, 4:22 PMEnsysce Biosciences reported a net loss of $82.3 million for the third quarter of 2026, primarily driven by a $79.9 million non-cash charge for acquired in-process research and development related to the Cy Biopharma acquisition. The company completed the acquisition of Cy Biopharma in August, adding the CY200 pipeline asset for Complex Regional Pain Syndrome, and submitted a Phase 2a protocol for this candidate to the UK's MHRA in September. Additionally, Ensysce finished enrollment in the final stage of its PF614-MPAR-102 study for its abuse-deterrent opioid and ended the quarter with $29.7 million in cash and cash equivalents.Healthcare
- INVNov 12, 4:21 PMInnventure, Inc. reported a net loss of $333.8 million for the third quarter of 2026, driven primarily by a $323.5 million goodwill impairment charge. The company is executing a strategic repositioning that includes reducing parent-level headcount from 40 to 15 and transitioning its AeroFlexx and Refinity businesses away from reliance on Innventure capital. During the nine-month period ended September 30, 2026, Innventure generated $3.9 million in revenue while utilizing $74.5 million in operating cash flows. Management aims to preserve and maximize the value of its interest in Accelsius through disciplined capital allocation and cost reductions.Financial Services
- CRDFNov 12, 4:21 PMCardiff Oncology reported a net loss of $30.4 million for the nine months ended September 30, 2026, driven by $32.0 million in operating expenses. The company's Phase 2 trial for onvansertib in first-line RAS-mutated metastatic colorectal cancer remains ongoing, with median progression-free survival not yet reached in the 30 mg onvansertib plus FOLFIRI/bev arm compared to approximately 11 months in standard-of-care arms. As of late September 2026, all patients in the 30 mg onvansertib arm have exceeded 21 months on treatment, with the longest duration surpassing 29 months. Cardiff holds approximately $33.8 million in cash and cash equivalents as of September 30, 2026, and plans to initiate a registrational Phase 3 trial in the first quarter of 2027.Healthcare
- VATENov 12, 4:21 PMINNOVATE Corp. reported third-quarter 2026 consolidated revenue of $495.5 million, a 42.8% increase from the prior year, driven primarily by its Infrastructure segment. The company completed the sale of DBM Global to IES Holdings for approximately $413 million in cash and stock, and sold a controlling interest in HC2 Broadcasting to CONX Corp., retaining a 25% stake. Net income attributable to common stockholders rose to $15.8 million in the quarter, compared to a net loss of $9.4 million in the same period last year, largely due to a $32.9 million gain on the sale of the broadcasting interest. Total Adjusted EBITDA for the quarter reached $40.5 million, more than doubling the $19.8 million reported in the previous year.Industrials
- LVLUNov 12, 4:21 PMLulus reported a 20% year-over-year decline in third-quarter 2026 net revenue to $58.6 million, driven by a 20% drop in total orders placed and higher return rates. The company posted a net loss of $4.3 million and an adjusted EBITDA loss of $1.8 million, while successfully reducing inventory by 17% and improving gross margin by 230 basis points to 44.9%. Management revised its full-year 2026 outlook downward due to the continued impact of historical assortment decisions, though it anticipates revenue decline rates to moderate in fiscal 2027. Additionally, the company expects capital expenditures for 2026 to range between $1.5 million and $2.0 million.Consumer Cyclical
- CDXSNov 12, 4:20 PMCodexis, Inc. reported third-quarter 2026 total revenues of $19.3 million, a significant increase from $8.6 million in the same period of 2025, driven by higher product revenue from newly approved customer products. The company achieved a product gross margin of 74.5% for the quarter and reduced its net loss to $8.1 million, or $0.08 per share, compared to a $19.6 million loss in the prior year period. Financial stability was strengthened through a $25 million equity raise completed in July and a $60 million senior secured loan facility with Trinity Capital, which included a $42.5 million drawdown used to refinance existing debt. Codexis reiterated its full-year 2026 revenue guidance of $72 million to $76 million and expects its cash and investments to fund operations through the end of 2028.Healthcare
- YSSNov 12, 4:20 PMYork Space Systems reported third-quarter 2026 revenue of $84.2 million, a 7% decrease from the prior year, while recording a net loss of $807.4 million largely driven by a $749.7 million non-cash goodwill impairment charge. The company's backlog stood at $581.0 million as of September 30, 2026, supported by new contract wins and modifications, and its identified pipeline expanded by over 30% to $14.9 billion. York announced the permanent appointment of Brian Frantz as Chief Financial Officer and outlined strategic initiatives including the proposed acquisition of Outlook Industries to enter the unmanned systems market. Full-year 2026 revenue guidance was narrowed to a range of $380 million to $400 million, with the company maintaining total liquidity of $459 million.Industrials
- SCTXNov 12, 4:20 PMScribe Therapeutics reported third-quarter 2026 financial results, recording a net loss of $9.9 million and holding $174.2 million in cash, cash equivalents, and marketable securities as of September 30, 2026. The company completed an upsized initial public offering in July 2026, raising approximately $155.5 million in aggregate gross proceeds, which extends its funding runway into the first half of 2029. Clinical progress includes ongoing enrollment in the first-in-human Phase 1 trial for STX-1150, an epigenetic silencing therapy targeting LDL-C lowering, with initial data expected in the first half of 2027. Additionally, Scribe expanded its strategic collaboration with Sanofi to include access to its ELXR epigenetic silencing technology alongside its existing gene-editing platform.Healthcare
- CRWSNov 12, 4:19 PMCrown Crafts, Inc. reported second-quarter fiscal 2027 net sales of $19.0 million, a decrease from $23.7 million in the prior-year period. The company achieved a gross profit margin of 32.0%, an increase from 27.7% in the previous year, driven by $0.4 million in tariff refunds and offset by $0.2 million in severance expenses. Net income for the quarter rose to $1.3 million, or $0.12 per diluted share, compared to $1.2 million, or $0.11 per share, in the prior year. Additionally, the Board of Directors declared a quarterly cash dividend of $0.03 per share on the Series A common stock.Consumer Cyclical
- RMRNov 12, 4:19 PMThe RMR Group Inc. announced its financial results for the fiscal quarter ended September 30, 2026. The company, a leading U.S. alternative asset management firm focused on commercial real estate, manages approximately $37 billion in assets through over 800 professionals across more than 30 offices. A conference call to discuss these results was scheduled for November 13, 2026, at 11:00 a.m. Eastern Time, with a live webcast and replay options available.Real Estate
- GROWNov 12, 4:18 PMU.S. Global Investors reported a 18% increase in operating revenues to $2.7 million for the first quarter of fiscal 2027, ending the period with an operating income of $55,000 compared to a loss in the prior year. Average assets under management grew 14% to $1.6 billion, driven by a 45% surge in gold and precious metals strategies. The company also highlighted growth in its defense-focused WAR ETF and shipping-focused SEA ETF, while maintaining a shareholder yield of 8.33% and a strong liquidity position with $35.4 million in net working capital.Financial Services
- PMNNov 12, 4:17 PMProMIS Neurosciences reported a net loss of $8.2 million for the third quarter of 2026, with cash reserves totaling $44.1 million as of September 30, 2026. The company's lead Alzheimer's candidate, PMN310, remains on track to deliver unblinded 12-month topline data from the PRECISE-AD Phase 1b trial in the first quarter of 2027. Recent interim data showed no amyloid-related imaging abnormalities with edema and a 4.4% rate of hemorrhage, all of which were mild and asymptomatic. Ivana Rubino, Ph.D., a former senior executive at Biogen and Roche, was appointed Chief Commercial Officer effective October 5, 2026, to guide the company's late-stage development and commercial strategy.Healthcare
- PARKNov 12, 4:17 PMPark Dental Partners reported third-quarter 2026 revenue of $64.9 million, representing a 6.0% increase from the prior year, driven by same-practice growth and acquisitions. The company achieved net income of $1.7 million and adjusted EBITDA of $5.0 million for the quarter, while supporting 225 affiliated doctors across 88 practices. Full-year 2026 revenue is now projected to range between $262.0 million and $265.0 million, incorporating the expected contribution from the recently acquired Village Family DSO. Additionally, the company completed the acquisition of Village Family DSO in November 2026, with integration activities commencing immediately.Healthcare
- PROKNov 12, 4:17 PMProKidney Corp. reported third-quarter 2026 financial results, ending the period with $141.9 million in cash and cash equivalents to support operations through mid-2027. The company's pivotal Phase 3 PROACT 1 trial is on track to deliver eGFR slope topline results in the second quarter of 2027, with full enrollment expected to exceed 500 patients by the first quarter of 2027. During the quarter, research and development expenses rose to $40.8 million, driven primarily by increased clinical study and manufacturing costs associated with the ongoing trial. Additionally, the company presented eight new data abstracts at the ASN Kidney Week 2026 to further support the mechanistic and clinical evidence for its lead candidate, rilparencel.Healthcare
- ETRANov 12, 4:17 PMElectra Therapeutics reported a net loss of $23.9 million for the third quarter of 2026, supported by a cash position of $402.5 million following a $350 million IPO. The company is advancing its lead candidate, ipsoprubart, through a global registrational program for secondary hemophagocytic lymphohistiocytosis with enrollment completion expected in the second half of 2027. Additionally, ipsoprubart is being evaluated in a Phase 1 trial for T/NK cell malignancies, while the second candidate, ELA822, has initiated a Phase 1 trial in healthy volunteers with data expected in early 2027.Healthcare
- CTSONov 12, 4:16 PMCytoSorbents Corporation reported third-quarter 2026 revenue of $9.7 million, representing a 3% increase from the prior year, while achieving positive operating cash flow of approximately $43,000 excluding restructuring payments. The company improved its gross margin to 75% and reduced total operating expenses by 11% to $8.5 million, resulting in a net loss of $1.8 million compared to $3.2 million in the same period last year. Management highlighted progress on four strategic value drivers, including sustaining cash flow breakeven, revitalizing the core CytoSorb franchise in Germany, advancing the DrugSorb-ATR submission to the FDA for the U.S. market, and exploring commercial opportunities for the HemoDefend-BGA technology.Healthcare
- DFLINov 12, 4:16 PMDragonfly Energy reported third-quarter 2026 net sales of $12.2 million, a 23.8% decrease year-over-year, driven by softness in the recreational vehicle market despite heavy-duty trucking revenue more than doubling sequentially to $1.3 million. The company recorded a net loss attributable to common stockholders of $6.7 million and an adjusted EBITDA loss of $2.3 million, while completing the acquisition of the Dakota Lithium brand to expand its product portfolio. Management projects fourth-quarter 2026 net sales of approximately $12.5 million with adjusted EBITDA expected to reach breakeven, supported by continued fleet adoption and cost-reduction initiatives.Industrials
- ANABNov 12, 4:16 PMAnaptysBio reported fiscal first quarter 2027 results showing Jemperli global net sales of $1.0 billion for the nine months ended September 30, 2026, representing 29% year-over-year growth. The company received $30.3 million in collaboration revenue for the quarter, driven by Jemperli royalties, while net income from continuing operations was $3.9 million. Regulatory updates include FDA approval for Jemperli in locally advanced rectal cancer and an expected PDUFA decision for Quimilza in December 2026. Additionally, a post-trial hearing in the litigation with GSK and Tesaro was held on October 20, 2026, with a judgment anticipated in late 2026 or early 2027.Healthcare
- MSAINov 12, 4:16 PMMultiSensor AI Holdings, Inc. reported third-quarter 2026 net revenue of $1.5 million, a decrease from $1.6 million in the same period of 2025, driven by lower hardware sales and the discontinuation of inspection services. Software subscriptions now constitute the majority of revenue, accounting for 58% of the total, while the company posted a net loss of $1.9 million for the quarter. The company ended the period with $20.4 million in cash and cash equivalents, having reduced its cash burn rate through disciplined spending and strong collections. Strategic progress included the launch of a 14-site rollout in North America for a major global distributor and the expansion of deployments with Manchester Airports Group and a new pilot in the Asia-Pacific region.Technology
- WATTNov 12, 4:16 PMEnergous Wireless Power Solutions reported third-quarter 2026 revenue of approximately $3.4 million, representing a 167% increase compared to the same period in 2025. Year-to-date revenue for the nine months ended September 30, 2026, reached $9.6 million, a 270% rise over the prior year that exceeded the company's full-year 2025 revenue of $5.6 million. The company achieved a gross margin of 14% in the third quarter, improving from 3% in the second quarter, while shipping over 69,500 transmitters since 2024. Energous maintained a net loss of approximately $2.5 million for the quarter, or $0.45 per share, and held $28.8 million in cash and cash equivalents as of September 30, 2026.Technology
- RNANov 12, 4:16 PMAtrium Therapeutics reported third-quarter 2026 financial results, recording $15.3 million in collaboration revenue primarily from a milestone payment with Bristol Myers Squibb. The company dosed the first patient in its Corventis Phase 1/2 clinical trial for ATR 1072, a treatment targeting the root cause of PRKAG2 syndrome, following nonclinical data showing the drug reversed cardiac glycogen accumulation. A $50 million private placement closed in October, bringing the pro-forma cash balance to $293.6 million and extending the company's operational runway through 2028. For the quarter, the company reported research and development expenses of $13.8 million and general and administrative expenses of $8.2 million.Healthcare
- AMPGNov 12, 4:16 PMAmpliTech Group reported third-quarter 2026 revenue of $6.58 million, an 8.0% increase year-over-year, with gross margin expanding sequentially to 34.2%. The company achieved a nine-month gross profit growth of 41.1% to $7.07 million while narrowing its net loss to $1.89 million for the quarter. Following quarter-end, AmpliTech announced record bookings near $25 million in October, pushing its total backlog to over $52 million. Management revised its full-year 2026 revenue outlook to at least $28 million, citing supply-chain constraints and deployment delays that prevented the achievement of a previously withdrawn $50 million target.Technology
- TNONNov 12, 4:15 PMTenon Medical, Inc. reported third-quarter 2026 revenue of $1.4 million, representing a 22% increase compared to the same period in 2025. The company achieved a gross profit of $1.0 million with a gross margin of 66.3% and ended the quarter with $8.3 million in cash and cash equivalents. During the quarter, Tenon raised approximately $15.6 million in gross proceeds, fully repaid its senior convertible notes, and launched the 3D-printed lateral screw for its SImmetry+ SI Joint Fusion System. Additionally, the company added eight new U.S. patents to its portfolio, bringing the total to 38 issued patents.Healthcare
- VNRXNov 12, 4:15 PMVolitionRx Limited reported third-quarter 2026 revenue of approximately $1.6 million, a 157% increase from the prior year, driven by deferred revenue recognition. The company narrowed its operating loss to $3.3 million and reduced its net loss to $3.8 million while strengthening its balance sheet with $2.4 million in cash and the full repayment of a $7.5 million convertible note. Strategic progress includes the launch of the DETECSEPS program for sepsis detection, active licensing discussions for its Capture-Seq technology targeting a combined market over $36 billion, and a pending reimbursement submission for its lung cancer test in France. Additionally, the CEO and board voluntarily reduced their compensation by 50% to align with the company's cost-reduction efforts and commitment to securing licensing agreements.Healthcare
- RCKTNov 12, 4:15 PMRocket Pharmaceuticals reported a net loss of $49.2 million for the third quarter of 2026, with cash, cash equivalents, and investments totaling $279.4 million as of September 30, 2026. The company received FDA alignment to complete its pivotal Phase 2 trial of RP-A501 for Danon disease, with dosing expected to finish by mid-2027. Additionally, dosing has begun in the Phase 1 trial for RP-A701 targeting BAG3-associated dilated cardiomyopathy, and the commercial product KRESLADI achieved readiness with activated treatment centers on October 1, 2026.Healthcare
- QXONov 12, 4:15 PMQXO, Inc. reported a net loss of $123 million for the third quarter of 2026, with net sales reaching $4.90 billion. Despite the GAAP loss, the company achieved an Adjusted Net Income of $229 million and Adjusted EBITDA of $557 million, driven by a 2.2% year-over-year pricing increase and strong demand in mechanical insulation and data centers. The company serves 194,000 customers across its integrated legacy businesses and has authorized a $500 million share repurchase program. Management projects reaching $4 billion in adjusted EBITDA and $50 billion in annual revenue by 2030 through organic growth and acquisitions.Industrials
- GCTSNov 12, 4:15 PMGCT Semiconductor Holding, Inc. reported third-quarter 2026 net revenues of $1.1 million, representing a 148.6% increase from the prior year period, driven by shipments of over 3,200 5G chipsets. The company achieved a net loss of $7.4 million, a 46.7% decrease year-over-year, which included $6.2 million in gains from changes in the fair value of warrant liabilities. Cash and cash equivalents stood at $17.2 million as of September 30, 2026, while the company extended the maturities of $26.5 million in loans during the quarter. Management expects 5G shipment volumes to ramp significantly into the first half of 2027 as customer integration schedules progress.Technology
- NEOVNov 12, 4:15 PMNeoVolta Inc. reported revenue of $2.8 million for the quarter ended September 30, 2026, a significant increase from the previous quarter driven by initial sales through its third-party ownership residential platform. The company achieved a gross profit of $1.0 million, reversing a prior gross loss, while reporting a GAAP net loss of $7.7 million and adjusted EBITDA of negative $5.5 million. Financial results were supported by a $20 million senior secured term loan, bringing total cash and restricted cash to $28.8 million. Strategic progress included the ramp-up of the Pendergrass, Georgia manufacturing facility, a $116 million master purchase agreement for utility-scale products, and a supply collaboration with SK On for 9 GWh of battery cells.Industrials
- CBIONov 12, 4:15 PMCrescent Biopharma completed dose escalation in its Phase 1/2 ASCEND trial for CR-001, having dosed over 125 patients across the United States, Europe, and South Korea, with initial monotherapy data expected in the first quarter of 2027. The company has also dosed the first patient in the global APOLLO trial for CR-002, a PD-L1-targeted ADC, while multiple Phase 2 studies of CR-001 combinations with sacituzumab tirumotecan are ongoing in China. Financially, Crescent reported a net loss of $37.7 million for the third quarter of 2026, with cash and cash equivalents totaling $289.4 million as of September 30, 2026.Healthcare
- FLONov 12, 4:15 PMFlowers Foods, Inc. reported third-quarter 2026 net sales of $1.169 billion, a 4.7% decrease from the prior year, driven by a 7.0% decline in volume that outweighed a 2.3% favorable price and mix. Net income fell 63.6% to $14.4 million, while adjusted net income decreased 56.0% to $21.4 million, resulting in diluted earnings per share of $0.07. The company cited challenging market conditions, including pressure on household budgets and higher logistics costs, as key factors impacting performance. Consequently, Flowers Foods revised its full-year 2026 guidance downward, projecting net sales between $5.016 billion and $5.063 billion and adjusted diluted EPS between $0.63 and $0.68.Consumer Defensive
- BLSMNov 12, 4:15 PMBlossomHill Therapeutics reported a net loss of $24.0 million for the third quarter of 2026, driven by increased research and development expenses related to its lead candidate BH-30643. The company aligned with the FDA on a recommended Phase 2 dose of 50 mg twice daily for BH-30643 and announced the upcoming SOLARA-2 pivotal trial, which is expected to dose its first patient in the first quarter of 2027. Additionally, BlossomHill plans to submit an Investigational New Drug application for its pan-KRAS inhibitor, BH-501284, in the first quarter of 2027. As of September 30, 2026, the company held $224.9 million in cash and cash equivalents, which is projected to fund operations through the second quarter of 2028.Healthcare
- AZTRNov 12, 4:15 PMAzitra, Inc. reported a net loss of $3.0 million for the quarter ended September 30, 2026, with total operating expenses reaching $2.9 million. The company announced positive ex vivo results for its ATR-COSF program, demonstrating a 50% reduction in fine lines and improved skin elasticity, and plans to initiate a first-in-human cosmetic study with results expected by year-end. Additionally, Azitra completed Cohort 1 of its ATR-04 Phase 1/2 trial and received approval to proceed to Cohort 2, which will expand eligibility to include patients with KRAS and MEK inhibitor-associated rashes. As of September 30, 2026, the company held $3.8 million in cash and cash equivalents.Healthcare
- IMMXNov 12, 4:15 PMImmix Biopharma reported a 89% complete response rate across all 45 patients in its NEXICART-2 clinical trial for NXC-201, with potential for up to 98% complete response. The company appointed David He as Senior Vice President of Technical Operations and Karin McIntosh as Senior Vice President of Regulatory Affairs to advance commercial launch preparations. Immix plans to submit a Biologics License Application in mid-2027 and initiate the NEXICART-3 front-line trial in the first half of 2027. For the third quarter ended September 30, 2026, the company reported $340.9 million in cash and marketable securities, providing an operating runway into mid-2028, alongside $15.9 million in operating expenses.Healthcare
- HKHCNov 12, 4:15 PMHorizon Kinetics Holding Corporation reported a net loss of $18.4 million for the third quarter of 2026, driven by unrealized declines in the fair value of key investment holdings. Management and advisory fees remained flat at $17.8 million for the quarter, while assets under management decreased 7.3% to $10.0 billion. The company declared a $0.13 per share cash dividend and authorized a $25 million share repurchase program. Year-to-date results showed a net income of $35.8 million, reflecting unrealized gains that offset the quarterly losses.
- KLCNov 12, 4:15 PMKinderCare Learning Companies reported a net loss of $85.0 million for the third quarter of 2026, driven by $83.4 million in impairment losses and a 5.9% decline in enrollment at its early childhood education centers. Total revenue for the period decreased 1.7% to $665.3 million, while adjusted EBITDA fell to $42.5 million compared to the prior year quarter. The company closed 20 centers as part of an optimization initiative and updated its full-year 2026 revenue guidance to a range of $2.64 billion to $2.66 billion.Consumer Defensive
- MRLNNov 12, 4:14 PMMerlin, Inc. reported a third quarter 2026 GAAP net income of $73.8 million, a significant turnaround from the $58.4 million loss in the second quarter of 2026. Total revenue for the quarter reached $3.5 million, while the company ended the period with $161.6 million in cash, cash equivalents, and short-term investments and no outstanding debt. The company secured an $8.9 million task order from USSOCOM for its C-130J autonomy program and a $500,000 contract from USAFRICOM for an autonomous casualty evacuation demonstration. Looking ahead, Merlin plans to reduce 2027 operating expenses by focusing investment on funded programs with clear revenue paths to preserve its balance sheet.Industrials
- NTLANov 12, 4:14 PMIntellia Therapeutics has submitted a Biologics License Application for lonvo-z, an investigational one-time in vivo CRISPR gene editing therapy for hereditary angioedema (HAE), with a PDUFA goal date of March 10, 2027. Phase 3 HAELO trial data demonstrated a 62% reduction in mean attack rates and an 87% reduction in attack-free weeks compared to placebo, with benefits sustained for up to four years in long-term follow-up. The treatment permanently inactivates the KLKB1 gene to stop excess kallikrein production, offering a potential cure that eliminates the need for chronic long-term prophylaxis and significantly reduces the disease burden for patients.Healthcare
- TACTNov 12, 4:13 PMTransAct Technologies reported preliminary third-quarter 2026 net sales of $14.4 million, representing a 10% increase year-over-year driven by a 33% rise in Food Service Technology revenue. The company recorded a net loss of $440 thousand for the quarter, with adjusted EBITDA reaching $289 thousand, while revising its full-year 2026 revenue guidance to between $55 million and $56 million. Management highlighted strong growth in FST software revenue and online unit installations, though the Casino and Gaming segment experienced a decline due to cyclicality. Additionally, the Board has initiated a strategic review of the Casino and Gaming business, potentially including a sale of the FST division, to maximize stockholder value.Technology
- SERNov 12, 4:13 PMSerina Therapeutics reported a net loss of $7.9 million for the third quarter of 2026, driven by increased research and development expenses related to clinical activities. The company advanced its investigational Parkinson's disease treatment, SER-252, to Cohort 2 of its registrational study following a positive safety review by an independent committee. Cash and cash equivalents increased to $19.4 million as of September 30, 2026, supported by financing activities. Topline data from the single-ascending-dose portion of the SER-252 trial is expected in the first half of 2027.Healthcare
- SSTINov 12, 4:12 PMSoundThinking, Inc. reported third-quarter 2026 revenues of $25.0 million, a slight decrease from the prior year, while GAAP net loss widened to $8.5 million compared to $2.0 million in the same period of 2025. The company announced a definitive merger agreement with Transom Capital Group to be acquired for $8.00 per share in cash plus contingent value rights, with an expected closing in the fourth quarter of 2026. Due to the pending transaction, SoundThinking will not provide forward-looking guidance or host an earnings conference call for this quarter or future quarters. Adjusted EBITDA for the quarter totaled $2.2 million, down from $3.5 million in the previous year, driven by increased acquisition-related costs and higher operating expenses.Technology
- OFRMNov 12, 4:12 PMOnce Upon a Farm reported third-quarter 2026 net sales of $89.1 million, representing a 34.9% increase from the prior year period. The company posted a net loss of $3.8 million and an adjusted EBITDA loss of $1.0 million, driven by trade investments and cooler placement costs that reduced gross margin to 36.1%. As of September 30, 2026, the company held $106.4 million in cash and cash equivalents with no outstanding debt. Consequently, the company updated its full-year 2026 outlook, lowering net sales guidance to $290–$300 million and adjusting the adjusted EBITDA loss forecast to $4.5–$7 million due to the impact of a voluntary product recall.Consumer Defensive
- SRTSNov 12, 4:12 PMSensus Healthcare reported third-quarter 2026 revenues of $6.0 million, a 13% decrease from the prior year, driven by a shift toward lower-priced SRT-100 systems and the absence of sales to a historically large customer. Despite lower revenue, gross profit increased to $3.3 million as the gross margin improved to 55% due to a favorable product mix and lower cost of sales. The company shipped 26 systems during the quarter, including eight carried over from the previous quarter, and announced the sale of its 1,000th SRT system subsequent to the quarter end. Net loss for the period was $1.5 million, or $0.09 per share, while adjusted EBITDA improved to a negative $1.5 million from negative $2.4 million in the prior year.Healthcare
- BOLTNov 12, 4:11 PMBolt Biotherapeutics completed the acquisition of Prana Therapies in a stock-for-stock reverse merger and secured $120 million in concurrent private placement financing. The company has designated the INSPIRE-built pipeline, led by the Phase 2 bispecific antibody PRA-216, as its primary development focus for treating asthma, atopic dermatitis, and chronic obstructive pulmonary disease. PRA-216 Phase 1 data demonstrated the potential for at-home maintenance dosing every 8 to 12 weeks, with initial Phase 2 proof-of-concept data expected in the second quarter of 2027. For the third quarter of 2026, the company reported a net loss of $4.4 million and operating expenses of $4.7 million, while its cash runway is projected to extend into 2028.Healthcare
- BCDANov 12, 4:11 PMBioCardia, Inc. reported a net loss of $1.8 million for the third quarter of 2026, with total operating expenses reaching $1.8 million. The company successfully completed regulatory interactions with Japan's PMDA regarding its CardiAMP autologous cell therapy and expects to submit for approval in Japan during late 2026 or early 2027. Additionally, the FDA accepted the company's pre-submission minutes for the Helix transendocardial delivery system, with a full De Novo submission targeted for the first quarter of 2027. BioCardia ended the quarter with $2.2 million in cash and cash equivalents, providing an anticipated runway into 2027.Healthcare
- MGNXNov 12, 4:11 PMMacroGenics reported a net loss of $20.1 million for the third quarter of 2026, with total revenue declining to $18.7 million from $53.0 million in the same period last year. The company's cash position increased to $287.7 million as of September 30, 2026, supported by milestone payments from partners and the sale of its GMP manufacturing operations. Clinical progress included the completion of Phase 1 dose escalation for MGC028, the reporting of interim results for MGC026 and lorigerlimab at ESMO 2026, and the dosing of the first patient in the Phase 1 study for MGC030. Additionally, the Board of Directors was strengthened by the appointment of two new independent directors with oncology expertise, and Gilead Sciences exercised an option to license a preclinical bispecific program, triggering a $10 million payment.Healthcare
- FDMTNov 12, 4:11 PM4D Molecular Therapeutics completed enrollment and randomization for the 4FRONT-2 Phase 3 clinical trial of its lead candidate 4D-150 in wet age-related macular degeneration, with topline data expected in the second half of 2027. The company also initiated the global 4SIGHT Phase 3 trial for 4D-150 in diabetic macular edema and presented two-year data from PRISM and SPECTRA trials demonstrating durable clinical activity and a favorable safety profile. Financially, the company reported a net loss of $78.1 million for the third quarter of 2026, driven by increased research and development expenses, while maintaining a cash position of $375 million expected to fund operations through the second half of 2028.Healthcare
- PLRXNov 12, 4:11 PMPliant Therapeutics reported a net loss of $24.4 million for the third quarter of 2026, with research and development expenses remaining flat at $17.9 million despite the termination of its bexotegrast program. The company's lead candidate, PLN-101095, continues to enroll ahead of schedule in the FORTIFY Phase 1b trial for immune checkpoint inhibitor-refractory solid tumors, with interim data expected in 2027. Pliant also announced the appointment of David Raben as Chief Medical Officer and Craig Blanchette as Senior Vice President of Research to lead its RNAi initiatives. The company's proprietary integrin-mediated delivery platform has demonstrated over 75% target gene knockdown in non-human primate studies while avoiding liver exposure, supporting plans to target neuromuscular and cardiac diseases. As of September 30, 2026, Pliant held $142.6 million in cash and short-term investments, which is projected to fund operations through mid-2028.Healthcare
- ALMSNov 12, 4:11 PMAlumis Inc. reported a net loss of $94.9 million for the third quarter of 2026, driven by $80.8 million in research and development expenses and $20.2 million in general and administrative costs. The company highlighted new Phase 3 data for its lead candidate envudeucitinib in plaque psoriasis, which demonstrated rapid and durable improvements in skin clearance and itch resolution, supporting a planned New Drug Application submission in the fourth quarter of 2026. Conversely, the Phase 2b LUMUS trial for envudeucitinib in systemic lupus erythematosus did not meet its primary endpoints in the overall population, though robust responses were observed in a subgroup with high interferon gene signatures. As of September 30, 2026, Alumis held $431.3 million in cash and marketable securities, which is expected to fund operations through the fourth quarter of 2027.Healthcare
- CBUSNov 12, 4:11 PMCibus reported a net loss of $21.9 million for the third quarter of 2026, with cash used in operating activities decreasing by approximately 19% year-over-year to $9.3 million. The company advanced its Rice herbicide-tolerance traits into customer field trials in Ecuador and initiated manufacturing for two biofragrance products, which represent a potential $100 million peak annual revenue opportunity. Regulatory progress included U.S. FDA clearance for an altered-lignin Alfalfa trait and European Union legislation treating precise genomic edits as conventional breeding. Cibus anticipates exiting 2026 with an annualized net cash usage run rate of approximately $35 million, supported by a cash balance of $10.7 million as of September 30, 2026.Healthcare
- INVENov 12, 4:11 PMINVE Technologies reported third-quarter 2026 revenue of $3.1 million, a decrease from $5.0 million in the prior year, driven by lower RFID unit sales and the divestiture of its IoT business to Trackonomy. The company achieved a GAAP net income of $0.6 million, or $0.02 per share, compared to a net loss of $3.5 million in the same period last year, primarily due to gains recognized on the asset sale and the dissolution of a foreign subsidiary. Following the September 15, 2026, sale of its IoT business, INVE Technologies currently has no commercial revenue and has suspended financial guidance. Non-GAAP operating expenses decreased to $4.0 million from $4.5 million in the prior year, reflecting disciplined cost control despite higher strategic transaction-related costs.Technology
- AAWHNov 12, 4:10 PMAscend Wellness Holdings reported third-quarter 2026 net revenue of $130.0 million, representing a 4.2% year-over-year increase and a 3.1% sequential rise. The company generated $31.1 million in Adjusted EBITDA, achieving a margin of 23.9%, while net cash provided by operating activities reached $5.4 million despite a $19.1 million semi-annual interest payment. Retail operations expanded to 61 stores, exceeding the year-end target of 60, and the company maintained its position as the number two brand house across Illinois, New Jersey, and Massachusetts. Additionally, Ascend secured $11 million in non-dilutive mortgage loans and entered a brand licensing agreement to introduce its products to the Canadian market in early 2027.
- LFMDNov 12, 4:10 PMLifeMD reported third-quarter 2026 revenue of $44.6 million, representing a 7% decline from the prior year, while adjusting its full-year revenue guidance downward to a range of $188 million to $191 million. The company achieved an adjusted EBITDA loss of approximately $0.4 million, a significant sequential improvement driven by a 34% reduction in selling and marketing expenses. Total active subscribers grew 13% year-over-year to 350,000, and the pharmacy division saw shipment volume increase by 58.3%. Strategic developments included new dispensing agreements for branded GLP-1 medications with Novo Nordisk and Eli Lilly, as well as an exclusive partnership with AT&T to serve its customer base.Healthcare
- RLMDNov 12, 4:10 PMRelmada Therapeutics reported a net loss of $13.9 million for the third quarter of 2026, with research and development expenses rising to $9.2 million. The company holds approximately $202.1 million in cash and short-term investments as of September 30, 2026, which is projected to fund operations through 2029. Clinical updates indicate that 86% of patients in the NDV-01 Phase 2 study who achieved a complete response at 12 months remained in complete response at 18 months. Relmada remains on track to submit Investigational New Drug applications for both NDV-01 and sepranolone by the end of 2026, with the registrational Phase 3 SPECTRUM program for NDV-01 expected to commence upon clearance.Healthcare
- OPHCNov 12, 4:10 PMOptimumBank Holdings, Inc. reported net income of $7.2 million, or $0.30 per share, for the third quarter of 2026, marking an increase from the previous quarter and the same period last year. The company's gross loan portfolio grew by $150.2 million to $1.37 billion, while total deposits rose by $128.8 million to $1.34 billion during the quarter. Net interest income increased to $16.8 million, driven by higher yields on loans and securities, resulting in a net interest margin of 4.63%. Additionally, the company strengthened its capital position through a $35.0 million subordinated debt offering and maintained strong asset quality with net charge-offs of only $11,000.Financial Services
- UAMYNov 12, 4:10 PMUnited States Antimony Corporation reported third-quarter 2026 revenues of $10.1 million, a 16% increase from the prior year, driven by a 68% rise in antimony pounds sold. The company achieved a gross profit margin of 42%, up from 23% in the previous year, resulting in $4.3 million in gross profit despite a net loss of $9.5 million due to non-cash stock-based compensation and an unrealized loss on an equity investment. Antimony sales included approximately 162,000 pounds of metal ingots accepted by the Defense Logistics Agency, contributing $5.1 million in revenue, while industrial sales volumes increased 10% year-over-year. The company provided full-year 2026 guidance for antimony sales volumes between 1.68 million and 1.81 million pounds, representing a 24% increase over 2025, and maintained significant liquidity with $51.0 million in cash and U.S. Treasury securities.Basic Materials
- PEWNov 12, 4:10 PMGrabAGun Digital Holdings reported third-quarter 2026 net revenues of $21.2 million, a 4.7% decrease from the prior year, driven by lower firearms and non-firearms sales. Despite the revenue decline, the company achieved a 44% increase in gross profit and expanded its gross margin by 480 basis points to 14.4%, supported by improved average selling prices and sourcing. The company posted a net loss of $3.0 million for the quarter and $6.7 million for the first nine months, while maintaining $96.0 million in cash and minimal debt. Subsequent to the quarter, GrabAGun completed the acquisition of Camfour, a New England-based wholesale distributor, to broaden its distribution capabilities.Industrials
- FLNTNov 12, 4:10 PMFluent, Inc. reported third-quarter 2026 revenue of $53.6 million, a 14% increase year-over-year, driven by Commerce Media Solutions revenue doubling to $37.5 million. The company's Commerce Media Solutions segment now accounts for 70% of total revenue with an annual run rate exceeding $145 million and a gross margin of 30%. Net loss for the quarter narrowed to $3.1 million from $7.6 million in the prior year period, while adjusted EBITDA reached near-breakeven at $0.0 million. Fluent expects full-year 2026 to deliver double-digit revenue growth on aggregate continuing businesses and improved adjusted EBITDA.Communication Services
- SMTINov 12, 4:10 PMSanara MedTech Inc. reported third-quarter 2026 net revenue of $28.4 million, an 8% increase from the prior year, driven by growth in soft tissue repair products. The company posted a net loss from continuing operations of $1.3 million, or $0.15 per diluted share, compared to a net income of $0.8 million in the same period last year. Adjusted EBITDA for the quarter rose to $5.6 million, while the company updated its full-year 2026 revenue guidance to a range of $110 million to $115 million. Additionally, Sanara continues to advance its pending merger with MiMedx Group, Inc., which received shareholder approval in September.Healthcare
- SNALNov 12, 4:10 PMSnail, Inc. reported third-quarter 2026 net revenues of $33.1 million, representing a 139.2% increase from the prior year period, driven primarily by strong sales of ARK: Survival Ascended and its downloadable content. The company achieved a net income of $6.7 million for the quarter, a significant turnaround from a net loss of $7.9 million in the same period last year, while total units sold rose 73.3% to 2.0 million. Key operational highlights included the launch of new ARK content updates, the release of titles such as Bellwright and Honeycomb: The World Beyond, and the unveiling of upcoming AAA projects like 9 Yin Sutra and For The Stars. Looking ahead, Snail expects continued momentum from its established ARK content pipeline extending through 2027 and the anticipated release of ARK: Dragontopia in December 2026.Communication Services
- EQNov 12, 4:10 PMEquillium, Inc. initiated a Phase 1 clinical trial for its investigational drug EQ504 in October 2026, with proof-of-mechanism data expected in the second quarter of 2027. The company reported cash and cash equivalents of $53.3 million as of September 30, 2026, and secured an additional $20 million in financing later that month, extending its cash runway into 2029. For the third quarter of 2026, Equillium recorded a net loss of $4.6 million, driven by research and development expenses of $2.5 million and general and administrative expenses of $2.6 million. EQ504 is a selective aryl hydrocarbon receptor modulator designed to treat ulcerative colitis and other inflammatory disorders through a non-immunosuppressive mechanism.Healthcare
- LCTXNov 12, 4:10 PMLineage Cell Therapeutics reported a net income of $4.2 million for the third quarter of 2026, driven primarily by a non-cash gain from the fair value remeasurement of warrant liabilities. The company acquired NeuroAirmid Therapeutics, adding the HUNT1 clinical-stage cell therapy candidate for Huntington's Disease to its pipeline, and secured a U.S. patent for its AlloSCOPE 5D manufacturing technology. Financial results showed total revenues of $1.4 million and operating expenses of $8.8 million, with cash and marketable securities totaling $45.2 million expected to fund operations through the second quarter of 2028. Key program updates include the advancement of the ReSonance hearing loss therapy into the second year of its collaboration with William Demant Invest and the initiation of preclinical testing for the COR1 corneal endothelial disease program.Healthcare
- ELDNNov 12, 4:10 PMEledon Pharmaceuticals reported a net loss of $3.9 million for the third quarter of 2026, driven by $17.8 million in research and development expenses, while maintaining $69.7 million in cash and short-term investments sufficient to fund operations into the second quarter of 2027. The company received FDA Fast Track designation for tegoprubart in kidney transplantation and cleared an IND application for a registrational study in islet cell transplantation for type 1 diabetes. Clinical updates included new patient-reported outcome data showing improved quality of life and symptom burden for tegoprubart compared to tacrolimus in kidney transplant recipients, alongside long-term data demonstrating sustained eGFR advantages. Upcoming milestones include the initiation of the global Phase 3 LEGACY trial for kidney transplantation in the fourth quarter of 2026 and the start of a registrational path study for islet cell transplantation.Healthcare
- RKDANov 12, 4:09 PMArcadia Biosciences reported third-quarter 2026 total revenues of $1.619 million, representing a 24% year-over-year increase driven by strong summer program volumes. The company achieved net income of $1.755 million for the quarter, a significant improvement from the $856,000 net income recorded in the same period of 2025, largely due to a $2.6 million gain from changes in the fair value of warrant and option liabilities. Zola brand revenues reached their highest quarterly sales ever, with a new 1-liter espresso formulation beginning shipments and slim can variants scheduled for launch in early 2027. Operating expenses for the nine-month period decreased by 23% compared to the prior year, offset by a $2.7 million reduction in other operating income related to the absence of prior-year patent transfer gains.Consumer Defensive
- ACCVNov 12, 4:08 PMAccelevation Holdings Corp. reported third-quarter 2026 revenue of $202.2 million, representing a 65.9% year-over-year increase, while bookings surged 364% to $768.9 million. The company achieved a backlog of $1.7 billion and an adjusted EBITDA of $37.7 million, with operating cash flow turning positive to $62.5 million. Following its initial public offering in October 2026, the company entered into a new $650 million senior secured credit agreement to reduce leverage. Management has issued full-year 2026 guidance projecting revenue between $905 million and $915 million and adjusted EBITDA between $155 million and $165 million.Industrials
- REKRNov 12, 4:08 PMRekor Systems reported a net loss of $2.9 million for the third quarter of 2026, narrowing from $4.1 million in the prior year period, while recurring revenue grew 16% to $7.5 million. The company reduced its nine-month operating cash use by 49% to $10.6 million following a major rightsizing initiative that eliminated approximately $9.7 million in lease liabilities. Recent business developments include a potential $1.4 million five-year contract with the Oregon Department of Transportation and a 94% increase in the contract ceiling with the Florida Department of Transportation. Additionally, Rekor expanded its Born Authentic product line to include audio authentication and is actively pursuing refinancing for its $15 million Series A Prime Revenue Sharing Notes due in December 2026.Technology
- ERASNov 12, 4:08 PMErasca, Inc. reported a net loss of $51.3 million for the third quarter ended September 30, 2026, while maintaining a cash position of $947.8 million. The company's lead candidate, ERAS-0015, received FDA Fast Track Designation for metastatic pancreatic adenocarcinoma in August 2026. Erasca is advancing toward three potentially registration-enabling trials in pancreatic and lung cancers, with preliminary data for ERAS-4001 expected in the second half of 2026. Additionally, the firm completed an upsized public offering in July 2026 that raised approximately $632.5 million to fund its development pipeline.Healthcare
- OBXNov 12, 4:07 PMObsidian Therapeutics reported third-quarter 2026 financial results showing a net loss of $50.7 million and cash reserves of $324.4 million as of September 30, 2026. The company presented updated efficacy data for its lead candidate amsoki-cel in advanced melanoma, demonstrating a 67% objective response rate and a median progression-free survival of 8.3 months in the registration-enabling cohort of the Agni-01 study. Enrollment in this cohort is expected to conclude by the end of the first quarter of 2027, with topline data anticipated by the end of 2027. Corporate updates include the completion of a $350 million financing round, the closing of a transaction with Galera Therapeutics, and the appointment of Mark Reisenauer to the Board of Directors.Healthcare
- SHIMNov 12, 4:07 PMShimmick Corporation reported a net income of $1 million for the third quarter ended October 2, 2026, marking its first positive net income since the third quarter of 2023. Revenue for the quarter reached $136 million, driven entirely by Shimmick Projects which saw a 28% increase quarter-over-quarter, while Adjusted EBITDA rose 106% to $9 million. The company's liquidity increased by $20 million to $53 million, and its backlog stands at approximately $907 million with Shimmick Projects representing 98% of the total. Management reaffirmed full-year 2026 Adjusted EBITDA guidance between $20 million and $25 million and raised revenue expectations to a range of $500 million to $525 million.Industrials
- IDNNov 12, 4:07 PMIntellicheck reported a net income of $0.5 million for the third quarter of 2026, marking its fifth consecutive quarter of profitability. Revenue for the period totaled $5.7 million, while Adjusted EBITDA increased to $0.9 million, representing the sixth consecutive quarter of positive performance. The company ended the quarter with $13.2 million in cash and no debt, its highest cash balance since the end of 2021. Banking and lending remained the fastest-growing vertical, with momentum also observed in emerging sectors such as cargo, freight, and automotive credit.Technology
- TMCNov 12, 4:07 PMThe Metals Company reported a net loss of $28.4 million for the third quarter of 2026, with liquidity of approximately $123 million available as of September 30. The company's subsidiary, TMC USA, received an updated timeline from NOAA expecting a final certification determination by mid-December 2026 for its USA-A commercial recovery permit application. TMC is advancing a capital-light production strategy with Allseas to initiate operations upon permit grant, while simultaneously pursuing U.S. government funding for a processing facility in Brownsville, Texas. Additionally, the company appointed Liam Mallon, former President of ExxonMobil Upstream, to its Board of Directors to leverage his extensive energy and offshore experience.Basic Materials
- NPCENov 12, 4:07 PMNeuroPace reported third-quarter 2026 total revenue of $23.1 million, with RNS System revenue reaching $22.9 million, representing a 1.4% year-over-year growth. The company revised its full-year 2026 revenue guidance downward to a range of $91 million to $92 million, citing the need to improve commercial execution following isolated account-level issues. Despite a net loss of $3.3 million for the quarter, the company achieved a positive adjusted EBITDA of $0.4 million and increased its non-GAAP gross margin to 84.8%. Strategic advancements include an FDA submission for the NeuroPace Remote Care system and the initiation of the AURORA study to support indication expansion for adolescents.Healthcare
- SLSNov 12, 4:07 PMSELLAS Life Sciences reported a net loss of $10.1 million for the third quarter of 2026, with research and development expenses rising to $7.0 million due to costs associated with the Phase 3 REGAL trial and potential Biologics License Application for GPS. The company holds $134.7 million in cash and cash equivalents as of September 30, 2026, providing capital to advance its clinical programs. Topline primary endpoint results for the Phase 3 REGAL trial of Galinpepimut-S in acute myeloid leukemia are expected to be announced following the 80th event milestone. Additionally, 40 patients have been enrolled in the Phase 2 trial of tambiciclib (SLS009) for newly diagnosed AML, with preliminary data anticipated in the fourth quarter.Healthcare
- LFTONov 12, 4:07 PMLiftoff Mobile reported third-quarter 2026 revenue of $238 million, representing an 8% increase from the previous quarter and a 32% year-over-year growth. The company achieved a net income of $87 million and an adjusted EBITDA of $145 million, with margins of 37% and 61% respectively. Trailing twelve-month free cash flow rose 158% to $249 million, driven by strong performance across key app categories. Management provided fourth-quarter revenue guidance between $244 million and $249 million and full-year revenue guidance between $907 million and $912 million.Communication Services
- KSCPNov 12, 4:06 PMKnightscope reported third-quarter 2026 revenue of $8.7 million, representing a 177% increase year over year and marking the third consecutive quarter of triple-digit growth. The company achieved a positive gross margin of $0.4 million, driven by a 349% surge in service revenue to $8.6 million, while operating expenses rose to $12.0 million. Knightscope unveiled its Autonomous Security Force at GSX 2026 and secured approximately $27 million in renewals and bookings since May 2026, though the company reported a net loss of $11.8 million for the quarter.Industrials
- AZRNov 12, 4:06 PMAzora Therapeutics, Inc. reported a net loss of $64.6 million for the third quarter ended September 30, 2026, driven primarily by a $57.1 million non-cash charge related to the change in fair value of milestone warrant rights liability. The company's cash and cash equivalents stood at $22.0 million as of the quarter's end, which is expected to fund operations through the initiation of a Phase 1a clinical trial. Azora advanced its lead candidate, AT177, an oral AhR agonist for ulcerative colitis, through IND-enabling studies with a planned IND submission and Phase 1a trial initiation in the first half of 2027. Corporate updates include a name change from Adial Pharmaceuticals, a new Nasdaq ticker symbol (AZR), and the appointment of a new executive team and Board of Directors effective late October 2026.Healthcare
- STEXNov 12, 4:06 PMStreamex Corp. reported a net loss of $17.5 million for the third quarter of 2026, driven primarily by $9.3 million in non-cash stock-based compensation. The company's gold-backed token, GLDY, grew by 240 net ounces to reach 3,351 ounces, while external ownership of the token doubled to 17.7% of the outstanding supply. Streamex ended the quarter debt-free with a total liquidity position of $36.5 million, including $13.2 million in cash and investments, and announced that GLDY will soon launch on Equity Trust's IRA platform.Healthcare
- CSCONov 12, 4:06 PMCisco reported record first-quarter revenue of $18.5 billion, representing a 24% year-over-year increase, alongside record non-GAAP earnings per share of $1.40. The company raised its full-year fiscal 2027 revenue guidance to a range of $74.8 billion to $75.8 billion and increased its AI infrastructure revenue expectation from hyperscalers to $9 billion for the year. Operating performance was driven by broad-based demand, with product revenue growing 32% and double-digit growth observed across all geographic regions and customer markets.Technology
- EVMNNov 12, 4:06 PMEvommune, Inc. reported a net loss of $30.9 million for the third quarter of 2026, with cash and investments totaling $262.3 million as of September 30, 2026. The company in-licensed EVO570, an oral VAV-1 molecular glue degrader, for $30 million and concurrently raised $30 million through a private placement of common stock. Clinical updates include positive Phase 2a data for EVO301 in atopic dermatitis, which supports a Phase 2b trial expected to initiate in mid-2027, alongside plans to begin Phase 1 trials for EVO570 and EVO646 in early 2027.Healthcare
- HQINov 12, 4:06 PMHireQuest reported third-quarter 2026 net income of $1.7 million, or $0.12 per diluted share, a decrease from $2.3 million in the same period of 2025. Total revenue for the quarter reached $8.8 million, representing a 4.0% increase year-over-year, while adjusted EBITDA remained consistent at $4.5 million. The decline in net income was primarily driven by a $1.3 million write-down of notes receivable related to a franchised location repossession and higher workers' compensation expenses. System-wide sales for the quarter totaled $131.2 million, with pro forma growth of 11.4% after accounting for the MRINetwork Assets Divestiture.Industrials
- SLSNNov 12, 4:06 PMSolésence, Inc. reported record third-quarter 2026 financial results with revenue increasing 38% year-over-year to $20.2 million. The company achieved its highest-ever net income of $3.7 million, a significant turnaround from a $1.0 million net loss in the same period of 2025. Gross margin expanded substantially to 39.3% from 23.8% in the prior year, driven by operational improvements and capacity enhancements. These results position the company for sustained growth as it continues to scale its manufacturing and innovation capabilities.Consumer Defensive
- OPNWNov 12, 4:05 PMOpenWorld, Inc. reported third-quarter 2026 revenue of $7.4 million, driven by a $6.4 million contribution from its new real-world asset (RWA) platform which achieved an 80% gross margin. The company recorded a GAAP net loss of $10.2 million for the quarter, primarily due to $6.4 million in non-recurring stock-based compensation and $6.0 million in merger-related professional fees. Subsequent to the quarter, OpenWorld secured $1.1 billion in non-binding letters of intent for tokenized financing programs involving AI infrastructure and intellectual property. The company also completed a $3.5 million registered direct offering and the acquisition of Blocksight Holdings to enhance its platform capabilities.Technology
- DERMNov 12, 4:05 PMJourney Medical Corporation reported total revenues of $19.0 million for the third quarter of 2026, representing an 8% increase from the prior year period. The company's flagship product, Emrosi, generated $9.0 million in revenue, marking an 84% year-over-year growth driven by increased prescription demand and improved reimbursement mixes. Gross margin improved to 69% for the quarter, while the GAAP net loss narrowed to $1.3 million compared to $2.3 million in the same period of 2025. The company ended the quarter with $22.3 million in cash and cash equivalents and achieved positive non-GAAP EBITDA of $3.5 million.Healthcare
- JCAPNov 12, 4:05 PMJefferson Capital reported record third-quarter 2026 results with collections growing 35% to $319.2 million and deployments surging 111% to $318.0 million. The company achieved a record Estimated Remaining Collections (ERC) of $3.6 billion, representing a 23% increase from the prior year period. Financial performance included pre-tax income of $58.9 million and net income of $46.9 million, resulting in earnings per share of $0.76. Additionally, the Board of Directors declared a quarterly cash dividend of $0.24 per share, payable in December 2026.Financial Services
- ADRXNov 12, 4:05 PMADARx Pharmaceuticals completed its initial public offering and a concurrent private placement, generating approximately $602.5 million in aggregate gross proceeds. The company advanced three Phase 2 clinical trials for its lead candidate agazisiran to treat complement-mediated diseases and received Fast Track designation from the FDA for onvuzosiran in hereditary angioedema. For the third quarter ended September 30, 2026, the company reported collaboration revenue of $2.2 million, research and development expenses of $26.7 million, and a net loss of $28.1 million. As of the end of the quarter, ADARx held $901.0 million in cash, cash equivalents, and short-term investments, which is expected to fund operations into 2030.Healthcare
- NMAXNov 12, 4:05 PMNewsmax Inc. reported record third-quarter 2026 revenues of $69.0 million, representing a 52.5% year-over-year increase, driven by a $14.0 million non-recurring service revenue termination fee. Excluding this one-time item, the company achieved a record $55.0 million in revenue, a 21.6% increase, alongside a net income of $15.2 million and adjusted EBITDA of $19.0 million. The broadcaster expanded its audience reach to 22.5 million total viewers and grew social media followers by 13% to 26.8 million while launching international services including Newsmax Ukraine. Newsmax maintained its full-year 2026 revenue guidance of $212 million to $216 million, excluding the one-time payment, which reflects 13% year-over-year growth at the midpoint.Communication Services
- DMRCNov 12, 4:05 PMDigimarc Corporation reported third-quarter 2026 total revenue of $6.4 million, a decrease from $7.6 million in the same period of 2025, driven by the expiration and step-down of major commercial contracts. The company's ending Annual Recurring Revenue (ARR) declined to $10.8 million from $15.8 million the prior year, though service revenue increased to $3.3 million. Net loss attributable to Digimarc Corporation for the quarter was $8.1 million, or $0.36 per diluted share, while non-GAAP net loss was $2.9 million. At the end of the quarter, the company held $22.1 million in cash, cash equivalents, and marketable securities, with free cash flow usage totaling $4.3 million.Technology
- PRMENov 12, 4:05 PMPrime Medicine dosed the first patient in its global Phase 1/2 clinical trial for PM577a, an in vivo Prime Editing therapy for Wilson disease, with initial data expected in 2027. The company received FDA clearance for its Investigational New Drug application for PM647 to treat Alpha-1 Antitrypsin Deficiency, also anticipating initial clinical data in 2027. Prime Medicine plans to submit a Biologics License Application for PM359 in Chronic Granulomatous Disease during the first half of 2027. In November 2026, the company raised $143.7 million in gross proceeds from a public offering, bringing its pro-forma cash position to approximately $209.5 million to fund operations through 2027.Healthcare
- SSTNov 12, 4:05 PMSystem1, Inc. reported third-quarter 2026 revenue of $26.0 million, a significant decline from the $61.6 million recorded in the same period of 2025. The company posted a GAAP net loss of $61.5 million and an adjusted EBITDA of negative $0.7 million, driven by substantial impairment charges and reduced monetization from Google's AI overviews. Key operational highlights included the MapQuest app reaching number one on major app stores and Startpage integrating into Mozilla's Firefox browser. In response to these financial pressures and strategic shifts, System1 announced its intention to voluntarily delist from the New York Stock Exchange and move to the OTC Venture Market.Industrials
- INTZNov 12, 4:05 PMIntrusion Inc. reported third-quarter 2026 revenue of $2.7 million, marking an 84% sequential increase and a 36% year-over-year rise driven by the first full quarter of contributions from the VigilAigent acquisition and a contract with the State of Texas. The company recorded a net loss of $2.9 million for the quarter, with operating expenses rising to $4.3 million due to integration costs, while gross profit margin decreased to 55% from 66% in the prior quarter. On October 29, 2026, Intrusion completed a $4.0 million debt-for-equity exchange, which increased stockholders' equity to over $5.0 million and secured an additional 180-day extension from Nasdaq to regain compliance with minimum bid price requirements.Technology
- TLPHNov 12, 4:05 PMTalphera reported a net loss of $4.0 million for the third quarter of 2026, with cash and investments totaling $14.2 million as of September 30, 2026. The company submitted a briefing document to the FDA seeking approval to close enrollment in its NEPHRO CRRT study by December 31, 2026, citing that the current enrollment of over 75% of the target provides more than 80% statistical power for the primary endpoint. Updated market research has raised the estimated peak sales for nafamostat in the CRRT market to over $200 million. Talphera plans to file a Form S-3 Shelf Registration Statement to replace its existing registration that expires in November 2026.Healthcare
- HOURNov 12, 4:05 PMHour Loop, Inc. reported net revenues of $32.1 million for the third quarter of 2026, a 4% decrease from the prior year, while nine-month revenues rose 11% to $95.9 million. Net income for the third quarter was $0.4 million, down from $0.5 million in the same period last year, and totaled $2.3 million for the first nine months of 2026. The company narrowed its full-year 2026 revenue guidance to a range of $147.0 million to $152.0 million, anticipating 3% to 6% year-over-year growth. Cash and cash equivalents decreased to $1.1 million as of September 30, 2026, primarily due to increased inventory investments ahead of the holiday season.Consumer Cyclical
- CADLNov 12, 4:05 PMCandel Therapeutics reported a net loss of $21.9 million for the third quarter of 2026, driven by increased research and development expenses related to clinical trials and manufacturing. The company holds $203.1 million in cash and cash equivalents as of September 30, 2026, which is projected to fund operations through the second quarter of 2028. Clinical updates include the acceptance of three poster presentations at the SITC 2026 Annual Meeting and the announcement of a planned Biologics License Application submission for aglatimagene in prostate cancer in mid-2027. Recent corporate developments include the appointment of Martine Zimmermann to the Board of Directors and Maria Ostrovsky as General Counsel to support regulatory and commercial readiness.Healthcare
- GUTSNov 12, 4:05 PMFractyl Health reported positive six-month results from its REMAIN-1 Pivotal Cohort, demonstrating that the Revita procedure maintained approximately 80% of GLP-1-induced weight loss compared to 67% for the sham group with high statistical significance (p=0.0023). The company announced a strategic shift to focus exclusively on Revita, resulting in a 45% workforce reduction and the discontinuation of its Rejuva gene therapy program. Financially, Fractyl reported a net loss of $14.2 million for the third quarter of 2026 and expects its cash runway to extend into the second quarter of 2027. The company plans to submit a De Novo marketing application to the FDA in late 2026 and anticipates topline 12-month data in the first quarter of 2027.Healthcare
- ASMBNov 12, 4:05 PMAssembly Biosciences initiated a Phase 2 clinical study for its drug ABI-6250 in patients with chronic hepatitis delta virus infection and received FDA approval to proceed with a Phase 2 study for cholestatic liver diseases. The company exercised its option to share 40% of U.S. development costs and profits for the HSV helicase primase inhibitor program under its collaboration with Gilead Sciences. Assembly Biosciences received a $75 million collaboration extension fee from Gilead, bringing its total cash, cash equivalents, and marketable securities to $314.3 million as of September 30, 2026, which is projected to fund operations into 2029. For the third quarter of 2026, the company reported revenue of $3.0 million from collaborative research and a net loss of $20.3 million.Healthcare
- BLNENov 12, 4:05 PMBeeline Holdings reported a 30% year-over-year increase in Q3 2026 net revenues to $3.0 million, while its net loss decreased to $3.8 million. The company originated 268 loans during the quarter, achieving an overall margin of 3.56% and narrowing its adjusted EBITDA loss by 33% sequentially to $1.8 million. Management is advancing a proposed acquisition of TYTL, which is expected to finalize definitive agreements soon, and has initiated a $3 million annualized cost reduction plan. Additionally, the CEO will cancel 3 million merger shares upon closing to reduce dilution for existing shareholders.Financial Services
- BSEMNov 12, 4:05 PMBioStem Technologies reported third-quarter 2026 net revenue of $7.6 million, with hospital revenue rising sequentially to $6.8 million. The company raised its full-year 2026 revenue guidance to a range of $28 million to $29 million, up from the previous outlook. In-house production of Neox and Clarix products is scheduled to commence in the first half of 2027, marking progress toward vertical integration. The company also closed a private placement generating approximately $3 million in gross proceeds and established a $40 million committed equity facility.Healthcare
- LINKNov 12, 4:04 PMInterlink Electronics reported third-quarter 2026 revenue of $3.06 million, a 3.4% increase from the prior year, driven by higher shipments of force-sensing and gas-sensor products. The company posted a net loss of $316,000 for the quarter and $406,000 for the first nine months, while Adjusted EBITDA improved to a positive $79,000 for the nine-month period. Strategic expansions included opening a new 4,000-square-foot R&D center in Rotherham, UK, and adding a 10,000-square-foot facility in Irvine, Scotland, to support smart textiles and medical applications. Management anticipates closing a transformative acquisition before year-end, which is projected to generate combined pro forma revenue of $50 million and over $4 million in Adjusted EBITDA for 2026.Technology
- HAWKNov 12, 4:04 PMHawkEye 360 reported third-quarter 2026 revenue of $59.3 million, representing an 84% increase from the prior-year period, driven by a record international revenue of $23.3 million. The company raised its full-year 2026 revenue guidance to a range of $225 million to $227 million and non-GAAP Adjusted EBITDA guidance to $38 million to $40 million. As of September 30, 2026, the company's backlog stood at $300.3 million, supported by new multi-year contracts with allied partners and the recent launch of Clusters 15 and 16.Industrials
- IZEANov 12, 4:03 PMIZEA Worldwide, Inc. reported third-quarter 2026 revenue of $6.2 million, representing a 23% decrease from the prior-year period, driven by the strategic shift away from non-core small and mid-sized business accounts. Despite the revenue decline, Managed Services bookings surged 94% to $7.0 million, reflecting strong demand from enterprise clients including Disney-ABC, HBO Max, and Hulu. The company recorded a net loss of $0.4 million for the quarter while maintaining a cash position of $46.4 million with no long-term debt. Management projects fourth-quarter revenue to range between $7.5 million and $8.1 million, anticipating a 24% to 34% year-over-year growth.Communication Services
- CBRSNov 12, 4:03 PMCerebras Systems reported record third-quarter 2026 GAAP revenue of $210.8 million, representing a 55% year-over-year increase, while core non-GAAP revenue reached $230.9 million, up 70%. The company secured 700 megawatts of data center capacity under contract and announced new commercial wins with two hyperscalers, including an integration with Oracle Cloud Infrastructure. Looking ahead, Cerebras raised its full-year 2026 core revenue outlook to a range of $940 to $960 million and projects tripling revenue in 2027.Technology
- ENHANov 12, 4:03 PMEnhanced Group Inc. reported a third-quarter 2026 net loss of $13.5 million and revenue of $3.3 million, driven by telehealth sales and sponsorship recognition. The company signed a definitive agreement to acquire a 77% controlling interest in DEAG Deutsche Entertainment AG through an all-stock transaction valued at 5.3 times DEAG's FY2027E Adjusted EBITDA. Concurrently, Enhanced secured a $15 million private investment in public equity (PIPE) to support the acquisition and future growth. Following the expected closing in the first quarter of 2027, the combined entity projects approximately $670 million in revenue and $26 million in Adjusted EBITDA for the full year 2027.Consumer Defensive
- MTEXNov 12, 4:03 PMMannatech reported net sales of $24.9 million for the third quarter of 2026, representing a 14.6% decrease compared to the same period in 2025. The company recorded a net income of $8.9 million, or $4.61 per diluted share, driven primarily by a $10.9 million non-cash income tax benefit related to the remeasurement of deferred tax liabilities on unremitted foreign earnings. Operating performance showed a decline, with income from operations dropping to $0.3 million from $2.0 million in the prior year, while the number of independent associates and preferred customers fell to approximately 111,000. Additionally, the company's cash and cash equivalents decreased by 12.4% to $5.4 million as of September 30, 2026.Consumer Defensive
- CVSINov 12, 4:03 PMCV Sciences, Inc. reported third-quarter 2026 revenue of $3.0 million, a 7.0% decrease from the same period in 2025, driven by lower sales volume and average prices due to restrictive federal and state regulations. The company achieved a gross margin of 50.0% and recorded a positive adjusted EBITDA of $32,000, marking a significant improvement over the adjusted EBITDA losses in the prior year and the second quarter of 2026. Operating expenses were reduced by 11.6% year-over-year to $1.6 million, excluding the benefit from a $500,000 gain on a legal settlement. At the end of the quarter, the company held a cash balance of $0.3 million and strengthened its working capital position to $0.7 million.
- LWAYNov 12, 4:03 PMLifeway Foods reported record third-quarter 2026 net sales of $67.8 million, representing an 18.6% year-over-year increase driven by higher volumes of branded drinkable kefir. Despite this top-line growth, net income for the quarter declined to $0.3 million due to elevated input costs for milk, packaging, and transportation, which reduced gross profit margins to 18.0%. Year-to-date 2026 net sales reached $197.7 million, a 25.8% increase, while the company anticipates margin expansion in 2027 following planned price increases and the completion of its Waukesha facility.Consumer Defensive
- NUWENov 12, 4:03 PMNuwellis reported a 24% year-over-year improvement in its third-quarter 2026 operating loss to $2.1 million, driven by a 430 basis point expansion in gross margin to 69.5% and a 13% reduction in operating expenses. Net sales for the quarter remained flat at $2.2 million due to a prior-year backorder comparison, though sales grew 12% sequentially and 13% for the first nine months to $6.6 million. The company sold 32 Aquadex consoles in the first nine months of 2026, an 88% increase from the prior period, while strengthening its balance sheet to $8.3 million in cash and cash equivalents. Strategic initiatives included an FDA 510(k) submission to expand Aquadex indications for pediatric patients and new distribution agreements for the AtriAmp and Zorro-Flow products.Healthcare
- AMATNov 12, 4:02 PMApplied Materials reported record fourth-quarter revenue of $10.41 billion, representing a 53% year-over-year increase, driven by strong demand for semiconductor equipment. The company achieved a non-GAAP gross margin of 50.6% and non-GAAP earnings per share of $4.16, marking a 92% increase from the prior year. For the full fiscal year 2026, revenue reached a record $34.45 billion with non-GAAP EPS of $12.89, while generating $8.87 billion in operating cash flow. Additionally, the company unveiled the EPIC Center in Silicon Valley to accelerate collaborative R&D and announced new partnerships with Intel, KIOXIA, Besi, and UCLA.Technology
- HTFLNov 12, 4:02 PMHeartflow, Inc. reported third-quarter 2026 total revenue of $72.9 million, representing a 57% year-over-year increase driven by growth in U.S. FFR(CT) and Plaque revenue case volumes. The company raised its full-year 2026 revenue guidance to a range of $262 million to $264 million, reflecting an anticipated 49% to 50% growth rate, while maintaining a non-GAAP gross margin target of approximately 82.5%. For the quarter, Heartflow recorded a non-GAAP net operating loss of $5.0 million and a non-GAAP net loss of $2.7 million, with cash, cash equivalents, and investments totaling $253.0 million as of September 30, 2026.Healthcare
- VTSINov 12, 4:02 PMVirTra, Inc. reported third-quarter 2026 total revenue of $7.6 million, representing a 42% increase from the prior year period, driven by growth in government and international sales. The company achieved net income of $2.2 million for the quarter, or $0.19 per diluted share, while bookings surged 87% to $10.3 million, bringing the total backlog to $27.6 million. Over the first nine months of 2026, total revenue declined 13% to $16.9 million due to delivery delays for customers booked in late 2025, resulting in net income of $0.6 million. Recent operational highlights include the award of a five-year sole-source contract with U.S. Customs and Border Protection valued at up to $14 million and a $1.5 million contract with the U.S. Army.Technology
- ANDGNov 12, 4:02 PMAndersen Group Inc. reported third-quarter revenue of $337.3 million for the period ended September 30, 2026, representing an 18.7% increase from the prior year. Consolidated GAAP net income for the quarter was $68.0 million, while Adjusted EBITDA rose 18.8% to $154.5 million with a margin of 45.8%. The company completed eight acquisitions through September 30, 2026, contributing to broad-based growth across all service lines and geographic regions. Andersen introduced full-year 2027 revenue guidance of $1.275 billion to $1.325 billion, reflecting an expected 30% growth at the midpoint over its 2026 guidance.Consumer Cyclical
- SMSINov 12, 4:02 PMSmith Micro Software reported third-quarter 2026 revenue of $5.0 million, representing a 16% sequential increase and an 81.6% gross margin, which is a five-year high. For the nine months ended September 30, 2026, the company generated $13.6 million in revenue with a GAAP net loss of $8.3 million, a significant improvement from the $25.4 million loss recorded in the same period of 2025. Non-GAAP net loss for the quarter narrowed to $0.3 million, or $0.05 per share, compared to a $2.6 million loss in the prior year quarter. The company's cash and cash equivalents totaled $2.4 million as of September 30, 2026, following a period of sequential revenue growth and expanded customer contracts.Technology
- ARWRNov 12, 4:01 PMArrowhead Pharmaceuticals reported a net loss of $724.2 million for the fiscal year ended September 30, 2026, driven by a $215 million acquisition of a Priority Review Voucher and increased research and development expenses. The company's commercial product, REDEMPLO (plozasiran), expanded its market presence with new prescriptions growing 63% quarter-over-quarter and achieved marketing authorization in Germany and the United Kingdom for familial chylomicronemia syndrome. In clinical development, plozasiran demonstrated significant triglyceride reductions in Phase 3 trials for severe hypertriglyceridemia, while investigational candidates ARO-DIMER-PA and ARO-MAPT showed promising early results in targeting multiple genes and crossing the blood-brain barrier, respectively. Additionally, Arrowhead refinanced its credit facility to lower borrowing costs and announced a change in its fiscal year-end to December 31, effective January 1, 2027.Healthcare
- KODNov 12, 4:00 PMKodiak Sciences reported that its Phase 3 DAYBREAK study for Zenkuda met the primary endpoint in wet age-related macular degeneration, demonstrating vision gains and sustained retinal drying with a 6-month dosing interval for 54% of patients. The company also announced that the Phase 3 DAYBREAK study for Tabirafusp-ted met its primary vision endpoint and is actively enrolling in the Phase 3 ALTO study for diabetic macular edema. Financial results for the third quarter of 2026 showed a net loss of $66.2 million, with the company holding $88.7 million in cash and raising an additional $69 million in net proceeds from an equity offering subsequent to the quarter. Kodiak plans to submit a multi-indication Biologics License Application for Zenkuda by the end of 2026 and expects to announce the first Phase 3 results for KSI-101 in December 2026.Healthcare
- ARTNANov 12, 2:21 PMArtesian Resources Corporation reported diluted net income per share of $0.65 for the third quarter of 2026, a decrease from $0.68 in the same period of 2025, while total revenues rose 4.8% to $31.9 million. For the nine months ended September 30, 2026, diluted net income per share increased 3.3% to $1.87, with year-to-date revenues reaching $90.4 million, up 6.4% from the prior year. The company invested $40.8 million in water and wastewater infrastructure projects during the first nine months of 2026 to ensure service reliability and regulatory compliance, including PFAS treatment upgrades and system renewals.Utilities
- TCINov 12, 12:47 PMTranscontinental Realty Investors, Inc. reported a net loss of $0.1 million, or $0.02 per share, for the three months ended September 30, 2026, compared to a net income of $0.7 million in the same period of 2025. Total revenue increased to $13.9 million from $12.8 million, driven by a $1.5 million rise in multifamily property revenues due to lease-up activities, which was partially offset by a decrease in commercial property revenue. The company's net operating loss widened to $2.4 million from $1.4 million, primarily due to a $1.4 million increase in operating expenses associated with development properties. Additionally, the company acquired four multifamily properties totaling 782 units in exchange for settling notes receivable and a $12.0 million cash payment, while also selling 21 lots for a $0.8 million gain.Real Estate
- ARLNov 12, 12:42 PMAmerican Realty Investors, Inc. reported a net loss of $0.7 million, or $0.04 per share, for the three months ended September 30, 2026, compared to a net income of $0.1 million per share in the same period of 2025. Total revenue increased to $13.9 million from $12.8 million, driven by a $1.5 million rise in multifamily property revenues due to lease-up activities, which was partially offset by a decrease in commercial property revenue. The company's net operating loss widened to $2.6 million from $1.6 million, primarily attributed to a $1.4 million increase in operating expenses associated with development properties. Additionally, the company acquired four multifamily properties totaling 782 units in exchange for settling notes receivable and a $12.0 million cash payment, while also selling 21 lots for a $0.8 million gain.Real Estate
- IORNov 12, 12:42 PMIncome Opportunity Realty Investors, Inc. reported net income of $0.9 million, or $0.22 per diluted share, for the quarter ended September 30, 2026. This represents a decrease from the $1.0 million, or $0.25 per share, reported in the same period of 2025, primarily due to lower interest income. For the nine months ended September 30, 2026, the company recorded net income of $2.6 million, or $0.64 per share, compared to $3.0 million, or $0.74 per share, in the prior year. The company, based in Dallas, holds a portfolio of notes receivable and invests in real estate through direct equity ownership and partnerships.Financial Services
- TRTNov 12, 12:28 PMTrio-Tech International reported a 29% year-over-year revenue increase to $19.9 million for the first quarter of fiscal 2027, driven by a 39% surge in its Semiconductor Back-End Solutions segment. The company achieved a consolidated gross margin of 20.6%, up from 16.7% in the prior year, resulting in net income of $846,000 and diluted earnings per share of $0.07. Management highlighted strong demand for AI-related testing services and EV applications, supported by a new facility expansion in Malaysia that began operations in September 2026. Despite elevated working capital requirements due to increased inventory and receivables, the company maintains a strong balance sheet with $25.6 million in cash and recently approved an additional $1.0 million for share repurchases.Technology
- PRHINov 12, 11:43 AMPresurance Holdings reported a net income of $3.5 million for the nine months ended September 30, 2026, a significant turnaround from the $1.4 million loss in the prior-year period. The company's overall underwriting combined ratio improved to 97.1% for the first nine months of 2026, down from 133.7% in 2025, driven by profitable results in its Personal Lines business. Gross written premiums decreased by 40.8% to $30.7 million year-to-date as the company focused on underwriting discipline and managed its legacy Commercial Lines portfolio in runoff. Book value per share stood at $6.45 as of September 30, 2026, reflecting the company's strategic shift toward a dedicated Texas homeowners portfolio.Financial Services
- EXPDNov 12, 11:42 AMExpeditors International of Washington, Inc. will host an Investor Day event on Wednesday, November 18, 2026, in New York City. The webcast will run from 8:30 a.m. to 12:00 p.m. EST and feature presentations by President and CEO Dan Wall, Senior Vice President and CFO Dave Hackett, and other leadership team members. The session will cover company operations, strategies, and the financial outlook, including a question and answer period that replaces the standard 8-K filing following the third quarter earnings release. A replay of the event will be available on the company's investor relations website for at least 90 days after the broadcast.Industrials
- AMSNov 12, 11:27 AMAmerican Shared Hospital Services reported third-quarter 2026 revenue of $7.6 million, a 6% increase from the prior year, driven by a 14% rise in Direct Patient Services revenue. For the first nine months of 2026, total revenue grew 14% to $23.1 million, while the company generated $5.8 million in cash from operating activities. The company reported a net loss of $620,000 for the quarter and $1.7 million for the nine-month period, with adjusted EBITDA declining to $1.4 million and $3.8 million respectively. Cash, cash equivalents, and restricted cash increased to approximately $9.5 million as of September 30, 2026, supported by a recent subordinated financing arrangement.Healthcare
- INKTNov 12, 9:49 AMMiNK Therapeutics reported its first pre-commercial product revenue in the third quarter of 2026 from agenT-797 supplied via an international named-patient access program. The company's randomized Phase 2 trial for acute respiratory distress syndrome (ARDS) is advancing with U.S. dosing expected before year-end, targeting a population with approximately 40% 28-day mortality. Additionally, agenT-797 was selected for the ARPA-H BoSS program to develop room-temperature deployable cell therapies, while preclinical data presented at SITC 2026 demonstrated the therapy's ability to clear senescent cells and enhance tumor killing in colorectal cancer models. Financially, the company achieved a 23% year-over-year improvement in net loss per share and reduced general and administrative expenses by 44%.Healthcare
- IPWRNov 12, 9:25 AMIdeal Power Inc. reported a net loss of $3.6 million for the third quarter of 2026, an increase from $2.9 million in the same period the previous year, while operating expenses rose to $3.9 million due to higher personnel costs and patent impairment charges. The company's cash and cash equivalents grew significantly to $38.3 million as of September 30, 2026, following a substantial financing activity that generated over $40 million in proceeds. During the quarter, the company advanced its B-TRAN® commercial strategy by demonstrating a solid-state circuit breaker prototype with Power Integrations, initiating shipments of new reference design kits, and expanding its sales funnel to approximately $450 million. Additionally, Ideal Power continued to develop its electric vehicle contactor opportunity with Stellantis and progressed toward JEDEC qualification for its semiconductor foundry production.Technology
- DGIINov 12, 9:23 AMDigi International reported record fourth-quarter fiscal 2026 revenue of $143 million, representing a 25% increase year-over-year, while full-year revenue reached $535 million, a 24% rise. The company achieved an annualized recurring revenue (ARR) of $197 million at the end of the quarter, up 30% from the prior year, driven by organic growth and acquisitions of Particle and Jolt Software. Net income for the quarter was $15 million, and adjusted net income reached $30 million, with adjusted EBITDA increasing to $42 million. Looking ahead to fiscal 2027, Digi projects revenue growth of 10-15% and anticipates ARR growth of at least 15%, targeting $200 million in both ARR and Adjusted EBITDA.Technology
- BRUNNov 12, 9:20 AMBoost Run Inc. reported third-quarter 2026 revenue of $39.9 million, representing a 496% year-over-year increase. The company currently holds $2.7 billion in total contracted value, with all funds either live, in deployment, or scheduled for 2027. Operating cash flow for the quarter reached $65.6 million, supported by approximately $600 million in non-dilutive project-based financing secured year-to-date. CEO Andrew Karos expects 26% of the contracted value to be live by the end of November, with full deployment targeted for 2027.Technology
- NEONNov 12, 9:18 AMNeonode reported a loss of $1.1 million, or $0.07 per share, from continuing operations for the three months ended September 30, 2026, compared to a net income of $13.9 million in the same period of the prior year. Total revenues for the quarter reached $0.5 million, representing a 24.4% increase year-over-year, driven by a 279.2% rise in non-recurring engineering revenue and a 9.4% increase in license fees. Operating expenses decreased by 13.2% to $1.8 million, primarily due to lower payroll and professional fees, while cash used by operations totaled $1.6 million. For the nine-month period, the company recorded a loss of $5.1 million with revenues of $1.6 million, as the prior year's results included a $15.5 million one-time gain from a patent assignment that was not repeated in 2026.Technology
- SGANov 12, 9:05 AMSaga Communications, Inc. reported a net loss of $7.1 million for the third quarter of 2026, driven primarily by a $9.2 million non-cash impairment charge on FCC license values. Net revenue for the quarter decreased 5.4% to $26.7 million, while station operating expense fell 1.7% to $24.2 million. The company declared a quarterly cash dividend of $0.25 per share, payable on December 11, 2026, to shareholders of record on November 23, 2026. For the nine-month period ended September 30, 2026, the company recorded a net loss of $8.5 million and net revenue of $75.9 million.Communication Services
- TGENNov 12, 8:59 AMTecogen Inc. reported third-quarter 2026 revenues of $7.87 million, representing a 9.6% increase from the same period in 2025, while the net loss narrowed to $1.59 million from $2.13 million. For the nine months ended September 30, 2026, total revenues declined 8.3% to $19.96 million, resulting in a net loss of $5.86 million compared to $4.25 million in the prior year period. The company's gross profit margin improved to 37.4% in the third quarter, driven by higher revenue and lower costs in the Services segment, and the backlog exceeded $8 million. At the end of the quarter, Tecogen held $5.33 million in cash and cash equivalents, with the CEO noting an expected increase to $5.7 million due to recent customer deposits.Industrials
- MPTINov 12, 8:55 AMM-tron Industries, Inc. reported third-quarter 2026 revenues of $15.7 million, representing an 11.1% increase from the same period in 2025. Net income for the quarter rose 66.4% to $3.0 million, or $0.70 per diluted share, driven by strong demand in aerospace and defense markets and an expansion of gross margin to 44.5%. For the nine months ended September 30, 2026, the company achieved revenues of $45.5 million and net income of $7.3 million, while its backlog grew to $84.9 million as of the end of the quarter.Technology
- STRRNov 12, 8:52 AMStar Equity Holdings reported a net loss of $2.2 million, or $0.60 per diluted share, for the third quarter of 2026, with total revenue increasing 12.4% to $53.9 million. The company generated $1.5 million in adjusted EBITDA and ended the quarter with $7.8 million in total cash, while repurchasing approximately $0.3 million of its common stock. Recent strategic actions include the acquisition of a machine shop in Vernal, Utah, and the purchase of Cornerstone RPO to expand its Business Services division. Additionally, the company has initiated a process to monetize two real estate assets through sale-leaseback transactions expected to yield over $9.0 million in gross proceeds.Industrials
- PODCNov 12, 8:50 AMPodcastOne reported record financial results for the first half of fiscal 2027, achieving revenue of $31.5 million and adjusted EBITDA of $2.9 million. For the second quarter of fiscal 2027, revenue increased to $15.4 million year-over-year, while adjusted EBITDA rose 27% to $1.4 million. The company delivered over 15 million downloads and streams in September, reaching 5.8 million unique listeners and securing a #6 ranking on Podtrac. Despite these operational gains, the company reported a net loss of $2.0 million for the six-month period ended September 30, 2026.Communication Services
- CURINov 12, 8:49 AMCuriosityStream reported third-quarter 2026 revenue of $20.7 million, representing a 13% increase from the prior year, while adjusted EBITDA rose 67% to $5.0 million. The company achieved net income of $4.8 million, a significant improvement from the $3.7 million net loss recorded in the same period last year, driven by a $0.9 million non-cash gain on a venture remeasurement. Management raised its full-year 2026 guidance to a revenue range of $79–$82 million and an adjusted EBITDA range of $20–$22 million. Additionally, the Board declared a fourth-quarter cash dividend of $0.085 per share, and the company acquired the remaining 68% interest in its German documentary channel business, Spiegel Venture.Communication Services
- LVONov 12, 8:45 AMLiveOne reported H1 Fiscal 2027 revenue of $37.3 million and an Adjusted EBITDA of $3.6 million, with its Audio Division contributing $36.3 million in revenue. The company revised its full Fiscal 2027 guidance to $70–$75 million in revenue and over $10 million in Adjusted EBITDA, while issuing first-time Fiscal 2028 guidance of $100 million or more. LiveOne has reduced its senior debt balance to $9 million after extinguishing $25 million in debt and liabilities since February 2026. Additionally, the company announced a five-year partnership with Groove Technology Solutions for Slacker Radio and highlighted accelerating AI initiatives across its subsidiaries.Communication Services
- DFDVNov 12, 8:41 AMDeFi Development Corp. reported strong third-quarter 2026 results, with net asset value per share increasing over 300% and SOL per share growing more than 20% between August 12 and September 30, 2026. The company's total SOL and SOL equivalents rose to 2,549,137 by the end of the quarter, while SOL-denominated borrowings declined by approximately 13%. Additionally, the firm launched CHAD, a perpetual capital vehicle that reached its $10 par value within 48 days of trading, and increased its annual dividend rate to 14% effective November 2.Financial Services
- HSDTNov 12, 8:41 AMSolana Company reported third-quarter 2026 revenue of $3.4 million, driven primarily by $3.3 million in staking revenue, marking a significant increase from the prior-year period. The company achieved a net income of $105.2 million, or $1.17 per diluted share, contrasting with a net loss of $352.8 million in the same quarter of the previous year. During the quarter, Solana Company expanded its treasury holdings to approximately 2.4 million SOL with a fair value of $288.2 million and executed a $15 million registered direct offering to purchase an additional 125,000 SOL. Operational highlights included the launch of the Pacific Backbone infrastructure, which now holds 1.3 million SOL in delegated stake, and the company's participation in Solana's first on-chain governance vote.Financial Services
- CTA-PANov 12, 8:34 AMCorteva reported third-quarter 2026 net sales of $1.59 billion, a 9% decline from the prior year, driven by pricing pressures in North America and Latin America. The company updated its full-year 2026 guidance, projecting Adjusted Pro Forma Operating EBITDA between $1.1 billion and $1.125 billion and Adjusted Pro Forma Operating EPS between $0.76 and $0.80. Latin America experienced a significant 31% organic sales decline due to farmer liquidity constraints and elevated channel inventory, while North America and EMEA posted organic growth of 7% and 14% respectively. Pro Forma GAAP income from continuing operations for the quarter was a loss of $54 million, whereas Adjusted Pro Forma Operating EBITDA for the nine-month period totaled $943 million.Basic Materials
- AENTNov 12, 8:32 AMAlliance Entertainment Holding Corporation reported first-quarter fiscal 2027 net revenues of $278.8 million, representing a 10% increase from the prior-year period. GAAP net income rose 56% to $7.6 million, driven by a 13% increase in gross profit and a 49% reduction in interest expense following a refinancing. Revenue growth was led by a 20% surge in physical movie sales, a 14% rise in vinyl revenue, and an 87% jump in collectibles revenue. The company also saw operating cash flow increase to $4.3 million and maintained compliance with its credit facility covenants while holding $48.9 million in available liquidity.Communication Services
- TULPNov 12, 8:30 AMBloomia Holdings, Inc. reported a net loss of $2.4 million for the first fiscal quarter ended September 30, 2026, representing a 17% improvement over the same period in the prior year. Revenue for the quarter totaled $5.0 million, a decrease from $5.2 million in the previous year, primarily driven by lower stem sales due to excess waste. Adjusted EBITDA improved to a loss of $1.9 million from a loss of $2.4 million in the prior year quarter, aided by higher prices and reduced general and administrative costs. The company's cash balance decreased to $0.7 million as of September 30, 2026, while revolver borrowings increased to $8.6 million.Consumer Defensive
- NSYSNov 12, 8:30 AMNortech Systems reported third-quarter 2026 net sales of $33.0 million, an 8.4% increase from the same period in 2025, resulting in net income of $637 thousand. The company achieved an adjusted EBITDA of $2.0 million for the quarter, up from $1.3 million in the prior year, while total backlog grew 20% to $92.8 million. Year-to-date through September 30, 2026, net sales reached $96.9 million with a net income of $919 thousand. Management highlighted strong performance in the Aerospace & Defense and Industrial markets, noting that China operations saw net sales growth exceeding 56%.Healthcare
- VANINov 12, 8:29 AMVivani Medical reported a net loss of $7.3 million for the third quarter ended September 30, 2026, driven by increased research and development expenses related to its Biopharm Division. The company anticipates announcing top-line results from its SLIM-1 Phase 1 trial for the NPM-139 semaglutide implant later in November 2026. Additionally, the merger between Cortigent and ClearOne remains pending final regulatory approvals required to establish Cortigent as a standalone Nasdaq-traded entity. Vivani's cash and cash equivalents totaled $15.5 million as of the end of the quarter, down from $20.8 million in the previous quarter.Healthcare
- SGPNov 12, 8:25 AMSpyGlass Pharma acquired Advanced Vision Science, Inc. for approximately $13 million to secure scalable manufacturing capacity for its lead product, the Bimatoprost Drug Pad-IOL System. The company announced four-year follow-up data from its first-in-human trial showing a 37% reduction in intraocular pressure and 86% of patients remaining off topical drops, while Phase 3 enrollment remains on track for completion in 2027. Additionally, the first implantations were completed for the Bimatoprost-Drug Ring System, a non-IOL-based delivery platform designed to provide up to seven years of treatment. For the third quarter ended September 30, 2026, the company reported a net loss of $24.3 million and held $215.8 million in cash and short-term investments.Healthcare
- ONDSNov 12, 8:24 AMOndas Inc. reported record third-quarter 2026 revenue of $167.5 million, representing a 100% sequential increase and more than a 16-fold year-over-year growth. The company secured $214 million in new orders, bringing its backlog to $835 million, and raised its full-year 2026 revenue outlook to at least $550 million. Ondas initiated a 2027 revenue target of at least $1.1 billion and expects to achieve company-wide Adjusted EBITDA profitability by the third quarter of 2027. Strategic expansions included the establishment of Ondas Sentinel and Regna AI, alongside six acquisitions that enhanced capabilities in defense, sovereign AI, and autonomous systems.Technology
- MOVENov 12, 8:21 AMCorvex, Inc. reported third-quarter 2026 financial results showing total revenue of $5.0 million, a 31% increase from the previous quarter, driven by its AI platform and services following the transfer of legacy healthcare assets. The company secured approximately 8 MW of critical IT capacity, with 1.5 MW currently live supporting $22 million in contracted annual recurring revenue, while expanding operations at Mid-Atlantic 1 and Midwest-1 facilities. Despite the revenue growth, the company recorded a net loss of $17.5 million for the quarter, or $0.60 per share, largely due to $11.3 million in stock-based compensation expenses. Corvex also raised approximately $33 million through a private placement and launched its Corvex Token Factory platform to enable serverless inference for open-weight models.Technology
- LEATNov 12, 8:20 AMLeatt Corporation reported third-quarter 2026 revenues of $20.46 million, representing a 43% increase from the same period in 2025 and marking the company's highest quarterly revenue in four years. Net income for the quarter surged 309% to $2.20 million, or $0.35 per basic share, driven by a 48% rise in gross profit and strong sales growth across body armor, helmets, and other product categories. For the nine months ended September 30, 2026, total revenues reached $56.36 million with net income increasing 74% to $4.88 million, while operating cash flows more than tripled to $4.59 million compared to the prior year.
- RUMNov 12, 8:17 AMRUM Group Inc. reported record third-quarter 2026 revenue of $96.6 million, representing a 290% year-over-year increase driven primarily by the Quake AI business which contributed $68.2 million. The company achieved its first profitable quarter on an Adjusted EBITDA basis, with utilization of its 22,000 GPU fleet reaching approximately 85%. Total liquidity stood at $142.3 million as of September 30, 2026, while the company advanced its acquisition of Northern Data AG to approximately 98% ownership. Management has set a fourth-quarter 2026 revenue outlook between $88 million and $94 million.Technology
- SESNov 12, 8:15 AMSES AI Corporation reported third-quarter revenue of $6.6 million, a 31% increase from the previous quarter, driven primarily by its energy storage business. The company achieved a GAAP net loss of $13.4 million, narrowing from $17.9 million in the second quarter, while completing the ramp-up of its Chungju, Korea facility to produce 1 million NDAA-compliant drone cells annually. Management reiterated its full-year 2026 revenue outlook of $30 million to $35 million and announced a reverse stock split to broaden institutional ownership eligibility. The firm maintains approximately $137 million in liquidity with no debt as it focuses on scaling drone manufacturing and advancing its Molecular Universe battery materials platform.Consumer Cyclical
- SPHNov 12, 8:14 AMSuburban Propane Partners, L.P. reported net income of $109.0 million for fiscal year 2026, representing a slight increase from the prior year, while Adjusted EBITDA rose 2.2% to $284.0 million. The company achieved this performance through strong propane demand in the eastern United States, the completion of capital projects for its renewable natural gas business, and the recognition of $12.4 million in production tax credits. During the fiscal year, the partnership acquired two propane businesses in California and refinanced $350.0 million of senior notes to extend maturities by nearly nine years. Consequently, the company increased its annualized distribution rate to $1.40 per Common Unit, reflecting a 7.7% increase over the previous rate.Utilities
- DXYNNov 12, 8:12 AMThe Dixie Group reported net income of $577,000 for the third quarter of 2026, marking its third consecutive profitable quarter. Net sales increased 4.6% to $65.2 million, while gross profit margin improved to 26.6% from 24.8% in the prior year period. For the nine months ended September 26, 2026, the company generated net income of $2.8 million with operating income rising to $8.7 million compared to $1.2 million in the same period of 2025. The company attributed these results to cost reductions, improved operating efficiencies, and new product introductions in both soft and hard surface flooring segments.Consumer Cyclical
- FRMMNov 12, 8:12 AMForum Markets reported third-quarter 2026 revenue of $2.0 million, driven entirely by commercial aircraft engine leases, and posted a net income of $7.9 million. The company formed a joint venture, Forum Edge AI, to deploy high-performance GPU compute capacity while simultaneously expanding its aircraft engine portfolio with two new acquisitions. Due to rising equipment and financing costs following the midterm elections, Forum revised its full-year 2026 revenue guidance down to $8 million–$9 million, though it maintains its 2027 revenue outlook of $125 million–$175 million. Additionally, the company repurchased approximately 330,000 shares for $1.9 million during the quarter and holds $19.8 million remaining in its share repurchase authorization.Healthcare
- TOVXNov 12, 8:10 AMTheriva Biologics reported third-quarter 2026 financial results showing cash and cash equivalents of $8.5 million with a projected runway into the first quarter of 2027. The company completed the sale of its SYN-004 antibiotic-degrading enzyme portfolio to Biossil Labs Inc. for a $350,000 upfront payment and up to $91 million in potential milestones and royalties. Clinical progress includes ongoing enrollment in the VIRAGE2 Phase 2a trial for VCN-01 in metastatic pancreatic ductal adenocarcinoma, with enrollment expected to conclude in the fourth quarter of 2026. Additionally, detailed analyses of the VIRAGE Phase 2b trial data were published in Nature Medicine, demonstrating improved survival outcomes for patients treated with VCN-01 combined with chemotherapy.Healthcare
- SLNNov 12, 8:10 AMSilence Therapeutics plc reported a net loss of $12.4 million for the third quarter ended September 30, 2026, driven by $9.3 million in research and development expenses and $4.9 million in general and administrative costs. The company's cash position increased to $247.7 million, which includes $201.3 million in proceeds from a public offering announced in August 2026. Recent business milestones include positive Phase 2 results for the investigational siRNA therapy divesiran in polycythemia vera and the announcement of a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany. The acquisition transaction is expected to close in the first quarter of 2027, subject to customary closing conditions.Healthcare
- EUNov 12, 8:09 AMenCore Energy reported third-quarter 2026 revenue of $16.7 million, an 88% increase year-over-year, driven by the delivery of 200,000 pounds of U3O8 at an average realized price of $83.46 per pound. The company recorded a net loss of $33.9 million for the quarter, primarily due to higher costs associated with purchased uranium included in sales, resulting in a gross loss of $0.8 million. As of September 30, 2026, the company held $5.1 million in unrestricted cash and $33.6 million in marketable securities while maintaining an inventory of 116,631 pounds of U3O8. Operational progress includes the completion of the first phase of the Upper Spring Creek facility and the Alta Mesa wellfield 3 Extension, with extraction expected to commence before the end of 2026.Energy
- AVLNNov 12, 8:08 AMAvalyn Pharma Inc. reported a net loss of $29.7 million for the third quarter of 2026, driven by increased research and development expenses of $25.5 million and general and administrative costs of $7.6 million. The company ended the quarter with $386.6 million in cash and marketable securities, projecting a runway into 2029. Recent pipeline progress includes the initiation of a Phase 1 study for the fixed-dose combination AP03 in healthy volunteers, the presentation of new AP01 data at the ERS Congress, and the publication of AP02 Phase 1 results in Respiratory Research. Additionally, Robert J. Meyer, MD, was appointed to the company's Board of Directors in September.Healthcare
- MGTXNov 12, 8:08 AMMeiraGTx reported a net loss of $51.3 million for the third quarter of 2026, driven by increased research and development expenses and a loss on its equity method investee, while cash and cash equivalents rose to $184.7 million. The company plans to submit a Marketing Authorisation Application for its lead candidate, botaretigene sparoparvovec, to the European Medicines Agency in December 2026, followed by a Biologics License Application to the FDA in early 2027. Operational milestones include the completion of enrollment for the pivotal Phase 2 AQUAx2 study for radiation-induced xerostomia, with data expected in mid-2027, and the initiation of a Phase 3 study for AAV-GAD in Parkinson's disease in the first quarter of 2027. Additionally, MeiraGTx strengthened its leadership team with new appointments to the executive and board levels and highlighted upcoming presentations on its AAV-BDNF program for genetic obesity.Healthcare
- LUCDNov 12, 8:05 AMLucid Diagnostics reported that Medicare now fully reimburses its EsoGuard esophageal DNA test nationwide, enabling the company to accelerate commercialization efforts. In the third quarter of 2026, the company recognized $1.2 million in revenue from 2,871 tests, with October setting a record volume of over 1,800 tests. The company announced a $15 million private placement to strengthen its balance sheet and reported a GAAP net loss of $6.7 million for the quarter. Additionally, Lucid highlighted the publication of a large-scale real-world study and the inclusion of its test in draft American Gastroenterological Association guidelines as alternatives to endoscopy.Healthcare
- AKTSNov 12, 8:05 AMAktis Oncology reported a net loss of $29.9 million for the third quarter ended September 30, 2026, while increasing its cash position to $492.9 million. The company initiated its third Phase 1b clinical trial, BActinium-2, to evaluate AKY-2519 in non-small cell lung cancer and other B7-H3 expressing tumors. Additionally, backfill cohorts were started in the ongoing NECTINIUM-2 and BActinium-1 trials to further assess safety and antitumor activity for AKY-1189 and AKY-2519. Aktis expects to present preliminary data for AKY-1189 in the first quarter of 2027 and for AKY-2519 later in 2027.Healthcare
- COHNNov 12, 8:03 AMCohen & Company Inc. reported third-quarter 2026 financial results with total revenues of $32.4 million and net income attributable to the company of $6.7 million, or $0.12 per fully diluted share. The company's investment banking and new issue revenue declined to $12.7 million due to $17.6 million in mark-to-market losses, while its gestation repo book reached an all-time high of $4.5 billion. The Board of Directors declared a quarterly dividend of $0.25 per share, payable on December 14, 2026, to stockholders of record as of November 30, 2026. Daniel G. Cohen was appointed Chief Executive Officer, succeeding his role as Executive Chairman.Financial Services
- KYTXNov 12, 8:01 AMKyverna Therapeutics has completed the submission of a rolling Biologics License Application to the FDA for miv-cel in stiff person syndrome, requesting priority review under its Regenerative Medicine Advanced Therapy designation. The company reports that miv-cel demonstrated durable efficacy and a well-tolerated safety profile in registrational trials, with no high-grade cytokine release syndrome or neurotoxicity observed. Financial results for the third quarter of 2026 show a net loss of $41.9 million, while the company maintains $170.6 million in cash and marketable securities to support operations into 2028. Additionally, enrollment for the Phase 3 gMG trial is on track for completion in mid-2027, and the KYV-102 program has been deprioritized to focus resources on late-stage neurologic indications.Healthcare
- GRCENov 12, 8:01 AMGrace Therapeutics reported a net loss of $2.1 million for the three months ended September 30, 2026, driven by increased research and development expenses related to its dual-source manufacturing strategy for GTx-104. The company completed a $10 million private placement in August 2026, extending its cash runway through the end of 2028 to support regulatory resubmission efforts for its New Drug Application. Following a Complete Response Letter from the FDA in April 2026, Grace Therapeutics is addressing chemistry, manufacturing, and controls issues while initiating technology transfer to a second U.S.-based contract manufacturer. As of September 30, 2026, the company held $21.3 million in cash and cash equivalents to fund operations and resolve FDA-identified items.Healthcare
- MNPRNov 12, 8:01 AMMonopar Therapeutics reported a net loss of $6.2 million for the third quarter of 2026, with cash and investments totaling $129.4 million sufficient to fund operations through March 31, 2028. The company initiated a rolling New Drug Application submission to the FDA for ALXN1840, a first-in-class treatment for Wilson disease, and appointed Jeffrey D. Kent as Executive Vice President of Medical Affairs. Financial results showed increased research and development expenses driven by contractor and personnel costs, while interest income rose due to higher cash balances from a prior capital raise.Healthcare
- BTCSNov 12, 8:01 AMBTCS Inc. reported a record third quarter 2026 gross profit of $3.5 million with an 86% gross margin, surpassing its full-year target of $6 million within the first nine months of the year. Total revenues for the quarter increased 67% to $4.1 million, driven primarily by a 133% quarter-over-quarter growth in DeFi revenues from its Imperium business line. The company expanded its Imperium liquidity pool positions from approximately $8 million to $41 million and integrated operations on the Base network. Net income for the quarter was $54.5 million, largely attributed to $58.3 million in non-cash unrealized gains on digital assets due to Ethereum price appreciation.Financial Services
- IMNNNov 12, 8:00 AMIMUNON, Inc. reported a net loss of $3.8 million for the third quarter of 2026, with operating expenses totaling $3.4 million. The company advanced its lead candidate IMNN-001 in a Phase 3 trial for advanced ovarian cancer, supported by a new Cooperative Research and Development Agreement with the National Cancer Institute. Recent corporate developments include a debt-for-equity exchange reducing debt by approximately 43% and an agreement to sell rights to ThermoDox to VoxelDox Therapeutics. As of September 30, 2026, the company held $4.0 million in cash and cash equivalents alongside $5.0 million in restricted cash.Healthcare
- ARXNov 12, 8:00 AMAccelerant Holdings reported third-quarter 2026 results showing a 27% year-over-year increase in Exchange Written Premium to $1.33 billion, with third-party direct written premium accounting for 49% of the volume. The company recorded a GAAP net loss of $9.2 million, or $0.06 per diluted share, while reporting adjusted net income of $38.2 million and adjusted EBITDA of $71.3 million. Accelerant added 26 Managing General Agents during the quarter, bringing the total member count to 340, and announced a definitive merger agreement with Thoma Bravo expected to close in the first half of 2027. Due to the pending transaction, the company will not host an earnings conference call or provide guidance for the remainder of 2026.Financial Services
- ICUNov 12, 8:00 AMSeaStar Medical Holding Corporation reported net revenue of $635,000 for the third quarter of 2026, representing a 247% increase compared to the same period in 2025, driven by the adoption of its QUELIMMUNE therapy for pediatric acute kidney injury. The company achieved nearly 75% enrollment in its NEUTRALIZE-AKI pivotal clinical trial for adult patients and received Breakthrough Device Designation from the FDA for treating hyperinflammation in adults with sepsis. During the quarter, the company reported a net loss of $4.5 million, or $1.03 per share, while maintaining cash reserves of $4.0 million as of September 30, 2026.Healthcare
- CRMDNov 12, 8:00 AMCorMedix Therapeutics reported third-quarter 2026 consolidated revenue of $54.5 million and a net loss of $14.7 million, resulting in adjusted EBITDA of $3.1 million. The company announced a definitive agreement to acquire substantially all assets of Heron Therapeutics, a transaction expected to close in the first quarter of 2027 and contribute between $125 million and $150 million in revenue for the full year 2027. DefenCath sales declined to $17.2 million due to post-TDAPA pricing pressures, while the remainder of the portfolio generated $37.3 million in revenue. CorMedix maintained its full-year 2026 revenue guidance of $325 million to $345 million but narrowed its adjusted EBITDA guidance to $130 million to $140 million, while suspending 2027 DefenCath revenue guidance pending further clarity on CMS reimbursement frameworks.Healthcare
- LTCHNov 12, 7:51 AMLatch, Inc., operating as DOOR, reported third-quarter 2026 total revenue of $14.1 million, an 18.9% decrease year-over-year driven by lower hardware shipments and professional services activity. Software revenue grew 18.1% to $6.3 million, contributing to an expanded gross margin of 55.2% despite a net loss of $20.5 million that included a $13.6 million non-cash goodwill impairment charge. The company launched its OpenDOOR developer platform and executed a restructuring plan expected to reduce annualized operating costs by $10 million to $12 million. Additionally, DOOR settled a Securities and Exchange Commission investigation with a $1.0 million civil penalty and aims to achieve positive cash flow by the second half of 2027.Technology
- SGMTNov 12, 7:48 AMSagimet Biosciences initiated its registrational U.S. AURORA Phase 3 clinical trial for denifanstat in moderate to severe acne, with topline data expected in the second half of 2027. The company completed an underwritten offering of Series A common stock and pre-funded warrants in October 2026, generating $115 million in gross proceeds. As of September 30, 2026, Sagimet reported a pro forma cash balance of approximately $356 million, which is projected to fund operations through mid-2029. Additionally, the company presented positive 52-week efficacy data from its license partner Ascletis' Phase 3 trial in China and announced plans to initiate a Phase 2 trial for its FASN inhibitor TVB-3567 before the end of 2026.Healthcare
- EROCNov 12, 7:48 AMERock, Inc. reported a third quarter 2026 net income of $8.9 million and Adjusted EBITDA of $12.6 million, marking a nearly fourfold increase in revenue quarter-over-quarter to $152.8 million. The company began construction on a 366-megawatt generation facility for Meta in El Paso and expanded its manufacturing capacity with a new Atlas facility in Houston. ERock ended the quarter with $549 million in unrestricted cash, no outstanding debt, and a backlog reaching a new record level. The company reaffirmed its full-year 2026 guidance, projecting revenue between $435 million and $465 million and Adjusted EBITDA between $3 million and $9 million.Industrials
- ENVXNov 12, 7:44 AMEnovix Corporation reported Q3 2026 revenue of $11.0 million, representing a 38% year-over-year increase driven by strong demand in the drone and defense sectors. The company achieved a record non-GAAP gross margin of 34.5% and announced a new fiscal year 2027 revenue guidance range of $65 million to $85 million. Strategic initiatives included retiring $128 million of 2030 Notes at a 36% discount, executing a restructuring to reduce annual costs by $8.5 million, and expanding battery production capacity in South Korea. Additionally, Enovix declared a warrant dividend to retire its 2028 Notes and shifted its silicon-anode development focus toward smart eyewear applications following qualification challenges in the smartphone market.Industrials
- TSHANov 12, 7:38 AMTaysha Gene Therapies reported a net loss of $39.1 million for the third quarter of 2026, driven by increased research and development expenses related to its TSHA-102 clinical trials. The company successfully completed a BLA-enabling Process Performance Qualification manufacturing campaign for TSHA-102, which met all predefined product specifications and comparability criteria. As of November 2026, TSHA-102 has been generally well tolerated across 33 patients in the REVEAL and ASPIRE trials with no severe treatment-related serious adverse events or dose-limiting toxicities observed. Taysha expects to report topline data from the six-month interim analysis of the REVEAL pivotal trial and receive FDA feedback on its BLA submission pathway in the first half of 2027.Healthcare
- FBYDNov 12, 7:35 AMFalcon's Beyond Global, Inc. reported consolidated revenue of $7.3 million for the third quarter of 2026, representing an 80% increase compared to the prior year period. The company recorded a consolidated net loss of $7.7 million and an Adjusted EBITDA loss of $7.4 million for the quarter, though both metrics showed improvement over the previous year. Key unconsolidated entities contributed significantly to the results, with Falcon's Creative Group generating $5.2 million in revenue and the joint venture Producciones de Parques generating $11.8 million. The company's contracted pipeline for attractions and creative services totaled $28.0 million as of the end of the quarter.Industrials
- CAPSNov 12, 7:35 AMCapstone Holding Corp. reported third-quarter 2026 revenue of $20.0 million, representing a 46% year-over-year increase, with income from operations reaching $0.4 million. The company's Stone Business Adjusted EBITDA for the quarter was $1.5 million, and full-year revenue guidance was revised downward to approximately $70 million due to higher interest rates impacting housing activity. Despite these macroeconomic headwinds, organic revenue grew 7.5% in the third quarter, and all three operating businesses outperformed their respective markets.Basic Materials
- SBDSNov 12, 7:35 AMSolo Brands, Inc. reported fiscal 2026 third-quarter net sales of $43.7 million, a 17.6% decrease from the prior year period, driven by lower unit volumes and retail channel softness. Despite the revenue decline, the company achieved positive operating cash flow of over $6 million and improved segment adjusted EBITDA across its Solo Stove, Chubbies, and Watersports divisions. Consolidated net loss for the quarter was $20.8 million, while adjusted net loss narrowed to $11.6 million, reflecting disciplined cost management and reduced promotional activity. For the full year 2026, the company updated its guidance to project net sales between $270 million and $290 million and adjusted EBITDA between $21 million and $25 million.Consumer Cyclical
- ALTNov 12, 7:33 AMAltimmune, Inc. reported a net loss of $31.6 million for the third quarter ended September 30, 2026, driven by increased research and development expenses related to its PERFORMA Phase 3 trial in MASH and RESTORE Phase 2 trial in ALD. The company holds $480 million in cash, cash equivalents, and investments as of the end of the quarter. Clinical progress includes the ongoing global PERFORMA Phase 3 trial in MASH with topline data anticipated in 2029, positive RECLAIM Phase 2 data in AUD presented at AASLD, and a scheduled End-of-Phase 2 meeting with the FDA for the AUD program in December 2026. Additionally, enrollment is complete for the RESTORE Phase 2 trial in ALD, with topline data expected in the second half of 2027.Healthcare
- LUNRNov 12, 7:32 AMIntuitive Machines reported record third-quarter 2026 revenue of $269 million, driven by satellite production, lunar delivery, and ground communication services. The company achieved a gross margin of $69 million (26%) and generated positive free cash flow of $33 million during the quarter. Backlog reached a record $1.9 billion, an increase of $1.7 billion from the end of 2025, fueled by new awards including NASA's CLPS 2 contract and the Accelerated Missile Defense Tranche 3 constellation. Full-year 2026 revenue is projected to fall between $920 million and $950 million, with the company expecting positive Adjusted EBITDA for the year.Industrials
Research Reports
Technology →Sep 30, 2026 to Nov 14, 2026 · 398 companies
Technology Earnings Report — 2026-09-30 to 2026-11-14
Report generated: 2026-11-14 19:05:28 EST
Overview
Companies reported: 398 (2026-09-30 - 2026-11-14). The technology sector delivered broadly positive results driven primarily by surging demand for AI infrastructure, which fueled record revenues and earnings growth for hyperscalers, data center operators, and semiconductor equipment makers. While leaders such as CoreWeave (CRWV), Applied Materials (AMAT), and Microsoft (MSFT) reported double-digit revenue and profit expansions, the sector exhibited a clear bifurcation with legacy hardware and consumer-focused firms like GoPro (GPRO) and Health In Tech (HIT) facing significant revenue declines and profitability challenges.
Leaderboard
Top 5 by Revenue Growth (YoY)
| # | Company | Ticker | Revenue Growth YoY | Revenue |
|---|---|---|---|---|
| 1 | Palladyne AI | PDYN | 895% | $8.6 million |
| 2 | Boost Run | BRUN | 496% | $39.9 million |
| 3 | Corvex | MOVE | 1,294% | $5.0 million |
| 4 | CoreWeave | CRWV | 168% | $3.66 billion |
| 5 | Airgain | AIRG | 9% | $15.3 million |
Note: Airgain (AIRG) is listed as the fifth entry based on the lowest positive growth rate among companies with reported YoY revenue growth figures in the provided summaries, as fewer than five companies reported positive growth rates exceeding 100% in the specific subset of summaries containing explicit YoY percentage growth data.
Top 5 by Net Income Growth (YoY)
| # | Company | Ticker | Net Income Growth YoY | Net Income |
|---|---|---|---|---|
| 1 | Strategy Inc | MSTR | 599.8% | $19.53 billion |
| 2 | Core Scientific | CORZ | n/a | $1.2 billion |
| 3 | Netlist Inc | NLST | n/a | $85.4 million |
| 4 | KULR Technology Group | KULR | n/a | $4.47 million |
| 5 | Spruce Power Holding Corp | SPRU | n/a | $6.0 million |
Net income growth for Core Scientific, Netlist, KULR, and Spruce Power is listed as n/a because the summaries report absolute net income figures or a swing from loss to profit without providing the specific prior-year net income value required to calculate a precise percentage growth rate.
Themes
- AI infrastructure demand is a primary growth driver across the sector, with hyperscalers and data center operators accelerating buildouts; companies like CoreWeave (CRWV), Cerebras (CBRS), and Super Micro Computer (SMCI) reported record revenues and backlogs, while semiconductor equipment makers such as Applied Materials (AMAT) and KLA (KLAC) cited AI-driven demand for advanced nodes and packaging.
- Revenue growth is heavily concentrated in AI-related segments, including data center networking, high-performance computing, and specialized silicon; Cisco (CSCO) noted a "networking supercycle," Arista Networks (ANET) saw 58% revenue growth, and AMD (AMD) reported a 97% surge in its Data Center segment.
- Gross margins are expanding for many firms due to favorable product mix shifts toward higher-margin software, services, and AI-enabled hardware; Diodes (DIOD), Netlist (NLST), and Marvell (MRVL) highlighted margin improvements driven by AI infrastructure demand and premium product adoption.
- Capital allocation strategies increasingly focus on share repurchases and dividends to return value to shareholders, with Apple (AAPL), Microsoft (MSFT), and Broadcom (AVGO) leading in buyback volumes, while others like Fortinet (FTNT) and Palo Alto Networks (PANW) have expanded authorization levels.
- Strategic M&A activity is accelerating as companies seek to acquire AI capabilities, data assets, and complementary technologies; Microsoft (MSFT) invested in OpenAI, Adobe (ADBE) acquired Figma (FIG), and several semiconductor firms like onsemi (ON) and Marvell (MRVL) pursued acquisitions to bolster their AI portfolios.
- Supply chain constraints and component shortages persist, particularly for advanced semiconductors and networking equipment, leading to extended lead times and inventory buildups; Intel (INTC) and AMD (AMD) noted capacity constraints, while suppliers like Amkor (AMKR) and Ultra Clean (UCTT) reported record orders amid tight supply.
- Cost management and operational efficiency remain critical, with many companies implementing restructuring plans to reduce operating expenses and improve profitability; ServiceNow (NOW), Adobe (ADBE), and others are leveraging AI to automate processes and optimize cost structures.
- Recurring revenue models, particularly SaaS and subscription-based services, continue to gain traction, providing stability and visibility; companies like Salesforce (CRM), Adobe (ADBE), and ServiceNow (NOW) reported strong ARR growth and high retention rates, supporting valuation multiples.
- Geopolitical risks and regulatory uncertainties, including export controls and trade tensions, are influencing supply chain strategies and market access; companies like Intel (INTC) and Micron (MU) are navigating complex regulatory environments, while others are diversifying manufacturing footprints to mitigate risks.
- The sector is experiencing a bifurcation between companies successfully capitalizing on the AI boom and those facing headwinds from macroeconomic softness, legacy product declines, or execution challenges; while leaders like NVIDIA (NVDA) and Microsoft (MSFT) thrive, others like Intel (INTC) and legacy hardware firms face pressure to adapt.
Market Outlook & Trends
- Revenue growth is being driven primarily by AI infrastructure demand, with hyperscalers and data center operators fueling record bookings and shipments for companies like Cerebras (CBRS), CoreWeave (CRWV), and Super Micro Computer (SMCI), while semiconductor equipment and materials firms such as Applied Materials (AMAT) and KLA (KLAC) report surging demand from advanced node and packaging transitions.
- Demand for AI-related networking and optical components has accelerated significantly, with Cisco (CSCO) citing the "very early stages of a multi-year networking supercycle" and Lumentum (LITE) securing multi-billion dollar orders for optical switching, though some legacy consumer segments like smartphone and PC remain soft for firms like Diodes (DIOD) and Synaptics (SYNA).
- Backlog levels are reaching record highs across the sector, with companies like Avnet (AVT), TE Connectivity (TEL), and Teradyne (TER) reporting order books that support strong visibility into 2027, while others like Lattice Semiconductor (LSCC) and Astera Labs (ALAB) highlight design wins and bookings as key indicators of future revenue.
- Pricing power and gross margins are expanding for many players due to product mix shifts toward higher-value AI and industrial solutions, as seen with Marvell (MRVL), Monolithic Power Systems (MPWR), and Fortinet (FTNT), although some firms like Netgear (NTGR) and KULR (KULR) face margin compression from supply chain costs, inventory write-offs, or initial production inefficiencies.
- Capacity constraints and supply chain lead times remain a critical risk, with Intel (INTC), AMD (AMD), and Micron suppliers noting extended lead times and tight channel inventory, while companies like Wolfspeed (WOLF) and Key Tronic (KTCC) cite manufacturing constraints and capital limitations that could delay order fulfillment.
- Strategic pivots toward software, recurring revenue, and AI-enabled services are reshaping business models, with firms like NetSol (NTWK), FiEE (FIEE), and Workiva (WK) reporting strong SaaS growth and margin expansion, while others like TransAct (TACT) and TransAct (TACT) face soft demand in legacy hardware segments.
- M&A activity is intensifying as companies seek to acquire AI capabilities and expand market share, with major transactions including Marvell's acquisition of Lumentum, onsemi's deal for Synaptics, and numerous smaller acquisitions by firms like Cadence (CDNS), Broadcom (AVGO), and others to integrate IP and technology.
- Capital allocation strategies are shifting toward share buybacks and dividends for profitable firms like Apple (AAPL), Microsoft (MSFT), and Cisco (CSCO), while high-growth infrastructure players like CoreWeave (CRWV) and Cerebras (CBRS) are raising significant debt and equity to fund massive capital expenditure programs for data center build-outs.
- Risks identified by management include geopolitical tensions, export control disruptions, regulatory uncertainties, and the potential for customer concentration, with several firms like Netlist (NLST) and Intel (INTC) explicitly noting exposure to litigation, trade policies, and the timing of government contract awards.
- The sector is experiencing a bifurcation where AI and data center leaders are seeing double-digit growth and profitability, while companies reliant on consumer electronics, legacy hardware, or specific regional markets like residential solar face headwinds from inventory corrections, tariff impacts, and macroeconomic softness.
Key Numbers
- Cisco Systems (CSCO) reported record quarterly revenue of $18.5 billion, up 24% year-over-year, with GAAP net income rising 59% to $4.6 billion and non-GAAP net income increasing 39% to $5.6 billion.
- Applied Materials (AMAT) posted record Q4 FY2026 revenue of $10.41 billion, up 53% year-over-year, and full-year revenue of $34.45 billion, up 21%, while non-GAAP EPS reached a record $4.16, up 92%.
- Super Micro Computer (SMCI) saw net sales surge 298% year-over-year to $19.9 billion in Q1 FY2027, with net income rising to $1,594 million and non-GAAP diluted EPS reaching $1.81.
- CoreWeave (CRWV) revenue surged 168% year-over-year to $3.66 billion for Q3 2026, with Adjusted EBITDA rising 169% to $2.26 billion, though net loss widened to $709 million.
- Palantir Technologies (PLTR) total revenue grew 96% year-over-year to $2.313 billion, with GAAP net income of $1.128 billion and adjusted free cash flow of $1.216 billion.
- Microsoft (MSFT) revenue reached $92.3 billion, up 19% year-over-year, driven by a 25% increase in Agents and Infra revenue, while net income grew 32% to $36.6 billion.
- Shopify (SHOP) revenue grew 32% year-over-year to $3,742 million, with net income rising to $462 million and free cash flow increasing to $816 million.
- AMD (AMD) reached record Q3 revenue of $13.4 billion, up 45% year-over-year, driven by a 97% surge in Data Center segment revenue to $8.5 billion, while GAAP net income rose 95% to $2.4 billion.
- Marvell Technology (MRVL) reported preliminary Q3 FY2027 revenue consistent with guidance, maintaining the midpoint while narrowing the expected range from ±5% to ±2%.
- Arista Networks (ANET) Q3 2026 total revenue reached $3.66 billion, a 58.5% year-over-year increase, with non-GAAP diluted EPS rising to $1.20 from $0.77.
Outliers
- CoreWeave (CRWV) posted the strongest report with Q3 revenue surging 168% year-over-year to $3.66 billion and Adjusted EBITDA rising 169% to $2.26 billion, driven by massive infrastructure build-out and a $132.5 billion revenue backlog.
- Applied Materials (AMAT) delivered the second strongest performance with Q4 FY2026 revenue hitting a record $10.41 billion, up 53% year-over-year, supported by a 64% surge in Semiconductor Systems and record non-GAAP EPS of $4.16.
- GoPro (GPRO) issued the weakest report, citing substantial doubt regarding its ability to continue as a going concern, material weaknesses in internal controls, and a 41% revenue decline to approximately $96 million.
- Health In Tech (HIT) reported the second weakest results, with Q3 revenue falling 22% to $6.6 million and a net loss widening to $7.1 million due to a $5.3 million credit loss provision, prompting a downward revision of full-year guidance to approximately $30 million.
Earnings Call Transcripts
More →- NVDAFROM AI FACTORIES TO INTELLIGENT CITIES - NVIDIA CORP 7h ago
- NVDAEarnings Call - NVIDIA CORP 8h ago
- NBISNebius Q3 2026 Earnings Call - NEBIUS GROUP NV 1d ago
- ALLNAll-In Podcast: Jensen OUT as Nvidia CEO: "Spy" Scandal, Export Restrictions, Market Impact - All-In Podcast 1d ago
- DEFTAutoCanada Inc. - Third Quarter 2026 Results - DEFI TECHNOLOGIES INC 1d ago
- PYRGFThird Quarter 2026 Business Update Conference Call - PYROGENESIS CANADA INC 1d ago
- USASAmericas Gold and Silver Third Quarter 2026 Webcast - AMERICAS GOLD & SILVER CORP 1d ago
- WPRTAetherion Technologies Q3 2026 Conference Call - AETHERION TECHNOLOGIES INC 1d ago
- PHXWhiteHawk Minerals 3Q26 Earnings Call - PHX MINERALS INC 1d ago
- DEFTK-Bro Linen Inc. - Third Quarter 2026 Results - DEFI TECHNOLOGIES INC 1d ago
- DEFTK-Bro Linen Inc. - Third Quarter 2026 Results - DEFI TECHNOLOGIES INC 1d ago
- PHXWhiteHawk Minerals 3Q26 Earnings Call - PHX MINERALS INC 1d ago
- BRAGBragg Gaming Group 3Q26 Earnings Conference Call - BRAGG GAMING GROUP INC 1d ago
- DEFTCorby Q1 2027 Earnings Call - DEFI TECHNOLOGIES INC 1d ago
- LFTLument Finance Trust, Inc. - Q3 2026 Earnings and Investor Call - LUMENT FINANCE TRUST INC 1d ago
- LMFAPowerCompute's 3Q 2026 Earnings Call - POWERCOMPUTE INC 1d ago
- GEMIGemini Third Quarter 2026 Earnings Call - GEMINI SPACE STATION INC 1d ago
- CNVSCineverse Corp Reports Second Quarter Fiscal 2027 Results - CINEVERSE CORP 1d ago
- OWLTOwlet Q3'26 Earnings Conference Call - OWLET INC 1d ago
- DEFTCipher Pharmaceuticals Inc. - Third Quarter 2026 Financial Results Call - DEFI TECHNOLOGIES INC 1d ago
- CPHRCipher Pharmaceuticals Inc. - Third Quarter 2026 Financial Results Call - CIPHER PHARMACEUTICALS INC 1d ago
- RPMSYSCO CORPORATION ANNUAL MEETING OF STOCKHOLDERS - RPM INTERNATIONAL INC 1d ago
- YTRAYatra 2Q27 Earnings Conference Call - YATRA ONLINE INC 1d ago
- YTRAYatra 2Q27 Earnings Conference Call - YATRA ONLINE INC 1d ago
- DMACDiaMedica Therapeutics Third Quarter 2026 Financial Results and Business Update Conference Call - DIAMEDICA THERAPEUTICS INC 1d ago
- PARKPark Dental Partners Reports 2026 Third-Quarter Results - PARK DENTAL PARTNERS INC 1d ago
- LMFAPowerCompute's 3Q 2026 Earnings Call - POWERCOMPUTE INC 1d ago
- DLODLOCAL Third Quarter 2026 Results - DLOCAL LTD 2d ago
- KLCKinderCare Third Quarter 2026 Earnings Call - KINDERCARE LEARNING COMPANIES INC 2d ago
- DEFTGrown Rogue International Inc. - Third Quarter 2026 Results - DEFI TECHNOLOGIES INC 2d ago
Press Releases
More →- MATHot Wheels Crowns 2026 Legends Tour Winner Following Global Search Across 19 Countries Business Wire · 6h ago
- AIIONew to The Street Show #780 Premieres Tonight on Bloomberg Television with Robo.ai, American Fusion, Stewards Investment Capital and FreeCast ACCESS Newswire · 6h ago
- LLYLilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale PR Newswire · 7h ago
- AMLXAmylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting Business Wire · 7h ago
- WWBInnovative Immunology Biotech Windward Bio Lists on Nasdaq PR Newswire · 8h ago
- BETRBetter Home & Finance Holding Company (BETR) Down 61% Between May 6 and August 6, 2026; Class Period Expanded to End August 6, 2026 PR Newswire · 10h ago
- RKLBRocket Lab Hits 100 Electron Launches, Fastest Commercial Rocket to Reach the Milestone GlobeNewswire · 17h ago
- AGPUCORRECTION: Axe Compute to Host Q3 2026 Financial Results Conference Call GlobeNewswire · 20h ago
- ZLABZai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China’s 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products Business Wire · 20h ago
- WWBInnovative Immunology Biotech Windward Bio Lists on Nasdaq PR Newswire · 20h ago
- ECSUPERINTENDENCY OF INDUSTRY AND COMMERCE CLOSES THE INVESTIGATION INITIATED AGAINST ECOPETROL AND ITS SUBSIDIARIES CENIT AND OCENSA PR Newswire · 22h ago
- HSTXFRETRANSMISSION: Heliostar Presents Q3 2026 Financial and Operating Results with Record Mine Operating Earnings and Cash Balance ACCESS Newswire · 22h ago
- QSIQuantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · 23h ago
- SCNDScientific Industries Reports Third Quarter Fiscal 2026 Results ACCESS Newswire · 23h ago
- NURNuRAN Wireless Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency ACCESS Newswire · 23h ago
- BAMPartners Value Investments L.P. Announces Q3 2026 Interim Results GlobeNewswire · 23h ago
- BAMPartners Value Investments Inc. Announces Q3 2026 Interim Results GlobeNewswire · 23h ago
- CNSCohen & Steers Announces Changes to Realty Indexes PR Newswire · 23h ago
- BTQ/C O R R E C T I O N - BTQ Technologies Corp./ PR Newswire · 1d ago
- DANDana Announces Pricing, Expiration and Results of Tender Offers for Any and All of its Outstanding 4.250% Senior Notes due 2030 and 4.500% Senior Notes due 2032 PR Newswire · 1d ago
- AZNPerioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer Business Wire · 1d ago
- BKHChime Financial Set to Join S&P MidCap 400 PR Newswire · 1d ago
- SVCService Properties Trust Receives Statement of Support from Shareholder Flat Footed LLC Business Wire · 1d ago
- SXLXFSLAM Announces Proposed Extension of Warrant Expiry Dates ACCESS Newswire · 1d ago
- OGIOrganigram Provides NASDAQ Listing Update Business Wire · 1d ago
- MDGLKaplan Fox is Investigating Claims on Behalf of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) Investors for Potential Securities Law Violations GlobeNewswire · 1d ago
- FHNFirst Horizon Bank, Catholic Charities and AltCap Leverage New Markets Tax Credits to Build $25 Million Family Opportunity Center PR Newswire · 1d ago
- OPTXSyntec Optics' (Nasdaq: OPTX) Q3 Hits All Time High Revenue, Profits Grow to Double-Digit Adj EBITDA, and Net Income Surges Positive GlobeNewswire · 1d ago
- VVVVThe NYSE Welcomes vVARDIS as a Publicly Listed Company PR Newswire · 1d ago
- AEPKentucky Power Files Plans to Deliver Customer Savings and Advance Kentucky's Economic Future PR Newswire · 1d ago
BNN Bloomberg
More →- Novo’s Wegovy pill helps patients lose about 6% of weight in three months, real-world data show 47m ago
- What Canadians should know about their air passenger rights amid U.S. travel chaos 1h ago
- Italy fines Meta US$887 for using Android gallery photos and videos on Facebook 2h ago
- SpaceX’s Starship returns from orbit and is captured by launch pad arms in a dramatic first 2h ago
- Faulty equipment blamed by Trump administration for FAA ground stop. Follow for live updates. 6h ago
- More than 2,000 flights cancelled on Saturday after U.S. FAA lifts ground stop. Live updates here. 11h ago
- More than 42,000 Honda and Acura vehicles recalled in Canada due to steering issue 14h ago
- Canadian airports warn more delays expected after U.S. FAA lifts ground stop 20h ago
- PM Carney says Canada, Philippines conclude free-trade talks, target deal by 2027 20h ago
- U.S. FAA lifts nationwide ground stop that cancelled thousands of flights around the world. Live updates here. 22h ago
- PM Carney requests ethics screen with close friend’s company, Telesat 23h ago
- Carney arrives in Manila for ASEAN summit, seeks trade pact with Philippines 1d ago
- FAA issues ‘ground stop’ for all flights across the U.S. due to safety issue. Live updates here. 1d ago
- Court allows news publishers' copyright lawsuit against OpenAI to go ahead 1d ago
- Federal government won’t clarify stance on possibility of future streamer payments for CanCon 1d ago
- TikTok says it has taken down deepfake videos spreading trade falsehoods 1d ago
- Alberta gov’t promises 10-year royalty framework with oilsands growth program 1d ago
- Investor Outlook: AI helps accelerate quantum computing development 1d ago
- Market Outlook: Political hurdles could slow U.S. AI expansion 1d ago
- H&R REIT calls off sale after unitholders vote against transaction 1d ago
- Great Outdoors Comedy Festival organizer enters bankruptcy 1d ago
- Climate change could force more than 200 million from homes: UN migration chief 1d ago
- METAJason Del Vicario’s Top Picks for Nov. 13, 2026 1d ago
- Stelco to recall 175 laid-off workers in Hamilton, Ont., on Dec. 1 1d ago
- Saudi Arabia’s The Helicopter Company orders 12 Bombardier jets in fixed-wing aviation push 1d ago
- Ottawa, province hope 'aggressive package' can prevent Stellantis plant sale: Joly 1d ago
- Bessent blames Lutnick’s U.S. Commerce Department for not restricting Nvidia chips to China 1d ago
- Canadian-made ‘Paralives’ thrives despite gaming sector turmoil 1d ago
- S&P/TSX composite little changed in late-morning trading 1d ago
- Judge orders cognitive checks on Hermès heir who says his fortune was stolen, Reuters sources say 1d ago
Earnings Reports
More →- NVDAEarnings Call - NVIDIA CORP 8h ago
- HSTXFRETRANSMISSION: Heliostar Presents Q3 2026 Financial and Operating Results with Record Mine Operating Earnings and Cash Balance 22h ago
- BYFCBroadway Financial Corporation Reports Third Quarter 2026 Results Highlighted by Improved Earnings, Strong Deposit Growth and Stable Credit Quality 1d ago
- HSTXFHeliostar Presents Q3 2026 Financial and Operating Results with Record Mine Operating Earnings and Cash Balance 1d ago
- NBISNebius Q3 2026 Earnings Call - NEBIUS GROUP NV 1d ago
- PHXWhiteHawk Minerals 3Q26 Earnings Call - PHX MINERALS INC 1d ago
- PHXWhiteHawk Minerals 3Q26 Earnings Call - PHX MINERALS INC 1d ago
- BRAGBragg Gaming Group 3Q26 Earnings Conference Call - BRAGG GAMING GROUP INC 1d ago
- DEFTCorby Q1 2027 Earnings Call - DEFI TECHNOLOGIES INC 1d ago
- BOFBranchOut Food Announces Third Quarter 2026 Earnings Call and Shareholder Update 1d ago
- LFTLument Finance Trust, Inc. - Q3 2026 Earnings and Investor Call - LUMENT FINANCE TRUST INC 1d ago
- XGPUReliance Global Group Schedules Third Quarter 2026 Financial Results and Business Update Conference Call 1d ago
- LMFAPowerCompute's 3Q 2026 Earnings Call - POWERCOMPUTE INC 1d ago
- GEMIGemini Third Quarter 2026 Earnings Call - GEMINI SPACE STATION INC 1d ago
- KNDIKandi Technologies to Report Third Quarter 2026 Financial Results on Wednesday, November 18, 2026 1d ago
- CNVSCineverse Corp Reports Second Quarter Fiscal 2027 Results - CINEVERSE CORP 1d ago
- OWLTOwlet Q3'26 Earnings Conference Call - OWLET INC 1d ago
- ALLRAllarity Therapeutics Reports Third Quarter 2026 Results and Provides Full Year 2026 Financial Guidance 1d ago
- YTRAYatra 2Q27 Earnings Conference Call - YATRA ONLINE INC 1d ago
- YTRAYatra 2Q27 Earnings Conference Call - YATRA ONLINE INC 1d ago
- DMACDiaMedica Therapeutics Third Quarter 2026 Financial Results and Business Update Conference Call - DIAMEDICA THERAPEUTICS INC 1d ago
- RMIXSuncrete Announces Q3 2026 Earnings Results 1d ago
- PARKPark Dental Partners Reports 2026 Third-Quarter Results - PARK DENTAL PARTNERS INC 1d ago
- LMFAPowerCompute's 3Q 2026 Earnings Call - POWERCOMPUTE INC 1d ago
- CSIQCanadian Solar Schedules Third Quarter 2026 Earnings Conference Call for December 3 1d ago
- HDLSuper Hi to Report Third Quarter 2026 Financial Results on Wednesday, November 25, 2026 1d ago
- FINVFinVolution Group to Report Third Quarter 2026 Financial Results on Wednesday, November 25, 2026 1d ago
- GSWhy European Companies Are Forecast to Have Robust Earnings Growth 1d ago
- KLCKinderCare Third Quarter 2026 Earnings Call - KINDERCARE LEARNING COMPANIES INC 2d ago
- DEFTGrown Rogue International Inc. - Third Quarter 2026 Results - DEFI TECHNOLOGIES INC 2d ago
FDA Approvals
More →- BYSIBeyondSpring Reports Third-Quarter 2026 Financial Results and Provides Corporate Update GlobeNewswire · 1d ago
- CINGWCingulate Inc. Reports Third Quarter 2026 Financial Results and Provides Regulatory Update on CTx-1301 NDA Resubmission GlobeNewswire · 1d ago
- VTGNVistagen Reports Fiscal Year 2027 Second Quarter Financial Results and Provides Corporate Update GlobeNewswire · 1d ago
- NTHINeOnc Showcases Two Brain Cancer Drug Programs at SNO as FDA Meetings Approach GlobeNewswire · 1d ago
- TNDMTandem Mobi Now FDA Cleared as World’s First and Only Tubeless AID System with up to Seven Days of Wear Business Wire · 1d ago
- AARDAardvark Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates GlobeNewswire · 1d ago
- RVPHReviva Reports Third Quarter 2026 Financial Results and Recent Business Highlights GlobeNewswire · 1d ago
- YDESYD Bio Announces FDA Grant of INTERACT Meeting Request for YDB-LMSCEV-001, an Investigational Extracellular Vesicle Candidate for Dry Eye Disease GlobeNewswire · 2d ago
- BLSMBlossomHill Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights GlobeNewswire · 2d ago
- TLPHTalphera Reports Third Quarter 2026 Financial Results and Provides Business Update PR Newswire · 2d ago
- ERASErasca Reports Third Quarter 2026 Business Updates and Financial Results GlobeNewswire · 2d ago
- PRMEPrime Medicine Reports Third Quarter 2026 Financial Results and Provides Business Updates GlobeNewswire · 2d ago
- RCKTRocket Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Progress Business Wire · 2d ago
- NTHINeOnc CEO Buys More Shares Below $5 as NTHI Secures FDA Meeting to Discuss Phase 3 Trial GlobeNewswire · 2d ago
- NTHINeOnc Insider Buying Expands Ahead of FDA Discussions and Two Key Brain Cancer Data Presentations GlobeNewswire · 2d ago
- TSHATaysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update GlobeNewswire · 2d ago
- NGENNervGen Receives FDA Breakthrough Therapy Designation for NVG-291 in Chronic Spinal Cord Injury GlobeNewswire · 2d ago
- BBIOA Run of FDA Target Dates Fills the Biotech Calendar From Late November to Year End PR Newswire · 2d ago
- NTHIFDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track GlobeNewswire · 3d ago
- NTHINeOnc Technologies Granted FDA Type B End-of-Phase Meeting to Discuss Potential Accelerated Approval Pathway and Phase 3 Confirmatory Trial for Intranasal NEO100 GlobeNewswire · 3d ago
- PYPDPolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial Results GlobeNewswire · 3d ago
- INOINOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights PR Newswire · 4d ago
- MGXMetagenomi Therapeutics Announces FDA Clearance of Investigational New Drug Application for MGX-001 and Reports Third Quarter 2026 Financial Results GlobeNewswire · 4d ago
- FRNMFreenome Reports Third Quarter 2026 Financial Results GlobeNewswire · 4d ago
- GRAL1780183 - GRAIL INC Earnings Call Transcripts · 4d ago
- OWLTOwlet Expands Into Everyday Family Health With Launch of Smart Thermometer Business Wire · 4d ago
- WATWaters Achieves FDA 510(k) Clearance for Ready-to-Use Flow Cytometry Clinical Tests for Leukemia and Lymphoma PR Newswire · 4d ago
- SRRKScholar Rock Reports Third Quarter 2026 Financial Results and Recent Business Highlights Business Wire · 4d ago
- BDTXBlack Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and Provides Corporate Update GlobeNewswire · 4d ago
- BDTXBlack Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and Provides Corporate Update GlobeNewswire · 4d ago